0001144204-13-045992.txt : 20130815 0001144204-13-045992.hdr.sgml : 20130815 20130814175637 ACCESSION NUMBER: 0001144204-13-045992 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130814 DATE AS OF CHANGE: 20130814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS INC CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS SHOPPING GOODS STORES [5940] IRS NUMBER: 870652870 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53404 FILM NUMBER: 131039366 BUSINESS ADDRESS: STREET 1: 2626 SOUTH LOOP, SUITE 180 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 8329716616 MAIL ADDRESS: STREET 1: 2626 SOUTH LOOP, SUITE 180 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 10-Q 1 v352628_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________________

Commission file number: 000-53404

Bio-Path Holdings, Inc.

(Exact name of registrant as specified in its charter)

Utah		87-0652870
(State or other jurisdiction of		(I.R.S. employer
incorporation or organization		identification No.)

2626 South Loop, Suite 180, Houston, TX 77054

(Address of principal executive offices)

Registrant's telephone no., including area code: (832) 971 -6616

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

At August 5, 2013, the Company had 75,380,214 outstanding shares of common stock, no par value.

Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not strictly historical in nature are forward-looking statements. These statements may include, but are not limited to, statements about: the timing of the commencement, enrollment, and completion of our anticipated clinical trials for our product candidates; the progress or success of our product development programs; the status of regulatory approvals for our product candidates; the timing of product launches; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and our estimates for future performance, anticipated operating losses, future revenues, capital requirements, and our needs for additional financing. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “goal,” and similar expressions intended to identify forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. The underlying information and expectations are likely to change over time. Actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the caption “Risk Factors” in “ITEM 1. BUSINESS” of our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012, and those set forth in our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

TABLE OF CONTENTS

		Page

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	4
	Consolidated Balance Sheets	4
	Consolidated Statements of Operations	5
	Consolidated Statements of Cash Flows	6
	Notes to Unaudited Consolidated Financial Statements Ending June 30, 2013	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	25
Item 4.	Controls and Procedures	25

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	26

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

Unaudited

	June 30,			December 31,
	2013			2012

ASSETS

Current assets
Cash	$	1,927,226		$	534,046
Prepaid drug product for testing		279,180			195,000
Other current assets		46,411			42,575

Total current assets		2,252,817			771,621

Other assets
Technology licenses - related party		2,500,374			2,500,374
Less Accumulated Amortization		(1,008,544	)		(928,231	)
		1,491,830			1,572,143

TOTAL ASSETS	$	3,744,647		$	2,343,764

LIABILITIES & SHAREHOLDERS' EQUITY

Current liabilities
Accounts payable		165,897			57,000
Accounts payable - related party		10,017			8,582
Accrued expense		4,892			137,662
Accrued expense - related party		37,050			26,000
Accrued license payments - related party		50,000			100,000

Total current liabilities		267,856			329,244

Long term debt		-			-

TOTAL LIABILITIES		267,856			329,244

Shareholders' Equity
Preferred Stock, $.001 par value		-			-
10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized		75,380			62,218
75,380,214 and 62,219,050 shares issued and outstanding as of
6/30/13 and 12/31/12, respectively
Additional paid in capital		16,615,942			13,321,075
Additional paid in capital for shares to be issued a/		-			762,510	a/
Accumulated deficit during development stage		(13,214,531	)		(12,131,283	)

Total shareholders' equity		3,476,791			2,014,520

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$	3,744,647		$	2,343,764

a/ Represents 2,541,700 shares of common stock

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

	Second Quarter						Year to Date						From inception
	April 1 to June 30						January 1 to June 30						05/10/07 to
	2013			2012			2013			2012			6/30/13

Revenue	$	-		$	-		$	-		$	-		$	-

Operating expense

Research and development a/		156,036			168,026			557,135			447,639			4,882,732
Research and development - related party b/		32,067			367,588			47,067			379,288			1,110,687
General & administrative c/		240,543			252,168			480,354			483,482			7,539,817

Total operating expense		428,646			787,782			1,084,556			1,310,409			13,533,236

Net operating loss	$	(428,646	)	$	(787,782	)	$	(1,084,556	)	$	(1,310,409	)	$	(13,533,236	)

Other income (expense)
Interest income		1,531			213			1,655			742			78,744
Other income		-			-			-			-			244,479
Other expense		(129	)		(269	)		(345	)		(398	)		(4,518	)
Total Other Income (Expense)		1,402			(56	)		1,310			344			318,705

Net Loss	$	(427,244	)	$	(787,838	)	$	(1,083,246	)	$	(1,310,065	)	$	(13,214,531	)

Loss per share

Net loss per share, basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.28	)

Basic and diluted weighted average number of common shares outstanding		66,606,105			58,868,713			64,412,577			58,625,066			47,534,377

Research and development expense includes stock option expenses of $8,220 and $13,411 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $19,633 and $30,817 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $442,632 for the period from inception through 6/30/2013

Includes $345,000 technology impairment charge for the quarter and six month periods ending 6/30/12; and $690,000 for the period from inception through 6/30/2013

General & administrative expense includes stock for services, stock option and warrant expenses of $5,318 and $1,300 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $9,923 and $3,250 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $2,600,679 for the period from inception through 6/30/2013 for stock options and warrants and $318,500 in stock for services.

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

CONSOLIDATED STATEMENT OF CASH FLOWS

Unaudited

							From inception
	January 1, to June 30						05/10/2007 to
	2013			2012			6/30/2013

CASH FLOW FROM OPERATING ACTIVITIES

Net loss	$	(1,083,246	)	$	(1,310,065	)	$	(13,214,531	)

Adjustments to reconcile net loss to net cash used in operating activities
Amortization		80,312			96,612			1,057,047
Technology impairment		-			345,000			690,000
Common stock issued for services		-			18,500			318,500
Stock options and warrants		29,557			34,067			3,043,311
(Increase) decrease in assets
Prepaid drug product for testing		(84,180	)		(142,477	)		(279,180	)
Other current assets		(3,836	)		1,950			(46,411	)
Increase (decrease) in liabilities
Accounts payable and accrued expenses		(61,388	)		(73,108	)		267,856

Net cash used in operating activities		(1,122,781	)		(1,029,521	)		(8,163,408	)

CASH FLOW FROM INVESTING ACTIVITIES

Purchase of exclusive license - related party		-			(25,000	)		(884,710	)

Net cash used in investing activities		-			(25,000	)		(884,710	)

CASH FLOW FROM FINANCING ACTIVITIES

Proceeds from convertible notes		-			-			435,000
Cash repayment of convertible notes		-			-			(15,000	)
Net proceeds from sale of common stock		2,515,961			264,709			10,555,344

Net cash from financing activities		2,515,961			264,709			10,975,344


NET INCREASE (DECREASE) IN CASH		1,393,180			(789,812	)		1,927,226

Cash, beginning of period		534,046			952,252			-

Cash, end of period	$	1,927,226		$	162,440		$	1,927,226

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid for
Interest	$	-		$	-		$	445
Income taxes	$	-		$	-		$	-

Non-cash financing activities
Common stock issued upon conversion of convertible notes	$	-		$	-		$	420,000
Common stock issued to Placement Agent	$	448,950		$	-		$	1,040,516
Common stock issued to M.D. Anderson for technology license	$	-		$	-		$	2,354,167
Due diligence and commitment shares issued to Lincoln	$	-		$	1,750		$	210,755

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

BIO-PATH HOLDINGS, INC.

(A Development Stage Company)

Notes to the Unaudited Consolidated Financial Statements Ending June 30, 2013

The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended June 30, 2013, are not necessarily indicative of the results for a full-year period.

Organization and Business

Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, recently in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.

The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.

The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m². However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m², which had been increased from 50 mg/m²in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m².

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.

The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.

An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.

In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.

Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.

The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.

Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.

At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $345,000 at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (50%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $345,000, and cancel the license.

The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.

An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.

As of June 30, 2013, Bio-Path had $1,927,226 in cash on hand. During the second quarter of 2013, the Company received approximately $2.5 million in cash from the sale of shares of common stock in a private placement and direct offering that have both been closed. The Company has since opened a new private placement in the second quarter of 2013 with the goal of raising up to $4 million from the sales of shares of its common stock. Bio-Path plans to begin raising significant amounts of additional development capital at anticipated higher share prices once there is demonstration of proof-of-concept of Bio-Path’s technology in human patients.

As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.

Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2013 and 2012, MD Anderson related party research and development expense was $32,067 and $367,588, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2013 was comprised of MD Anderson clinical trial hospital expense of $22,050 and $10,017 in technology license patent maintenance fees. As of June 30, 2013 accounts payable related party was $10,017 for patent maintenance fees, accrued expense related party was $37,050 for MD Anderson clinical trial hospital expense (See Notes 4., 5. and 6.), and accrued license payments related party of $50,000 for past patent expenses. As of June 30, 2012, the Company had $367,588 in research and development expense related party expense comprised of $345,000 for technology license impairment expense (See Note 1.) and $22,588 for siRNA patent expense.

Prepaid Drug Product for Testing

Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future R&D activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $195,000 during 2012 pursuant to a Drug Supply Contract (See Note 10.) for the manufacture and delivery of the Company’s lead drug product for testing in a Phase I clinical trial. This amount was carried on the Balance Sheet as of December 31, 2012 at cost as Prepaid Drug Product for Testing. This product was delivered to the Company in the first quarter of 2013 and costs associated with this drug batch were expensed. Another drug batch was produced in the second quarter of 2013 and installment costs totaling $279,180 are carried on the Balance Sheet as of June 30, 2013 as Prepaid Drug Product for Testing (See Note 10.).

Accounts Payable

As of June 30, 2013, Current Liabilities included accounts payable of $165,897 comprised primarily of approximate amounts owed to the Company’s drug contract manufacturers totaling $114,200, $13,900 to several companies involved in research and development testing, $6,800 in fees for an industry conference at which the Company will be making a corporate presentation, $6,000 to outside consultants and $15,900 to the Company’s attorneys and auditors. As of June 30, 2013 Current Liabilities included accounts payable related party totaling $10,017 comprised of Technology License patent maintenance fees. (See Note 2.). As of December 31, 2012, Current Liabilities included accounts payable $57,000 and accounts payable related party of $8,582, which amounts were subsequently paid in 2013.

Accrued Expense

As of June 30, 2013, Current Liabilities included accrued expense of $4,892 for clinical trial operations management. Current Liabilities as of June 30, 2013 also included accrued expense related party of $37,050 for MD Anderson clinical trial hospital expense. (See Note 2.). As of December 31, 2012, Current Liabilities included accrued expense of $137,662 and accrued expense related party of $26,000.

Accrued License Payments – Related Party

Accrued license payments related party totaling $50,000 and $100,000 were included in Current Liabilities as of June 30, 2013 and December 31, 2012, respectively. The amount included for June 30, 2013 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license.

Additional Paid In Capital For Shares To Be Issued

During 2012 the Company sold shares of common stock for cash to investors in a private placement. As of December 31, 2012, there were 2,541,700 shares of common stock remaining to be issued, representing $762,510 in sales to accredited investors. The Company has closed this offering at the end of the first quarter 2013 and subsequently issued the shares of common stock to these investors in the second quarter of 2013.

Stockholders’ Equity

Issuance of Common Stock – In May and June of 2007, the Company issued 6,505,994 shares of common stock for $6,506 in cash to founders of the Company. In August of 2007, the Company issued 3,975,000 shares of common stock for $993,750 in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional 1,333,334 shares of common stock for $1,000,000 in cash to investors in the Company pursuant to a second round of financing. The Company issued 530,833 in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued 3,138,889 shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.

In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued 38,023,578 shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained 3,600,000 shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued 80,000 shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued 200,000 shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $180,000. In April of 2008, the Company recorded an additional 24 shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued 100,000 shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $40,000. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued 660,000 shares of common stock and warrants to purchase an additional 660,000 shares of common stock for $165,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 66,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.

In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $675,000 in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors 2,700,000 shares of common stock and warrants to purchase an additional 2,700,000 shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In January 2010, the Company also sold an additional 900,000 shares of common stock and warrants to purchase an additional 900,000 shares of common stock for $225,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $1.50 a share. In connection with these private placement sales of equity, the Company issued 360,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In May of 2010, the Company issued 780,000 shares of common stock and warrants to purchase an additional 780,000 shares of common stock for $273,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 78,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a 24-month period in amounts between $50,000 and $1,000,000 up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $200,000 from LPC as an initial purchase in exchange for 571,429 shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase 571,429 shares of the Company’s common stock at an exercise price of $1.50 per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC 12,000 shares of the Company’s common stock for its due diligence efforts and 566,801 shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.

In July of 2010, the Company received $150,000 from LPC in exchange for 375,000 shares of the Company’s common stock. LPC was also issued 6,251 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 375,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In September of 2010, the Company received $50,000 from LPC in exchange for 125,000 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In November of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

From November 2010 through April of 2011 the Company sold shares of common stock for $1,794,205 in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued 5,980,685 shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued 598,069 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.

In June of 2011, the Company received $50,000 from LPC in exchange for 164,853 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2011, the Company issued 1,920,000 shares of common stock for $576,000 to investors who exercised warrants from September to October 2011.

In November of 2011, the Company received $25,000 from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In December of 2011, the Company received $50,000 from LPC in exchange for 172,414 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In March of 2012, the Company received $50,000 from LPC in exchange for 166,667 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $25,000 from LPC in exchange for 89,286 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $25,000 from LPC in exchange for 96,154 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $50,000 from LPC in exchange for 185,185 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In June of 2012, the Company sold $150,000 in shares of its common stock pursuant to a private placement, with shares to be issued, and $18,500 in shares of its common stock for services with shares to be issued.

In August of 2012, the Company issued 50,000 shares of its common stock for the $18,500 shares for services previously recognized in June 2012.

In July through September of 2012, the Company sold $795,001 in shares of its common stock pursuant to a private placement, with shares to be issued.

In October through December of 2012, the Company sold $708,600 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of December 31, 2012 the Company issued 3,300,337 shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.

In February and March of 2013, the Company sold $346,201 in shares of its common stock pursuant to a private placement, with shares to be issued.

In April and May of 2013, the Company sold $2,000,198 in shares of its common stock pursuant to a private placement, with shares to be issued, and $489,501 in shares of its common stock pursuant in a direct offering, with shares to be issued.

In June of 2013, the Company issued 11,664,665 shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued 1,496,499 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

As of June 30, 2013, there were 75,380,214 shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2013.

Stock Options and Warrants

Stock Option - In April of 2013, the Company made a stock option grant to purchase 25,000 shares of the Company’s common stock for service as a director of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is one year from the date of grant for the director service stock option. The exercise price of the option is $0.54 a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy five percent (175%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the effective term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total fair value of the stock option granted was determined using this methodology to be $12,975, which is being expensed following the date of grant based on the stock option vesting schedule.

The stock option grant in April of 2013 was not for current management of the Company and there were no other stock option awards during the quarter ending June 30, 2013. Total stock option expense for the quarter ending June 30, 2013 was $13,538.

Warrant - There were no warrants for services granted during the quarter ending June 30, 2013.

10.

Commitments and Contingencies

Technology License – Related Party - The Company has negotiated exclusive licenses from the MD Anderson Cancer Center to develop drug delivery technology for antisense and siRNA drug products. These licenses require, among other things, the Company to reimburse MD Anderson for ongoing patent expense. Related party accounts payable of $10,017 for patent expenses for the Technology License, and accrued license payments attributable to the Technology License totaling $50,000 are included in Current Liabilities as of June 30, 2013. Related party accrued expense totaling $37,050 as of June 30, 2013 represents hospital costs for the clinical trial and are not related to the Technology License. As of June 30, 2013, the Company estimates reimbursable past patent expenses will total approximately $75,000 for the Technology License. The Company will be required to pay when invoiced the past patent expenses at the rate of $25,000 per quarter. In addition, the Company decided to discontinue development of its siRNA technology and subsequently canceled its siRNA license in June of 2012 (See Note 1).

Drug Supplier Project Plan - In August of 2012, Bio-Path entered into two project plan agreements with the Company’s drug substance manufacturer and its final drug product manufacturer for the manufacture and delivery of final drug product incorporating the drug substance for expected delivery in the fourth quarter of 2012, with delivery subsequently revised to the first quarter of 2013. The project plans required the Company to pay approximately $340,000 in various stages as the drug substance and product are manufactured and delivered to the Company. Of this amount, $195,000 was paid for or owed by the Company and was carried on the Balance Sheet as of December 31, 2012 as Prepaid Drug Product for Testing. The drug product was delivered to the Company in the first quarter of 2013 and the Balance Sheet item Prepaid Drug Product for Testing totaling $195,000 was expensed in the first quarter 2013. Amounts owed to the Company’s manufacturers for this drug batch have been paid subsequent to year end. In addition, the Company signed another supply agreement in the first quarter of 2013 for a subsequent batch of drug product and a supply agreement with the drug substance supplier in the second quarter of 2013. Installment payments paid or in accounts payable to the Company’s drug manufacturers totaling $279,180 are being carried at cost on the Balance Sheet as of June 30, 2013 as Prepaid Drug Product for testing. A new supply agreement was signed for drug product for delivery in the fourth quarter of 2013, which is estimated to cost $165,000.

11.

Subsequent Events

In the third quarter of 2013, the Company received a shipment of drug product and the related costs will be expensed in the quarter. Costs associated with this drug batch have been substantially paid.

In July of 2012 the Company entered into a Placement Agent Agreement for the sale of up to $4 million in shares of the Company’s common stock to accredited investors through a private placement.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

When you read this section of this Quarterly Report on Form 10-Q, it is important that you also read the unaudited financial statements and related notes included elsewhere in this Form 10-Q and our audited financial statements and notes thereto included in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the matters discussed under the caption “Risk Factors” in “Item 1, BUSINESS” in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012, and other risks and uncertainties discussed in filings made with the Securities and Exchange Commission. See “Forward Looking Statements” for additional discussion regarding risks associated with forward-looking statements.

Overview

Bio-Path Holdings, Inc. (together with its subsidiary, "Bio-Path" or the "Company" or "we," "us" or "our") is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (“L-Grb-2” or “BP-100-1.01”), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Our business plan is to act efficiently as an intermediary in the process of translating newly discovered drug technologies into authentic therapeutic drug candidates. Our strategy is to selectively license potential drug candidates for certain cancers, and, primarily utilizing the comprehensive drug development capabilities of MD Anderson, to advance these candidates into initial human efficacy trials (Phase IIa), and then out-license each successful potential drug and/or the drug delivery technology to a pharmaceutical company or, if the final steps to commercialization are within the capabilities of the Company, finalize development and commercialization internally.

Our principal executive offices are located at 2626 South Loop, Suite 180, Houston Texas, 77054. Our telephone number is (832) 971-6616. Our Internet website address is www.biopathholdings.com, and all of our filings with the Securities and Exchange Commission are available free of charge on our website.

Research and Development

Our research and development is currently conducted through agreements we have with MD Anderson. We anticipate that new research and development relationships will be added in the future for pre-clinical testing services and future sites for clinical trials that require multiple sites for patient testing.

Basic Technical Information

Ribonucleic acid (RNA) is a biologically significant type of molecule consisting of a chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate. Although similar in some ways to DNA, RNA differs from DNA in a few important structural details. RNA is transcribed from DNA by enzymes called RNA polymerases and is generally further processed by other enzymes. RNA is central to protein synthesis. DNA carries the genetic information of a cell and consists of thousands of genes. Each gene serves as a recipe on how to build a protein molecule. Proteins perform important tasks for the cell functions or serve as building blocks. The flow of information from the genes determines the protein composition and thereby the functions of the cell.

The DNA is situated in the nucleus of the cell, organized into chromosomes. Every cell must contain the genetic information and the DNA is therefore duplicated before a cell divides (replication). When proteins are needed, the corresponding genes are transcribed into RNA (transcription). The RNA is first processed so that non-coding parts are removed (processing) and is then transported out of the nucleus (transport). Outside the nucleus, the proteins are built based upon the code in the RNA (translation).

Our basic drug development concept is to block the expression of proteins that cause disease. RNA is essential in the process of creating proteins. We intend to develop drugs and drug delivery systems that are intended to work by delivering short strands of DNA material that are inserted into a cell to block the production of proteins associated with disease.

The historical perspective of cancer treatments has been the use of drugs that affect the entire body. Advances in the past decade have shifted to treating the tumor tissue itself. One of the main strategies in these developments has been targeted therapy, involving drugs that are targeted to block the expression of specific disease causing proteins while having little or no effect on other healthy tissue. Nucleic acid drugs, specifically antisense, are a promising field of targeted therapy. Development of antisense, however, has been limited by the lack of a suitable method to deliver these drugs to the diseased cells with high uptake into the cell and without causing toxicity. Bio-Path’s currently licensed neutral-lipid based liposome technology is designed to accomplish this. Studies have shown a 10-fold to 30-fold increase in tumor cell uptake with this technology compared to other delivery methods.

BP-100-1.01

Indications for Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL)

BP-100-1.01 is our lead lipid delivery antisense drug candidate, which is being clinically tested in patients having Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL). If the results of the clinical tests are favorable, we expect there will be opportunities to negotiate non-exclusive license applications involving upfront cash payments with pharmaceutical companies developing antisense drugs that need systemic delivery technology.

The IND for BP-100-1.01 was submitted to the U.S. Food and Drug Administration (“FDA”) in February 2008 and included all in vitro testing, animal studies and manufacturing and chemistry control studies completed. The FDA requested some changes be made to the application submission. We resubmitted information to the FDA in response to such request. On March 12, 2010, we issued a press release announcing that the FDA had allowed an Investigational New Drug (“IND”) for Bio-Path's lead cancer drug candidate liposomal BP-100-1.01 to proceed into clinical trials. The IND review process was performed by the FDA's Division of Oncology Products and involved a comprehensive review of data submitted by us covering pre-clinical studies, safety, chemistry, manufacturing, and controls, and the protocol for the Phase I clinical trial. The primary objective of the Phase I clinical trial, as in any Phase I clinical trial, is the safety of the drug for treatment of human patients. Additional key objectives of the trial are to demonstrate the effectiveness of our drug delivery technology similar to that experienced in pre-clinical treatment of animals and to assess whether the drug candidate test article produces a favorable impact on the cancerous condition of the patient at the dose levels of the study.

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (“AML”), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (“CML”) and Acute Lymphoblastic Leukemia (“ALL”), or Myelodysplastic Syndrome (“MDS”) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.

The Principal Investigator for the Phase I clinical trial, Dr. Jorge Cortes (the “Principal Investigator”), is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort and he presented such results at the annual meeting of the American Society of Hematology in December of 2011. Results from the second cohort also demonstrated potential anti-leukemia benefits in treated patients and such results were included in the presentation to the American Society of Hematology. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.

Indications for Triple Negative Breast Cancer (TNBC) and Inflammatory Breast Cancer (IBC)

On July 22, 2013, we announced that we were initiating preclinical testing of BP-100-1.01 into two additional indications: Triple Negative Breast Cancer (“TNBC”) and Inflammatory Breast Cancer (“IBC”). TNBC tumors do not express estrogen receptors, progesterone receptors, and low Human Epidermal growth factor Receptor 2 (“HER2”). These negative results mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of too many HER2 receptors. Therefore, TNBC does not respond to hormonal therapy or therapies that target HER2 receptors. In addition, TNBC tumors are very aggressive. Approximately 15 to 20 percent of breast cancers are triple-negative. IBC is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.” IBC accounts for two to five percent of all breast cancers. IBC tumors are very aggressive and are frequently hormone receptor negative, which means hormone therapies may not be effective. Five year survival rate for IBC is approximately 40% versus approximately 87% for all breast cancers combined, making IBC a priority area for development of new treatments.

Our plan is to develop BP-100-1.01 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop BP-100-1.01 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop BP-100-1.01 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients. Following successful completion of the preclinical studies, we expect to start a Phase I clinical trial in TNBC and IBC in 2014. We believe that the observations that we learn from the on-going Phase I trial will allow us to progress relatively quickly in such Phase I trial in TNBC and IBC, as the toxicity profile of BP-100-1.01 is currently being established.

BP-100-1.02

BP-100-1.02 (“Bcl-2” or “BP-100-1.02”) is Bio-Path's co-lead compound. The scientific name for BP-100-1.02 is Liposomal Bcl-2, a liposome delivered antisense cancer drug that targets the lymphoma and certain solid tumor markets. Liposomal Bcl-2 has the potential to treat 40%-60% of solid tumors.

Bcl-2 is a protein that is involved in regulating apoptosis or programmed cell death. Apoptosis is a physiologic mechanism of cell turnover by which cells actively commit suicide in response to aberrant external signals. Over-expression of Bcl-2 prevents the induction of apoptosis in response to cellular insults such as treatment with chemotherapeutic agents. Bcl-2 is over-expressed in more than 90% of follicular B-cell non-Hodgkins lymphoma due to a chromosomal rearrangement and is the key factor in the initiation of this malignancy. Bcl-2 is also overexpressed in a wide variety of solid tumors (it is estimated to be over-expressed in 40 percent of cancers). For example, Bcl-2 over-expression has been associated with the progression of prostate cancer from hormone dependence to hormone independence and may contribute to the relative drug resistant phenotype typically observed in hormone independent prostate cancer.

Clinical targets for BP-100-1.02 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia.

Other Liposomal Antisense Products

As noted previously, the Company intends to apply its drug delivery technology template to new disease-causing protein targets as a means to develop new, liposomal antisense drug candidates. A new product identification template was recently approved that defines a process of scientific, pre-clinical, commercial and intellectual property evaluation of potential new drug candidates for inclusion into the Company’s drug product development pipeline. A significant amount of capital will be allocated for in-licensing promising protein targets that can be developed as new liposomal antisense drug candidates.

Projected Financing Needs

As of June 30, 2013, we anticipate that we need to raise approximately an additional $6,950,000 to complete our core clinical trials for our product candidates. This includes funds to complete the Phase I clinical trial for BP-100-1.01, one Phase II trial in BP-100-1.01, a Phase I clinical trial for BP-100-1.02, license and patent maintenance costs and general and administrative expense. However, including opportunities for two additional Phase II clinical trials for BP-100-1.01 and a Phase I clinical trial for breast cancer would add the requirement to raise an additional $5,500,000. Consequently, funding all of our opportunities for clinical trials would require us to raise as much as $12,450,000.

The remaining cost of the Phase I clinical trial of BP-100-1.01 is expected to be approximately $300,000, provided that the trial is completed after the next dose level. If the Phase I clinical trial in BP-100-1.01 is successful, we expect to follow with multi-site Phase II trials in BP-100-1.01. Successful Phase I and II trials of BP-100-1.01 are expected to provide clinical evidence to support BP-100-1.01 as a potential therapeutic drug product for treatment of AML, MDS and CML. The Phase II clinical trials in BP-100-1.01 are expected to cost approximately $2,000,000 each, or approximately $6,000,000 for all three.

Development of BP-100-1.01 to treat TNBC and IBC over the 30 month plan horizon is expected to require approximately $1,500,000. This amount is expected to fund the preclinical program and the Phase I clinical trial. It is anticipated that the Phase I clinical trial will cost less than a typical Phase I trial because the safety profile will have already been established upon conclusion of BP-100-1.01’s current clinical trial. This is expected to result in fewer patients being tested and a more efficient progression to an optimal biological dose.

The Phase I clinical trial of BP-100-1.02 (L-Bcl-2) is expected to cost approximately $2,000,000. Commencement of the Phase I clinical trial depends on the FDA approving the IND for BP-100-1.02. Success in the Phase I clinical trial will be based on the demonstration that the drug is well tolerated and other key outcomes. The Phase I clinical trial will likely be a dose-escalating study to determine the safety and tolerance of escalating doses of BP-100-1.02. The study will also likely determine the optimal biologically active dose for further development. The pharmacokinetics of BP-100-1.02 in patients will be studied, as well as down-regulation of the target protein to corroborate any positive anti-cancer effects in addition to confirming effectiveness of the delivery technology.

Approximately $300,000 has been allocated to identifying other protein targets for development into liposomal antisense drug candidates. The balance of the $12,450,000 in funding needs from our revised plan over 30 months is approximately $2,350,000, which is planned to fund patent expenses, licensing fees, pre-clinical costs, consulting fees and management and administration. Of the projected total of $12,450,000 in funding needs, approximately $10,000,000 in project costs is projected to be spent on clinical trials of our drug candidates and developing new drug candidates, and the balance is projected to be spent on period costs for professionals, management and license costs.

The scientific evidence that our liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers could potentially be very significant in helping to meet future funding needs. The Company envisions that it might be able to enter into licensing/development agreements with potential pharmaceutical company partners seeking systemic antisense drug treatments, which could potentially provide funding from the partner to Bio-Path to develop their liposomal antisense drug candidate, with residual milestone payments and potential back-end royalty payments if the drug candidate became an FDA approved drug. There are many potential licensing/development structures, which would vary in terms of favorability to the Company.

We have generated approximately five full years of financial information and have demonstrated that we have been able to expand our business through an increased investment in our technology and trials. We cannot guarantee that plans as described in this quarterly report will be successful or that we can continue to receive additional capital investment. Our business is subject to risks inherent in growing an enterprise, including limited capital resources and possible rejection of our new products and/or clinical development methods. If financing is not available on satisfactory terms or at all, we may be unable to continue expanding our operations. Equity financing will result in a dilution to existing shareholders.

There can be no assurance of the following:

(1)

That the actual costs of a particular trial will come within our budgeted amount.

(2)

That any trials will be successful or will result in drug commercialization opportunities.

(3)

That we will be able to raise the sufficient funds to allow us to complete our planned clinical trials.

Background Information about MD Anderson

We anticipate that our initial drug development efforts will be pursuant to our exclusive license agreement with MD Anderson. MD Anderson's stated mission is to "make cancer history" (www.mdanderson.org). Achieving that goal begins with integrated programs in cancer treatment, clinical trials, educational programs and cancer prevention. MD Anderson is one of the largest and most widely recognized cancer centers in the world: U.S. News & World Report's America's "Best Hospitals" survey has ranked MD Anderson as one of the top two best hospitals in the nation since the survey began in 1990. MD Anderson will treat more than 100,000 patients this year, of which approximately 11,000 will participate in therapeutic clinical research exploring novel treatments which is the largest such program in the nation. MD Anderson employs more than 15,000 people including more than 1,000 medical doctors and Ph.D clinicians and researchers, and is routinely conducting more than 700 clinical trials at any one time.

Each year, researchers at MD Anderson and around the globe publish numerous discoveries that have the potential to become or enable new cancer drugs. The pharmaceutical and biotechnology industries have more than four hundred cancer drugs in various stages of clinical trials. Yet the number of actual new drugs that are approved to treat this dreaded disease is quite small and its growth rate is flat or decreasing. A successful new drug in this market is a "big deal" and substantially impacts those companies who have attained it: Genentech's Avastin, Novartis' Gleevec, OSI's Tarceva and Millennium's Velcade are examples of such drugs.

Over the past several years MD Anderson has augmented its clinical and research prominence through the establishment of the Pharmaceutical Development Center ("PDC"). The PDC was formed for the sole purpose of helping researchers at MD Anderson prepare their newly discovered compounds for clinical trials. It has a full-time staff of professionals and the capability to complete all of the studies required to characterize a compound for the filing of an IND with the FDA, which is required to initiate clinical trials. These studies include pharmacokinetics, tissue distribution, metabolism studies and toxicology studies.

We anticipate being able to use the PDC as a possible source for some of the pre-clinical work needed in the future, potentially at a lower cost than what it would cost to use a for-profit contract research organization. There is no formal arrangement between the Company and PDC and there can be no certainty that we will have access to PDC or that even if we do have access, that our costs will be reduced over alternative service providers.

Relationship with MD Anderson

Bio-Path was founded to focus on bringing the capital and expertise needed to translate drug candidates developed at MD Anderson (and potentially other research institutions) into real treatment therapies for cancer patients. To carry out this mission, Bio-Path negotiated or plans to negotiate several agreements with MD Anderson that will:

Bio-Path's Chief Executive Officer is experienced in working with MD Anderson and its personnel. Bio-Path believes that if we obtain adequate financing, Bio-Path will be positioned to translate current and future MD Anderson technology into treatments for cancer patients. This in turn is expected to provide a steady flow of cancer drug candidates to commercialize or for out-licensing to pharmaceutical partners.

Licenses

We currently maintain an exclusive license agreement with MD Anderson (the “License Agreement”). We intend to use our relationship with MD Anderson to develop drug compounds covered by such License Agreement through Phase IIa clinical trials, the point at which we will have demonstrated proof-of-concept of the efficacy and safety for our product candidates in cancer patients. At such time, we may seek a development and marketing partner in the pharmaceutical or biotechnology industry. In certain cases, we may choose to complete development and market the products ourselves. Our basic guide to a decision of whether or not to obtain a license for a potential drug candidate is as follows:

Likelihood of efficacy: Are the in vitro pre-clinical studies on mechanism of action and the in vivo animal models robust enough to provide a compelling case that the “molecule/compound/technology” has a high probability of working in humans?

Does it fit with the Company’s expertise: Does Bio-Path possess the technical and clinical assets to significantly reduce the scientific and clinical risk to a point where a pharmaceutical company partner would likely want to license this candidate within 36-48 months from the date of Bio-Path acquiring a license?

Affordability and potential for partnering: Can the clinical trial endpoints be designed in a manner that is unambiguous, persuasive, and can be professionally conducted in a manner consistent with that expected by the pharmaceutical industry at a cost of less than $5-7 million dollars without “cutting corners”?

Intellectual property and competitive sustainability: Is the intellectual property and competitive analysis sufficient to meet “Big Pharma” criteria assuming successful early clinical human results?

Out-Licenses and Other Sources of Revenue

Subject to demonstrating proof of concept for our delivery technology and obtaining adequate capital, we intend to develop a steady series of drug candidates through Phase II clinical trials and then to engage in a series of out-licensing transactions to pharmaceutical and biotechnology companies. Such companies would then conduct later-stage clinical development, regulatory approval, and eventual marketing of the drug. We expect that such out-license transactions would include upfront license fees, milestone/success payments, and royalties. We intend to maximize the quality and frequency of these transactions, while minimizing the time and cost to achieve meaningful candidates for out-licensing. Our near-term strategy for these licensing transactions is to develop sufficient revenue to cover our burn rate and provide development capital for clinical testing of drug candidates through Phase II for out-licensing, and for some candidates, potentially through full development and commercialization. Longer term, out-licensing transactions will be viewed in terms of creating maximum shareholder value to add to the economic value of drug candidates fully developed and marketed by the Company, as noted below.

In addition to out-licensing revenue and value creation, we may fully develop one or more of our own drug candidates. For example, there are certain cancers that are primarily treated only in a comprehensive cancer center; of which there are approximately forty in the US and perhaps two hundred throughout the world. As a result, “marketing and distribution” can become a realistic possibility for select products. These candidates may be eligible for orphan drug designation by the FDA which provides additional incentives in terms of market exclusivities and non-dilutive grant funding for clinical trials.

Finally, there are technologies for which we anticipate acquiring licenses whose application goes well beyond cancer treatment. The ability to provide the delivery of antisense and small molecules, and their efficient uptake into cells is a very important technological asset that is expected to be commercialized in other areas of medicine.

License Agreement

We are currently maintaining the License Agreement with MD Anderson. The License Agreement relates to the delivery technology platform for antisense nucleic acids including two single nucleic acid (antisense) drug products. The License Agreement requires, among other things, that we reimburse MD Anderson for ongoing patent expense. Accounts payable – related party totaling $10,017 for current patent expenses are included in Current Liabilities as of June 30, 2013. Accrued license payments totaling $50,000 for accrued past patent expenses are included in Current Liabilities as of June 30, 2013. Past patent expenses represent patent expenses incurred by MD Anderson prior to executing the License Agreement with Bio-Path that are being amortized in quarterly payments. As of June 30, 2013, the Company estimates remaining reimbursable past patent expenses total approximately $75,000 for the antisense license. The Company will be required to pay these patent expenses at the rate of $25,000 per quarter when invoiced by MD Anderson. In addition, accrued expense-related party of $37,050 was included in current liabilities as of June 30, 2013 representing accrued hospital expense for MD Anderson services treating patients in Bio-Path’s clinical trial of BP-100-1.01. This expense is unrelated to the License Agreement.

Bio-Path is currently developing a neutral-lipid based liposome delivery technology of antisense for the treatment of cancer. The liposome targeting technology previously licensed was developed based on testing of tumor targeting of liposomal siRNA FAK drug candidate. Tumor targeting was a technology that was needed much more for liposomal siRNA technology than for liposomal antisense technology. As a result, with the Board’s decision in 2012 not to proceed with developing the siRNA technology at this time, tumor targeting will be developed at a later time with potentially another targeting technology.

Business Strategy

Previously, we developed a business plan with milestones that we currently anticipate will require us to raise approximately $7,000,000 to completely implement such business plan. The milestones include completion of the Phase I clinical trial of L-Grb-2, a Phase I clinical trial in an additional liposomal antisense drug product in addition to the drug product L-Grb-2 currently in a Phase I clinical trial and a multi-site Phase II clinical trial of L-Grb-2. In addition, our previous plan of operation included funds to in-license up to four new protein targets for development as liposomal antisense drug product candidates to add to our product pipeline for development. However, the results seen to date in the Phase I clinical trial of Liposomal Grb-2 have created the opportunity to conduct multi-site Phase II clinical trials of Liposomal Grb-2 in three separate blood cancers (specifically, AML, MDS and CML), a significant opportunity for the Company. We also believe that the opportunity to develop, in conjunction with MD Anderson, our lead cancer drug Liposomal Grb-2 to treat TNBC and IBC, two cancers characterized by formation of aggressive tumors and relatively high mortality rates, is promising. As a result of these two developments over the past year, Bio-Path has revised its business plan over the next 30 months to include (i) milestones for the additional two Phase II clinical trials for Liposomal Grb-2 and (ii) development of Liposomal Grb-2 treatments for TNBC and IBC, including a pre-clinical program and a Phase I clinical trial. The Company believes that the potential to enhance the value of the Company from these two project additions is significant; however, these projects are expected to cause the capital requirements for the Company over the next 30 months to increase to $12,450,000.

In order to capitalize on the growing need for new drug candidates by the pharmaceutical industry, and recognizing the value of clinical data, we have developed our commercialization strategy based on the following concepts:

	¨	Develop in-licensed compounds to proof-of-concept in patients through Phase II.

	¨	Manage trials as if they were being done by Big Pharma: seamless transition; quality systems; documentation; and disciplined program management recognized by Big Pharma diligence teams; trials conducted, monitored and data collected consistent with applicable FDA regulations to maximize Bio-Path’s credibility and value to minimize time to gain registration by partner.

	¨	Leverage outside testing firms for pre-clinical capabilities and MD Anderson for clinical development capabilities. Outside testing firms perform pre-clinical studies as well as clinical pharmacokinetics and pharmacodynamics while MD Anderson’s world-renowned clinics will be used for clinical trials, particularly for early clinical trials. This should allow us to develop our drug candidates with experienced professional staff at a reduced cost compared to using external contract research organizations to run clinical trials. This should also allow us to operate in an essentially virtual fashion, thereby avoiding the expense of setting up and operating laboratory facilities, and without losing control over timing, quality or IP contamination.

	¨	Use our Medical Advisory Board and the Board to supplement our Management Team to critically monitor existing programs and evaluate new technologies and/or compounds discovered or developed at MD Anderson, or elsewhere, for in-licensing.

	¨	Hire a small team of employees or consultants: business development, regulatory management, and project management.

	¨	Outsource manufacturing and regulatory capabilities. Bio-Path will not need to invest its resources in building functions where it does not add substantial value or differentiation. Instead, it will leverage an executive team with expertise in the selection and management of high quality contract manufacturing and regulatory firms. Future manufacturing capabilities may be developed at a later date as a means to control the technology and ensure adequate supplies of our future internally developed drug products and for out-licensed drug products.

Manufacturing

We have no manufacturing capabilities and intend to outsource the manufacturing function in the near future. The most likely outcome of the out-license of a Bio-Path drug to a pharmaceutical partner will be that the pharmaceutical partner will be responsible for manufacturing drug product requirements. However, in the event Bio-Path is required to supply a drug product to a distributor or pharmaceutical partner for commercial sale, Bio-Path will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. There are a limited number of manufacturers that operate under the FDA’s current good manufacturing practices (cGMP) regulations capable of manufacturing our future products. As noted previously, future manufacturing capabilities may be developed at a later date as a means to control the technology and ensure adequate supplies of our future internally developed drug products and for out-licensed drug products.

Intellectual Property

Patents, trademarks, trade secrets, technology, know-how, and other proprietary rights are important to our business. Our success will depend in part on our ability to develop and maintain proprietary aspects of our technology. To this end, we intend to have an intellectual property program directed at developing proprietary rights in technology that we believe will be important to our success.

We will actively seek patent protection in the U.S. and, as appropriate, abroad and closely monitor patent activities related to our business. In addition to patents, we will rely on trade secrets and proprietary know-how, which we seek to protect, in part, through confidentiality and proprietary information agreements.

Agreement with Acorn CRO

On April 23, 2009, we announced that had we entered into an agreement with ACORN CRO, a full service, oncology-focused clinical research organization (CRO), to provide us with a contract medical officer and potentially other clinical trial support services. Under such agreement, Bradley G. Somer, M. D., commenced serving as our Medical Advisor and medical liaison for the conduct of our Phase I clinical study of liposomal BP-100-1.01 in refractory or relapsed Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS).

Competition

We are engaged in fields characterized by extensive research efforts, rapid technological progress, and intense competition. There are many public and private companies, including pharmaceutical companies, chemical companies, and biotechnology companies, engaged in developing products for the same human therapeutic applications that we are targeting. Currently, all or most of our competitors have substantially greater financial, technical and human resources than Bio-Path and are more experienced in the development of new drugs than Bio-Path. In order for us to compete successfully, we may need to demonstrate improved safety, efficacy, ease of manufacturing, and market acceptance of our products over the products of our competitors.

We will face competition based on the safety and efficacy of our drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent position and other factors. Our competitors may develop or commercialize more effective, safer or more affordable products than we are able to develop or commercialize or obtain more effective patent protection. As a result, our competitors may commercialize products more rapidly or effectively than we may be able to, which would adversely affect our competitive position, the likelihood that our drug candidates, if approved, will achieve initial market acceptance and our ability to generate meaningful revenues from those drugs. Even if our drug candidates are approved and achieve initial market acceptance, competitive products may render such drugs obsolete or noncompetitive.

If any such drug is rendered obsolete, we may not be able to recover the expenses of developing and commercializing that drug. With respect to all of our drugs and drug candidates, Bio-Path is aware of existing treatments and numerous drug candidates in development by our competitors.

Government Regulation

Regulation by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacturing, and expected marketing of our future drug product candidates and in its ongoing research and development activities. The nature and extent to which such regulations will apply to Bio-Path will vary depending on the nature of any drug product candidates developed. We anticipate that all of our drug product candidates will require regulatory approval by governmental agencies prior to commercialization.

In particular, human therapeutic products are subject to rigorous pre-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with the appropriate federal statutes and regulations requires substantial time and financial resources. Any failure by us or our collaborators to obtain, or any delay in obtaining, regulatory approval could adversely affect the marketing of any drug product candidates developed by us, our ability to receive product revenues, and our liquidity and capital resources.

The steps ordinarily required before a new drug may be marketed in the United States, which are similar to steps required in most other countries, include:

pre-clinical laboratory tests, pre-clinical studies in animals, formulation studies and the submission to the FDA of an investigational new drug application;

adequate and well-controlled clinical trials to establish the safety and efficacy of the drug;

the submission of a new drug application or biologic license application to the FDA; and

FDA review and approval of the new drug application or biologics license application.

Bio-Path's business model relies on developing drug product candidates through Phase II and either entering into out-license agreements with pharmaceutical licensee partners who will be responsible for post-Phase II clinical testing and working with the FDA on necessary regulatory submissions resulting in approval of new drug applications for commercialization, or internally developing a drug product candidate through commercialization. For more detailed discussions on the clinical trial processes involvement with the FDA, please refer to Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012.

Results of Operations for the three and six months ended June 30, 2013 and 2012.

Revenues. We have no operating revenues since our inception.

Research and Development Expenses. Our research and development expense was $156,036 for the three month period ended June 30, 2013, a decrease of $11,990 from the three month period ended June 30, 2012. The decrease in research and development expense for the three months ended June 30, 2013 compared to the comparable period ended June 30, 2012 was primarily due to a $8,347 decrease in amortization expense and a decrease of $5,191 in stock option expense for personnel involved in research and development activities. Research and development expense-related party was $32,067 for the three month period ended June 30, 2013, a decrease of $335,521 compared to the comparable three month period ended June 30, 2012. The decrease in research and development expense-related party was due primarily to technology impairment expense that was recognized in the three month period ended June 30, 2012.

Our research and development expense was $557,135 for the six months ended June 30, 2013, an increase of $109,496 from the six months ended June 30, 2012. This increase was primarily the result of a drug batch that was received and expensed in the six month period ended June 30, 2013. Research and development expense - related party was $47,067 for the six months ended June 30, 2013, a decrease of $332,221 from the six months ended June 30, 2012. This decrease was a result of technology impairment expense that was recognized in the six month period ended June 30, 2012.

General and Administrative Expenses. Our general and administrative expenses were $240,543 for the three month period ended June 30, 2013, a decrease of $11,625 compared to the three month period ended June 30, 2012. The decrease in general and administrative expense for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was due to stock for services expense in the quarter ended June 30, 2012 that did not occur in the quarter ended June 30, 2013.

Our general and administrative expenses were $480,354 for the six month period ended June 30, 2013, a decrease of $3,128 from the six months ended June 30, 2012. The decrease in general and administrative expense for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 was due to stock for services expense in the six months ended June 30, 2012 that did not occur in the six month period ended June 30, 2013.

Net Loss. Our net loss was $ (427,244) for the three month period ended June 30, 2013 compared to a loss of $ (787,838) for the three month period ended June 30, 2012. The decrease in the net loss for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was due to research and development expense related party being higher in the quarter ended June 30, 2012 due to a $345,000 write-down to the carrying value of a certain technology license which resulted from the Company’s decision to abandon development of siRNA technology. Net loss per share, both basic and diluted, was $ (0.01) per share for the respective three month periods.

Our net loss was $ (1,083,246) for the six months ended June 30, 2013, compared to a loss of $ (1,310,065) for the six months ended June 30, 2012. Net loss per share, both basic and diluted, was $ (0.02) and $ (0.02) for the respective periods. The primary reason for the decrease in net loss for the six month period ended June 30, 2013 compared to the six month period ended June 30, 2012 was research and development expense related party being higher in the six months ended June 30, 2012 due to a $345,000 write-down to the carrying value of a certain technology license which resulted from the Company’s decision to abandon development of siRNA technology.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through private placements and direct private sales of our capital stock. We expect to finance our foreseeable cash requirements through cash on hand, cash from operations, public or private equity offerings and debt financings. Additionally, we will be seeking collaborations and license arrangements for our three product candidates. We may seek to access the public or private equity markets whenever conditions are favorable.

At June 30, 2013, we had cash of $1,927,226 compared to $534,046 at June 30, 2012. The increase in cash balances during the six month period ended June 30, 2013 results from $(1,122,781) in cash used in operations, offset by $2,515,961 in net proceeds received from the sale of shares of the Company’s common stock. We currently have no lines of credit or other arranged access to debt financing.

Net cash used in operations during the six months ended June 30, 2013 was $(1,122,781) compared to $(1,029,521) for the six months ended June 30, 2012. Inasmuch as we have not yet generated revenues, our entire expenses of operations are funded by proceeds from the sale of the shares of the Company’s common stock and other capital raising efforts.

Net cash provided by financing activities during the six month period ended June 30, 2013 was $2,515,961 compared to $264,709 for the six month period ended June 30, 2012. Since inception through June 30, 2013, we have net cash provided from financing activities of $10,975,344. We believe that our available cash and our ongoing capital raising efforts will be sufficient to fund our liquidity and capital expenditure requirements through the fourth quarter of 2013. We believe that we will need to raise approximately $12,450,000 in net proceeds to completely implement our current business plan over the next 30 months.

Contractual Obligations and Commitments

Bio-Path has entered into the License Agreement with MD Anderson. A summary of certain material terms of the License Agreement is detailed in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012.

In the first quarter of 2013, Bio-Path entered into a supply agreement with its drug product manufacturer for the manufacture of the Company’s drug product for delivery in May 2013. In addition, the Company signed a supply agreement with the drug substance supplier in the second quarter of 2013. Installment payments paid or in accounts payable to the Company’s drug manufacturers totaling $279,180 are being carried at cost on the Balance Sheet as of June 30, 2013 as Prepaid Drug Product for testing. The manufactured drug batch was subsequently completed and delivered to the Company after the end of the second quarter. Amounts owed for this batch have been substantially paid. In addition, a new supply agreement was signed for drug product for delivery in the fourth quarter of 2013, which is estimated to cost $165,000.

In April 2009, we entered into an agreement with ACORN CRO, a full service, oncology focused clinical research organization, to provide Bio-Path with a contract medical advisor and potentially other clinical trial support services. Concurrent with signing the agreement, Bradley G. Somer, M.D., served as Bio-Path’s Medical Officer and medical liaison for the conduct of the Company’s Phase I clinical study of liposomal BP-100-1.01 in refractory or relapsed Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS).

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States has required the management of the Company to make assumptions, estimates and judgments that affect the amounts reported in the financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. The Company considers its critical accounting policies to be those that require the more significant judgments and estimates in the preparation of financial statements. Our significant accounting policies are discussed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Information not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. We maintain a system of disclosure controls and procedures that is designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934, as amended (the “Exchange Act”) reports is recorded, processed, summarized and reported within the time periods specified in rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. As of June 30, 2013, our management, including our principal executive officer and principal financial officer, had evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) pursuant to Rule 13a-15(b) under the Exchange Act. Based upon and as of the date of the evaluation, our principal executive officer and principal financial officer concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods and is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic SEC reports. Based on the foregoing, our management determined that our disclosure controls and procedures were effective as of June 30, 2013.

(b) Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting that occurred during the period of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

Information not required for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

From April 1, 2013 through June 30, 2013, the Company issued and sold, at a price of $0.30 per share, an aggregate of 1,631,670 shares (the “Direct Shares”) of the Company’s common stock to certain “accredited investors” (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) resulting in gross proceeds from the sale thereof of approximately $490,000. The Company agreed to pay cash commissions to its placement agent equal to ten percent of the aggregate purchase price of the Direct Shares. In addition, the Company agreed to issue to its placement agent one share of the Company’s common stock for every ten Direct Shares sold as additional compensation.

The securities described above in this Item 2 will not be or have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Such securities were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

On August 8, 2013, Peter H. Nielsen, our President and Chief Executive Officer, and Douglas P. Morris, our Vice President of Corporate Development, were granted options to purchase 1,500,000 shares and 1,000,000 shares, respectively, of our common stock at an exercise price equal to the closing price per share for our common stock on the OTCQX on the date of such grant. One-half of such options vested immediately and the remaining one-half of such options will vest on an equal monthly basis over the following three years, based on continuing service to the Company.

In connection with such grants to Mr. Nielsen and Mr. Morris, our board of directors approved an amendment to our 2007 stock incentive plan to increase the number of shares in respect of awards granted thereunder to any participant in a calendar year from 500,000 to 1,500,000. The foregoing description of the amendment to our 2007 stock incentive plan is qualified in its entirety by reference to such amendment, a copy of which is filed as Exhibit 10.1 to this quarterly report and is incorporated by reference herein.

ITEM 6. EXHIBITS

Exhibit No.		Description of Exhibit
2.1		Agreement and Plan of Merger and Reorganization dated September 27, 2007, by and among Ogden Golf Co. Corporation, a Utah corporation (the registrant), Biopath Acquisition Corp., a Utah corporation and wholly owned subsidiary of the registrant, and Bio-Path, Inc., a Utah corporation (incorporated by reference to exhibit 2.1 to the registrant’s current report on Form 8-K filed on September 27, 2007).
3.1		Restated Articles of Incorporation (incorporated by reference to exhibit 3.2 to the registrant’s current report on Form 8-A filed on September 10, 2008).
3.2		Bylaws (incorporated by reference to exhibit 3.2 to the registrant’s current report on Form 8-A filed on September 10, 2008).
3.3		Articles of Merger relating to the merger of Biopath Acquisition Corp. with and into Bio-Path, Inc. (incorporated by reference to exhibit 3.2 to the registrant’s current report on Form 8-K filed on February 19, 2008).
3.4		Amendment No. 1 to Bylaws (incorporated by reference to exhibit 3.2 to the registrant’s current report on Form 8-K filed on June 21, 2010).
4.1		Specimen Stock certificate (incorporated by reference to exhibit 3.2 to the registrant’s current report on Form 8-A filed on September 10, 2008).
10.1*		First Amendment to First Amended 2007 Stock Incentive Plan.
31*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

*	Filed herewith.

SIGNATURE

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 14, 2013	BIO-PATH HOLDINGS, INC.

	By	/s/ Peter H. Nielsen,
		Chief Executive Officer, President/Principal Executive
		Officer, Chief Financial Officer, Principal Financial Officer

EX-10.1 2 v352628_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

FIRST AMENDMENT TO

FIRST AMENDED 2007 STock INCENTIVE PLAN

This First Amendment (the “First Amendment”) to that certain First Amended 2007 Stock Incentive Plan (the “2007 Plan”) of Bio-Path Holdings, Inc., a Utah corporation (the “Company”), is made effective as of the 8th day of August, 2013. All capitalized and undefined terms used herein shall have the meanings ascribed to such terms in the 2007 Plan.

WHEREAS, pursuant to Section 21 of the 2007 Plan, the board of directors (the “Board”) of the Company is authorized to amend the 2007 Plan; and

WHEREAS, the Board unanimously approved an amendment to the 2007 Plan as set forth herein.

NOW, THEREFORE, in connection with the foregoing, the 2007 Plan is hereby amended as follows:

1. The last sentence of Section 2.1 of the 2007 Plan is hereby deleted in its entirety and replaced with the following:

“Subject to adjustment in accordance with Section 18.4, in any calendar year, no Participant shall be granted Awards in respect of more than 1,500,000 shares of Common Stock (whether through grants of options or SARs or other Awards of Common Stock or rights with respect thereto).”

2. Except as amended and modified by this First Amendment, the 2007 Plan shall continue in full force and effect, and the 2007 Plan and this First Amendment shall be construed as one and the same instrument.

IN WITNESS WHEREOF, the Company executed this First Amendment as of the date first above written.

	BIO-PATH HOLDINGS, INC.

	By:	/s/ Peter H. Nielsen
	Name:	Peter H. Nielsen
	Title:	President and Chief Executive Officer

EX-31 3 v352628_ex31.htm EXHIBIT 31

Exhibit 31

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

I, Peter H. Nielsen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2013	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		(Principal Executive Officer)
		Chief Financial Officer
		(Principal Financial Officer)

EX-32 4 v352628_ex32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Bio-Path Holdings, Inc. (the “Company”) for the quarter ended June 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Peter H. Nielsen, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2013	By:	/s/ Peter H. Nielsen
		Peter H. Nielsen
		Chief Executive Officer
		Chief Financial Officer

EX-101.INS 5 bpth-20130630.xml XBRL INSTANCE DOCUMENT 0001133818 2011-01-01 2011-12-31 0001133818 2012-01-01 2012-06-30 0001133818 2013-01-01 2013-06-30 0001133818 2013-02-01 2013-03-31 0001133818 2008-04-01 2008-04-30 0001133818 2012-04-01 2012-06-30 0001133818 2013-04-01 2013-04-30 0001133818 2013-04-01 2013-06-30 0001133818 2008-04-30 0001133818 2007-05-10 2013-06-30 0001133818 2013-06-30 0001133818 2012-07-01 2012-07-31 0001133818 2012-07-01 2012-09-30 0001133818 2012-08-01 2012-08-31 0001133818 2013-08-05 0001133818 2011-10-01 2011-10-31 0001133818 2012-10-01 2012-12-31 0001133818 2012-12-31 0001133818 2011-12-31 0001133818 2007-05-09 0001133818 2012-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2007-05-10 2013-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2012-04-01 2012-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0001133818 us-gaap:GeneralAndAdministrativeExpenseMember 2007-05-10 2013-06-30 0001133818 bpth:AllOtherMember 2013-04-01 2013-06-30 0001133818 bpth:AllOtherMember 2012-04-01 2012-06-30 0001133818 bpth:AllOtherMember 2013-01-01 2013-06-30 0001133818 bpth:AllOtherMember 2012-01-01 2012-06-30 0001133818 bpth:AllOtherMember 2007-05-10 2013-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2013-04-01 2013-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2012-04-01 2012-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2013-01-01 2013-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2012-01-01 2012-06-30 0001133818 bpth:RelatedPartyTransactionsMember 2007-05-10 2013-06-30 0001133818 bpth:PlacementAgentMember 2013-01-01 2013-06-30 0001133818 bpth:PlacementAgentMember 2012-01-01 2012-06-30 0001133818 bpth:PlacementAgentMember 2007-05-10 2013-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2013-01-01 2013-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2012-01-01 2012-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2007-05-10 2013-06-30 0001133818 bpth:PhaseOneMember 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember bpth:MdAndersonCancerCenterMember 2012-04-01 2012-06-30 0001133818 bpth:MdAndersonCancerCenterMember 2012-01-01 2012-06-30 0001133818 bpth:MdAndersonCancerCenterMember 2013-01-01 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember bpth:TechnologyLicensesMember 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember bpth:ClinicalTrialsMember 2013-06-30 0001133818 bpth:MdAndersonCancerCenterMember 2013-06-30 0001133818 us-gaap:ResearchAndDevelopmentExpenseMember 2013-06-30 0001133818 bpth:FoundersMember 2007-05-01 2007-05-31 0001133818 bpth:FoundersMember 2007-05-01 2007-06-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2007-08-01 2007-08-31 0001133818 us-gaap:InvestorMember bpth:AdditionalSharesMember 2007-08-01 2007-08-31 0001133818 bpth:PlacementAgentMember 2007-08-01 2007-08-31 0001133818 bpth:MdAndersonCancerCenterMember 2007-11-01 2007-11-30 0001133818 bpth:BioPathHoldingsIncMember 2008-02-01 2008-02-29 0001133818 bpth:OgdenGolfCorporationMember 2008-02-01 2008-02-29 0001133818 bpth:BioPathHoldingsIncMember 2008-04-01 2008-04-30 0001133818 bpth:InvestorRelationsServicesMember 2008-12-01 2008-12-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-06-01 2009-06-30 0001133818 us-gaap:PrivatePlacementMember 2009-06-01 2009-06-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-06-30 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2009-06-01 2009-06-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-11-01 2009-11-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2009-12-01 2009-12-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 us-gaap:InvestorMember bpth:AdditionalSharesMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2010-01-01 2010-01-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-05-01 2010-05-31 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-05-31 0001133818 bpth:PlacementAgentMember us-gaap:PrivatePlacementMember 2010-05-01 2010-05-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember us-gaap:MinimumMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember us-gaap:MaximumMember 2010-06-01 2010-06-30 0001133818 us-gaap:WarrantMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-30 0001133818 bpth:FinancingAgreementMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-01 2010-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-07-01 2010-07-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-09-01 2010-09-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-10-01 2010-10-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-11-01 2010-11-30 0001133818 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2010-11-01 2011-04-30 0001133818 us-gaap:InvestorMember 2011-06-01 2011-06-30 0001133818 bpth:PlacementAgentMember 2011-06-01 2011-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-06-01 2011-06-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-11-01 2011-11-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2011-12-01 2011-12-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2012-03-01 2012-03-31 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioOneMember 2012-04-01 2012-04-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioTwoMember 2012-04-01 2012-04-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioThreeMember 2010-09-01 2010-09-30 0001133818 us-gaap:EquityUnitPurchaseAgreementsMember bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember bpth:ScenarioThreeMember 2012-04-01 2012-04-30 0001133818 us-gaap:PrivatePlacementMember 2012-06-01 2012-06-30 0001133818 us-gaap:InvestorMember 2012-12-31 0001133818 us-gaap:PrivatePlacementMember 2013-04-01 2013-04-30 0001133818 us-gaap:IPOMember 2013-05-01 2013-05-30 0001133818 us-gaap:InvestorMember 2013-01-01 2013-06-30 0001133818 bpth:PlacementAgentMember 2013-01-01 2013-06-30 0001133818 bpth:LincolnParkCapitalFundLimitedLiabilityCompanyMember 2010-06-30 0001133818 bpth:TechnologyLicensesMember 2013-06-30 0001133818 us-gaap:PatentedTechnologyMember 2013-06-30 xbrli:shares iso4217:USD xbrli:shares iso4217:USD bpth:Number iso4217:USD bpth:Unit xbrli:pure 10-Q false 2013-06-30 2013 Q2 BPTH 75380214 BIO-PATH HOLDINGS INC 0001133818 --12-31 Smaller Reporting Company

0.001

10000000

0.001

200000000

75380214

62219050

75380214

62219050

2541700

1927226

534046

279180

195000

46411

42575

2252817

771621

2500374

1008544

928231

1491830

1572143

3744647

2343764

165897

57000

10017

8582

4892

137662

37050 26000

50000

100000

267856

329244

267856

329244

75380

62218

16615942

13321075

762510

13214531

12131283

3476791

2014520

3744647

2343764

8220

13411

19633

30817

442632

345000

690000

5318 1300 9923 3250 2600679 318500

156036

168026

557135

447639

4882732

32067

367588

47067

379288

1110687

240543

252168

480354

483482

7539817

428646

787782

1084556

1310409

13533236

-428646

-787782

-1084556

-1310409

-13533236

1531

213

1655

742

78744

244479

129

269

345

398

4518

1402

-56

1310

344

318705

-427244

-787838

-1083246

-1310065

-13214531

-0.01

-0.02

-0.28

66606105

58868713

64412577

58625066

47534377

80312

96612

1057047

345000

690000

18500

318500

29557

34067

3043311

84180

142477

279180

3836

-1950

46411

-61388

-73108

267856

-1122781

-1029521

-8163408

25000

884710

-25000

-884710

435000

15000

2515961

264709

10555344

2515961

264709

10975344

1393180

-789812

1927226

952252

162440

445

420000

448950

1040516

2354167

1750

210755

345000

0.5 345000

2500000

<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>1.</strong></div> </td> <td> <div><strong>Organization and Business</strong></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, recently in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m<sup>2</sup>. However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m<sup>2</sup>, which had been increased from 50 mg/m<sup>2</sup>in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m<sup>2</sup>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $<font style=" FONT-SIZE: 10pt">345,000</font> at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (<font style=" FONT-SIZE: 10pt">50</font>%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $<font style=" FONT-SIZE: 10pt">345,000</font>, and cancel the license.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, Bio-Path had $<font style=" FONT-SIZE: 10pt">1,927,226</font> in cash on hand. During the second quarter of 2013, the Company received approximately $<font style=" FONT-SIZE: 10pt">2.5</font> million in cash from the sale of shares of common stock in a private placement and direct offering that have both been closed. The Company has since opened a new private placement in the second quarter of 2013 with the goal of raising up to $<font style=" FONT-SIZE: 10pt">4</font> million from the sales of shares of its common stock. Bio-Path plans to begin raising significant amounts of additional development capital at anticipated higher share prices once there is demonstration of proof-of-concept of Bio-Path’s technology in human patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.</div> </div>

4000000 3

32067

367588

345000

22588

10017

22050 37050

165897

57000

114200

6800

6000 15900

13900

<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>8.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>Stockholders’ Equity</strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong><em> </em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Issuance of Common Stock</em></strong>  In May and June of 2007, the Company issued <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"> 6,505,994</font></font> shares of common stock for $<font style=" FONT-SIZE: 10pt">6,506</font> in cash to founders of the Company. In August of 2007, the Company issued <font style=" FONT-SIZE: 10pt">3,975,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">993,750</font> in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional <font style=" FONT-SIZE: 10pt">1,333,334</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">1,000,000</font> in cash to investors in the Company pursuant to a second round of financing. The Company issued <font style=" FONT-SIZE: 10pt">530,833</font> in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued <font style=" FONT-SIZE: 10pt">3,138,889</font> shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued <font style=" FONT-SIZE: 10pt">38,023,578</font> shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained <font style=" FONT-SIZE: 10pt">3,600,000</font> shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued <font style=" FONT-SIZE: 10pt">80,000</font> shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued <font style=" FONT-SIZE: 10pt">200,000</font> shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style=" FONT-SIZE: 10pt">180,000</font>. In April of 2008, the Company recorded an additional <font style=" FONT-SIZE: 10pt"> 24</font> shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued <font style=" FONT-SIZE: 10pt">100,000</font> shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style=" FONT-SIZE: 10pt">40,000</font>. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued <font style=" FONT-SIZE: 10pt"> 660,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">660,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">165,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style=" FONT-SIZE: 10pt">66,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">675,000</font></font> in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors <font style=" FONT-SIZE: 10pt"> 2,700,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">2,700,000</font> shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In January 2010, the Company also sold an additional <font style=" FONT-SIZE: 10pt">900,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt"> 900,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">225,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with these private placement sales of equity, the Company issued <font style=" FONT-SIZE: 10pt">360,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May of 2010, the Company issued <font style=" FONT-SIZE: 10pt"> 780,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">780,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">273,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style=" FONT-SIZE: 10pt">78,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a <font style=" FONT-SIZE: 10pt">24</font>-month period in amounts between $<font style=" FONT-SIZE: 10pt">50,000</font> and $<font style=" FONT-SIZE: 10pt">1,000,000</font> up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $<font style=" FONT-SIZE: 10pt">200,000</font> from LPC as an initial purchase in exchange for <font style=" FONT-SIZE: 10pt"> 571,429</font> shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase <font style=" FONT-SIZE: 10pt">571,429</font> shares of the Company’s common stock at an exercise price of $<font style=" FONT-SIZE: 10pt">1.50</font> per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC <font style=" FONT-SIZE: 10pt">12,000</font> shares of the Company’s common stock for its due diligence efforts and <font style=" FONT-SIZE: 10pt">566,801</font> shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July of 2010, the Company received $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">150,000</font></font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">375,000</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">6,251</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the <font style=" FONT-SIZE: 10pt">375,000</font> shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In September of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">125,000</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">135,135</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">135,135</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From November 2010 through April of 2011 the Company sold shares of common stock for $<font style=" FONT-SIZE: 10pt">1,794,205</font> in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued <font style=" FONT-SIZE: 10pt"> 5,980,685</font> shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued <font style=" FONT-SIZE: 10pt">598,069</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2011, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">164,853</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October of 2011, the Company issued <font style=" FONT-SIZE: 10pt">1,920,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">576,000</font> to investors who exercised warrants from September to October 2011.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November of 2011, the Company received $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In December of 2011, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">172,414</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In March of 2012, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">166,667</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">89,286</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">96,154</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">50,000</font></font> from LPC in exchange for <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"> 185,185</font></font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">2,084</font></font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">150,000</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style=" FONT-SIZE: 10pt">18,500</font> in shares of its common stock for services with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August of 2012, the Company issued <font style=" FONT-SIZE: 10pt">50,000</font> shares of its common stock for the $<font style=" FONT-SIZE: 10pt">18,500</font> shares for services previously recognized in June 2012.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July through September of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">795,001</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October through December of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">708,600</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of December 31, 2012 the Company issued <font style=" FONT-SIZE: 10pt">3,300,337</font> shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February and March of 2013, the Company sold $<font style=" FONT-SIZE: 10pt">346,201</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April and May of 2013, the Company sold $<font style=" FONT-SIZE: 10pt">2,000,198</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style=" FONT-SIZE: 10pt">489,501</font> in shares of its common stock pursuant in a direct offering, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2013, the Company issued <font style=" FONT-SIZE: 10pt"> 11,664,665</font> shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued <font style=" FONT-SIZE: 10pt">1,496,499</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, there were <font style=" FONT-SIZE: 10pt"> <font style=" FONT-SIZE: 10pt">75,380,214</font></font> shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2013.</div> </div>

6505994

6506

3975000

993750

1333334

1000000

530833

3138889 180000 24 38023578 3600000

80000

200000

100000 40000 660000 660000 165000

1.50

66000

675000 675000 2700000 2700000 1.50 900000 900000 225000 1.50

360000

780000 780000 273000

1.50

78000

7000000 P24M 50000 1000000

200000

571429

1.50

12000

566801 6251 0

150000

375000

50000

125000

2084 0

50000

135135

2084 0

50000

135135

2084 0

1794205

5980685 598069

50000

164853

2084 0 1920000 576000

25000

50000

172414

2084 0

50000

166667

2084 0

25000

89286

1042

25000

96154

1042

50000

185185

2084

50000

185185

2084 150000 18500 50000 18500

795001

708600

3300337

346201

2000198

489501

11664665

1496499

83333

1042 2 years 2 years 2 years 2 years

1.50

25000

0.54

1.75

12975

13538

P1Y

37050

75000

25000 340000 165000

50000

10017

4000000

<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended June 30, 2013, are not necessarily indicative of the results for a full-year period.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div>

Represents 2,541,700 shares of common stock Research and development expense includes stock option expenses of $8,220 and $13,411 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $19,633 and $30,817 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $442,632 for the period from inception through 6/30/2013 Includes $345,000 technology impairment charge for the quarter and six month periods ending 6/30/12; and $690,000 for the period from inception through 6/30/2013 General & administrative expense includes stock for services, stock option and warrant expenses of $5,318 and $1,300 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $9,923 and $3,250 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $2,600,679 for the period from inception through 6/30/2013 for stock options and warrants and $318,500 in stock for services. EX-101.SCH 6 bpth-20130630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Related Party link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Prepaid Drug Product for Testing link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Accounts Payable link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Accrued Expense link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Accrued License Payments - Related Party link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Additional Paid In Capital For Shares To Be Issued link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock Options and Warrants link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Organization and Business - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Related Party - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Prepaid Drug Product for Testing - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Accounts Payable - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Accrued Expense - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Accrued License Payments - Related Party - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Stock Options and Warrants - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 bpth-20130630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 bpth-20130630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 bpth-20130630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement Of Financial Position [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets Current [Abstract] Current assets Cash Cash Cash, beginning of period Cash, end of period Other Inventory, Gross Prepaid drug product for testing Prepaid drug product for testing Other inventory, gross Other Assets Current Other current assets Assets, Current, Total Total current assets Other Assets Noncurrent [Abstract] Other assets Finite Lived License Agreements Gross Technology licenses - related party Finite Lived Intangible Assets Accumulated Amortization Less Accumulated Amortization Intangible Assets, Net (Excluding Goodwill), Total Intangible Assets, Net (Excluding Goodwill), Total Assets, Total TOTAL ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES & SHAREHOLDERS' EQUITY Liabilities Current [Abstract] Current liabilities Accounts Payable Current Accounts payable Accounts Payable, Related Parties, Current Accounts payable - related party Accounts payable - related party Accrued Liabilities Current Accrued expense Accrued Liabilities Related Parties Current Accrued expense - related party Accrued Liabilities, Related Parties, Current Due To Related Parties, Current Accrued license payments - related party Liabilities, Current, Total Total current liabilities Long-term Debt, Excluding Current Maturities, Total Long term debt Liabilities, Total TOTAL LIABILITIES Stockholders Equity [Abstract] Shareholders' Equity Preferred Stock Value Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding Common Stock Value Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively Additional Paid in Capital, Total Additional paid in capital Other Additional Capital Additional paid in capital for shares to be issued Other Additional Capital Development Stage Enterprise, Deficit Accumulated During Development Stage Accumulated deficit during development stage Stockholders Equity Attributable to Parent, Total Total shareholders' equity Liabilities and Equity, Total TOTAL LIABILITIES & SHAREHOLDERS' EQUITY Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Issued Preferred Stock, shares issued Preferred Stock Shares Outstanding Preferred Stock, shares outstanding Common Stock, Par or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock Shares Issued Common Stock, shares issued Common Stock Shares Outstanding Common Stock, shares outstanding Common Stock Issuable Shares Issuable Additional paid in capital for shares to be issued, shares of common stock Common stock issuable shares issuable Common Stock Issuable Shares, Issuable Statement Of Cash Flows [Abstract] Statement Scenario [Axis] Scenario Unspecified [Domain] Placement Agent [Member] Placement Agent Placement Agent [Member] Related Party Transactions [Member] MD Anderson for License Related Party Transactions [Member] Lincoln Park Capital Fund Limited Liability Company [Member] LPC Lincoln Park Capital Fund, LLC [Member] Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOW FROM OPERATING ACTIVITIES Net Income (Loss) Attributable to Parent, Total Net loss Net Loss Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Amortization, Total Amortization Amortization Other Asset Impairment Charges Technology impairment Technology impairment charge Impairment of License Issuance of Stock and Warrants for Services or Claims Common stock issued for services Share-based Compensation, Total Stock options and warrants Increase Decrease In Operating Assets [Abstract] (Increase) decrease in assets Increase (Decrease) in Inventories, Total Prepaid drug product for testing Increase Decrease In Other Current Assets Other current assets Increase Decrease In Operating Liabilities [Abstract] Increase (decrease) in liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOW FROM INVESTING ACTIVITIES Payments To Acquire Intangible Assets Purchase of exclusive license - related party Net Cash Provided by (Used in) Investing Activities, Total Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOW FROM FINANCING ACTIVITIES Proceeds From Convertible Debt Proceeds from convertible notes Repayments Of Convertible Debt Cash repayment of convertible notes Proceeds From Issuance Of Common Stock Net proceeds from sale of common stock Proceeds from issuance of common stock and warrant from LPC Net Cash Provided by (Used in) Financing Activities, Total Net cash from financing activities Cash, Period Increase (Decrease) NET INCREASE (DECREASE) IN CASH Supplemental Cash Flow Elements [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash Paid During Period For [Abstract] Cash paid for Cash Paid During Period For [Abstract] Interest Paid, Total Interest Income Taxes Paid Income taxes Cash Flow Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activities Conversion of Stock, Amount Converted Common stock issued upon conversion of convertible notes Stock Issued Common stock issued Income Statement [Abstract] All Other [Member] All Other All Other [Member] Revenues, Total Revenue Operating Expenses [Abstract] Operating expense Research and Development Expense, Total Research and development Research and Development Expense General and Administrative Expense, Total General & administrative Operating Expenses, Total Total operating expense Operating Income (Loss), Total Net operating loss Nonoperating Income Expense [Abstract] Other income (expense) Investment Income, Interest Interest income Other Nonoperating Income Other income Other Nonoperating Expense Other expense Nonoperating Income (Expense), Total Total Other Income (Expense) Earnings Per Share [Abstract] Loss per share Earnings Per Share, Basic and Diluted, Total Net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic and Diluted Basic and diluted weighted average number of common shares outstanding Research and Development Expense [Member] Research and Development Expense Research and Development Expense General and Administrative Expense [Member] General and Administrative Expense Allocated Share-based Compensation Expense, Total Equity compensation Share Based Compensation Stock Option and Warrant Expense Stock option and warrant expense Share Based Compensation, Stock Option And Warrant Expense Stock Based Compensation Expense For Services Stock for services Stock Based Compensation Expense For Services Organization and Business [Abstract] Nature Of Operations Organization and Business Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Prepaid Drug Product For Testing [Abstract] Research and Development Disclosure [Text Block] Prepaid Drug Product for Testing Research And Development Disclosure [Text Block] Accounts Payable Disclosure [Abstract] Accounts Payable Disclosure [Text Block] Accounts Payable Accounts Payable Disclosure [Text Block] Accrued Liabilities [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expense Accrued License Payment Related Party [Abstract] Collaborative and License Arrangement Disclosure [Text Block] Accrued License Payments - Related Party Collaborative and License Arrangement Disclosure [Text Block] Shares To Be Issued [Abstract] Shares To Be Issued [Text Block] Additional Paid In Capital For Shares To Be Issued Shares To Be Issued [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Stock Options and Warrants [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Stock Options and Warrants Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Disclosure Organization and Business Additional Information [Abstract] Disclosure - Organization and Business - Additional Information [Abstract] Organization and Nature Of Operations [Table] Organization and Nature of Operations [Table] Product Or Service [Axis] Products and Services [Domain] Phase One [Member] Phase I clinical trial Phase 1 [Member] Subsidiary, Sale Of Stock [Axis] Sale Of Stock, Name Of Transaction [Domain] Private Placement [Member] Private Placement memorandum Private Placement Statement Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Range [Axis] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Organization and Nature Of Operations [Line Items] Organization and Nature of Operations [Line Items] Organization and Nature of Operations [Line Items] Number Of Patients Number patients benefited from Liposomal Grb-2 treatment Number of Patients Percentage Of Change In Depreciation Amortization Of Intangible Assets and Asset Impairment and Other Charges Operating Percentage of Charge Percentage of Change in Depreciation Amortization of Intangible Assets and Asset Impairment and Other Charges Operating Other Asset Impairment Charges Sirna License Carrying value of the siRNA license Other Asset Impairment Charges Sirna License Proceeds From Issuance Of Private Placement Proceeds from issuance of private placement Proceeds from issuance of private placement Schedule Of Related Party Transactions, By Related Party [Table] Related Party [Axis] Related Party [Domain] Md Anderson Cancer Center [Member] MD Anderson Cancer Center Md Anderson Cancer Center [Member] Income Statement Location [Domain] Technology Licenses [Member] Technology Licenses Technology Licenses [Member] Income Statement Location [Axis] Component Of Other Operating Cost And Expenses [Axis] Related Party Transaction, Expenses from Transactions with Related Party Cash paid to MD Anderson Cancer Center for expenses Disclosure Prepaid Drug Product For Testing Additional Information [Abstract] Disclosure - Prepaid Drug Product for Testing - Additional Information [Abstract] Inventory Disclosure [Table] Inventory Disclosure [Table] Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Inventory Disclosure [Line Items] Accounts Payable [Table] Accounts Payable Accounts payable Accounts Payable, Trade Accounts payable, trade Accounts Payable, Other, Current Accounts payable, other, current Accounts Payable To Professional Fees Current Accounts Payable To Professional Fees Current Carrying value as of the balance sheet date of obligations incurred and payable to professional. Accounts Payable To Public Filing Services Accounts Payable To Public Filing Services Carrying value as of the balance sheet date of obligations incurred and payable for business wire and public filing services. Disclosure Accrued Expense Additional Information [Abstract] Disclosure - Accrued Expense - Additional Information [Abstract] Accounts Payable and Accrued Liabilities [Table] Accounts Payable and Accrued Liabilities [Table] Nature Of Expense [Axis] Interim Period Costs Not Allocable [Domain] Legal Fee [Member] Legal Fee Legal Fee [Member] Stock Transfer Agent [Member] Stock Transfer fees Stock Transfer Agent [Member] Expenses [Member] Expenses Expenses [Member] Management Incentive Award [Member] Management Bonus Accrual Management Incentive Award [Member] Clinical Trials [Member] Clinical Trials Clinical Trials [Member] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Disclosure Accrued License Payments Related Party Additional Information [Abstract] Disclosure - Accrued License Payments - Related Party - Additional Information [Abstract] Reference Period Disclosure [Axis] Reference Period Disclosure Reference Period Disclosure [Domain] Reference Period Disclosure Previous [Member] Past Patent Expenses Previous [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Additional Paid In Capital For Shares To Be Issued [Table] Additional Paid In Capital For Shares To Be Issued [Line Items] Additional Paid In Capital For Shares To Be Issued [Line Items] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure - Stockholders' Equity - Additional Information [Abstract] Shareholders Equity [Table] Shareholders Equity [Table] Investor [Member] Investors Bio Path Holdings Inc [Member] BioPathHoldingsInc Bio Path Holdings Inc [Member] Ogden Golf Corporation [Member] Ogden Golf Co. Ogden Golf Corporation [Member] Equity Unit Purchase Agreements [Member] Equity Unit Purchase Agreements Financing Agreement [Member] LPC financing agreement Financing Agreement [Member] Statement Class Of Stock [Axis] Class Of Stock [Domain] Founders [Member] Founders Founders [Member] Additional Shares [Member] Additional Shares Additional Shares [Member] Due Diligence Efforts [Member] DueDiligenceEfforts Due Diligence Efforts [Member] EX-101.PRE 10 bpth-20130630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R8.xml IDEA: Organization and Business 2.4.0.8108 - Disclosure - Organization and Businesstruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_OrganizationAndBusinessAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Business [Abstract]2false 2us-gaap_NatureOfOperationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>1.</strong></div> </td> <td> <div><strong>Organization and Business</strong></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, recently in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m<sup>2</sup>. However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m<sup>2</sup>, which had been increased from 50 mg/m<sup>2</sup>in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m<sup>2</sup>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $<font style=" FONT-SIZE: 10pt">345,000</font> at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (<font style=" FONT-SIZE: 10pt">50</font>%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $<font style=" FONT-SIZE: 10pt">345,000</font>, and cancel the license.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, Bio-Path had $<font style=" FONT-SIZE: 10pt">1,927,226</font> in cash on hand. During the second quarter of 2013, the Company received approximately $<font style=" FONT-SIZE: 10pt">2.5</font> million in cash from the sale of shares of common stock in a private placement and direct offering that have both been closed. The Company has since opened a new private placement in the second quarter of 2013 with the goal of raising up to $<font style=" FONT-SIZE: 10pt">4</font> million from the sales of shares of its common stock. Bio-Path plans to begin raising significant amounts of additional development capital at anticipated higher share prices once there is demonstration of proof-of-concept of Bio-Path’s technology in human patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592 false0Organization and BusinessfalseOrganization and BusinessUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/OrganizationAndBusiness12 XML 12 R6.xml IDEA: CONSOLIDATED STATEMENTS OF CASH FLOWS 2.4.0.8106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWStruefalsefalse1false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0CASH FLOW FROM OPERATING ACTIVITIES2false 5us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-1083246-1083246USD$falsetruefalse2truefalsefalse-1310065-1310065USD$falsetruefalse3truefalsefalse-13214531-13214531USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 false2Net loss3true 5us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Adjustments to reconcile net loss to net cash used in operating activities4false 6us-gaap_AdjustmentForAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse8031280312USD$falsefalsefalse2truefalsefalse9661296612USD$falsefalsefalse3truefalsefalse10570471057047USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Amortization5false 6us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse345000345000USD$falsefalsefalse3truefalsefalse690000690000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false2Technology impairment6false 6us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaimsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse1850018500USD$falsefalsefalse3truefalsefalse318500318500USD$falsefalsefalsexbrli:monetaryItemTypemonetaryFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Common stock issued for services7false 6us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2955729557USD$falsefalsefalse2truefalsefalse3406734067USD$falsefalsefalse3truefalsefalse30433113043311USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Stock options and warrants8true 6us-gaap_IncreaseDecreaseInOperatingAssetsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0(Increase) decrease in assets9false 7us-gaap_IncreaseDecreaseInInventoriesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-84180-84180USD$falsefalsefalse2truefalsefalse-142477-142477USD$falsefalsefalse3truefalsefalse-279180-279180USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Prepaid drug product for testing10false 7us-gaap_IncreaseDecreaseInOtherCurrentAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-3836-3836USD$falsefalsefalse2truefalsefalse19501950USD$falsefalsefalse3truefalsefalse-46411-46411USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.No definition available.false2Other current assets11true 6us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Increase (decrease) in liabilities12false 7us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-61388-61388USD$falsefalsefalse2truefalsefalse-73108-73108USD$falsefalsefalse3truefalsefalse267856267856USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Accounts payable and accrued expenses13false 5us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-1122781-1122781USD$falsefalsefalse2truefalsefalse-1029521-1029521USD$falsefalsefalse3truefalsefalse-8163408-8163408USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 true2Net cash used in operating activities14true 4us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0CASH FLOW FROM INVESTING ACTIVITIES15false 5us-gaap_PaymentsToAcquireIntangibleAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse-25000-25000USD$falsefalsefalse3truefalsefalse-884710-884710USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Purchase of exclusive license - related party16false 5us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse-25000-25000USD$falsefalsefalse3truefalsefalse-884710-884710USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash used in investing activities17true 4us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0CASH FLOW FROM FINANCING ACTIVITIES18false 5us-gaap_ProceedsFromConvertibleDebtus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse435000435000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from convertible notes19false 5us-gaap_RepaymentsOfConvertibleDebtus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse-15000-15000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 false2Cash repayment of convertible notes20false 5us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse25159612515961USD$falsefalsefalse2truefalsefalse264709264709USD$falsefalsefalse3truefalsefalse1055534410555344USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Net proceeds from sale of common stock21false 5us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse25159612515961USD$falsefalsefalse2truefalsefalse264709264709USD$falsefalsefalse3truefalsefalse1097534410975344USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash from financing activities22false 4us-gaap_CashPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse13931801393180USD$falsefalsefalse2truefalsefalse-789812-789812USD$falsefalsefalse3truefalsefalse19272261927226USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 true2NET INCREASE (DECREASE) IN CASH23false 4us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse534046534046USD$falsefalsefalse2truefalsefalse952252952252USD$falsefalsefalse3truefalsefalse00USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash, beginning of period24false 4us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse19272261927226USD$falsefalsefalse2truefalsefalse162440162440USD$falsefalsefalse3truefalsefalse19272261927226USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash, end of period25true 5bpth_CashPaidDuringPeriodForAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Cash paid for26false 6us-gaap_InterestPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse445445USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid for interest during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 false2Interest27false 6us-gaap_IncomeTaxesPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse00USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 false2Income taxes28true 5us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Non-cash financing activities29false 6us-gaap_ConversionOfStockAmountConverted1us-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse420000420000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Common stock issued upon conversion of convertible notes30false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse10false USDtruefalse$P01_01_2013To06_30_2013_PlacementAgentMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePlacement Agentus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Placement Agent31true 5us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Non-cash financing activities32false 6us-gaap_StockIssued1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse448950448950USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse10405161040516USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe fair value of stock issued in noncash financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Common stock issued33false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse13false USDtruefalse$P01_01_2013To06_30_2013_RelatedPartyTransactionsMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson for Licenseus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_RelatedPartyTransactionsMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0MD Anderson for License34true 5us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Non-cash financing activities35false 6us-gaap_StockIssued1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse23541672354167USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe fair value of stock issued in noncash financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Common stock issued36false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse16false USDtruefalse$P01_01_2013To06_30_2013_LincolnParkCapitalFundLimitedLiabilityCompanyMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseLPCus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0LPC37true 5us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Non-cash financing activities38false 6us-gaap_StockIssued1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsetruefalse2truefalsefalse17501750USD$falsetruefalse3truefalsefalse210755210755USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe fair value of stock issued in noncash financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Common stock issuedfalseCONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/ConsolidatedStatementsOfCashFlows338 XML 13 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10.

Commitments and Contingencies

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)

3 Months Ended

6 Months Ended

74 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Revenue

$ 0

Operating expense

General & administrative

240,543

^[1]

252,168

^[1]

480,354

^[1]

483,482

^[1]

7,539,817

^[1]

Total operating expense

428,646

787,782

1,084,556

1,310,409

13,533,236

Net operating loss

(428,646)

(787,782)

(1,084,556)

(1,310,409)

(13,533,236)

Other income (expense)

Interest income

1,531

213

1,655

742

78,744

Other income

244,479

Other expense

(129)

(269)

(345)

(398)

(4,518)

Total Other Income (Expense)

1,402

(56)

1,310

344

318,705

Net Loss

(427,244)

(787,838)

(1,083,246)

(1,310,065)

(13,214,531)

Loss per share

Net loss per share, basic and diluted

$ (0.01)

$ (0.02)

$ (0.28)

Basic and diluted weighted average number of common shares outstanding

66,606,105

58,868,713

64,412,577

58,625,066

47,534,377

All Other

Operating expense

Research and development

156,036

^[2]

168,026

^[2]

557,135

^[2]

447,639

^[2]

4,882,732

^[2]

MD Anderson for License

Operating expense

Research and development

$ 32,067

^[3]

$ 367,588

^[3]

$ 47,067

^[3]

$ 379,288

^[3]

$ 1,110,687

^[3]

[1]	General & administrative expense includes stock for services, stock option and warrant expenses of $5,318 and $1,300 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $9,923 and $3,250 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $2,600,679 for the period from inception through 6/30/2013 for stock options and warrants and $318,500 in stock for services.
[2]	Research and development expense includes stock option expenses of $8,220 and $13,411 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $19,633 and $30,817 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $442,632 for the period from inception through 6/30/2013
[3]	Includes $345,000 technology impairment charge for the quarter and six month periods ending 6/30/12; and $690,000 for the period from inception through 6/30/2013

XML 15 R10.htm IDEA: XBRL DOCUMENT

Prepaid Drug Product for Testing

6 Months Ended

Jun. 30, 2013

Prepaid Drug Product For Testing [Abstract]

Prepaid Drug Product for Testing

Prepaid Drug Product for Testing

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R24.htm IDEA: XBRL DOCUMENT

Accrued License Payments - Related Party - Additional Information (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Accrued license payments - related party	$ 50,000	$ 100,000

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

XML 18 R29.xml IDEA: Subsequent Events - Additional Information (Detail) 2.4.0.8129 - Disclosure - Subsequent Events - Additional Information (Detail)truefalseIn Millions, unless otherwise specifiedfalse1false USDfalsefalse$P07_01_2012To07_31_2012http://www.sec.gov/CIK0001133818duration2012-07-01T00:00:002012-07-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_SubsequentEventLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Subsequent Event [Line Items]2false 4us-gaap_ProceedsFromIssuanceOfPrivatePlacementus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse40000004.0USD$falsetruefalse2truefalsefalse25000002.5USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from issuance of private placementfalseSubsequent Events - Additional Information (Detail) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/SubsequentEventsAdditionalInformationDetail22 XML 19 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

11.

Subsequent Events

In July of 2012 the Company entered into a Placement Agent Agreement for the sale of up to $4 million in shares of the Company’s common stock to accredited investors through a private placement.

XML 20 R25.xml IDEA: Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) 2.4.0.8125 - Disclosure - Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_AdditionalPaidInCapitalForSharesToBeIssuedLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Additional Paid In Capital For Shares To Be Issued [Line Items]2false 4bpth_CommonStockIssuableSharesIssuablebpth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse25417002541700falsefalsefalsexbrli:sharesItemTypesharesCommon Stock Issuable Shares, IssuableNo definition available.false1Common stock issuable shares issuable3false 4us-gaap_OtherAdditionalCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalse2truefalsefalse762510762510[1]USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional paid-in capital or capital from other sources not otherwise defined. Use this element if the registrant wishes to distinguish between Additional paid-in capital from Other Additional Capital. The following adjustments are some examples of Other Additional Capital: recording the issuance of debt issued with a beneficial conversion feature, the issuance of convertible debt at a substantial premium, certain tax consequences of equity instruments awarded to employees, and accounting for certain expenses and liabilities paid for by the principal shareholder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section T false2Other Additional Capital1Represents 2,541,700 shares of common stockfalseAdditional Paid In Capital For Shares To Be Issued - Additional Information (Detail) (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AdditionalPaidInCapitalForSharesToBeIssuedAdditionalInformationDetail23 XML 21 R27.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Apr. 30, 2013	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by share based payment award options grants in period	25,000	0
Share based compensation arrangement by share based payment award award vesting period	1 year
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price	$ 0.54
Share based compensation arrangement by share based payment award options grants in period grant date fair value	$ 12,975
Stock option expense		$ 13,538
Share based compensation arrangement by share based payment award average annual volitality rate	175.00%
Stock warrants granted for services, shares		0

XML 22 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended			2 Months Ended	3 Months Ended		6 Months Ended		74 Months Ended	1 Months Ended							1 Months Ended	2 Months Ended	1 Months Ended																	6 Months Ended		1 Months Ended						6 Months Ended	1 Months Ended				6 Months Ended	1 Months Ended
	Aug. 31, 2012	Oct. 31, 2011	Apr. 30, 2008	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	May 30, 2013 IPO	Jun. 30, 2010 Warrant	Apr. 30, 2013 Private Placement memorandum	Jun. 30, 2012 Private Placement memorandum	Jun. 30, 2009 Private Placement memorandum	Dec. 31, 2008 Investor Relations Services	Jun. 30, 2010 LPC	May 31, 2007 Founders	Jun. 30, 2007 Founders	Mar. 31, 2012 Equity Unit Purchase Agreements LPC	Dec. 31, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2011 Equity Unit Purchase Agreements LPC	Jun. 30, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2010 Equity Unit Purchase Agreements LPC	Oct. 31, 2010 Equity Unit Purchase Agreements LPC	Sep. 30, 2010 Equity Unit Purchase Agreements LPC	Jul. 31, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Minimum	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Maximum	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 1	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 2	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 3	Sep. 30, 2010 Equity Unit Purchase Agreements LPC Scenario 3	Jun. 30, 2010 LPC financing agreement LPC	Jun. 30, 2011 Investors	Jun. 30, 2013 Investors	Dec. 31, 2012 Investors	May 31, 2010 Investors Private Placement memorandum	Jan. 31, 2010 Investors Private Placement memorandum	Dec. 31, 2009 Investors Private Placement memorandum	Nov. 30, 2009 Investors Private Placement memorandum	Jun. 30, 2009 Investors Private Placement memorandum	Aug. 31, 2007 Investors Private Placement memorandum	Apr. 30, 2011 Investors Private Placement memorandum	Aug. 31, 2007 Investors Additional Shares	Jan. 31, 2010 Investors Additional Shares Private Placement memorandum	Jun. 30, 2011 Placement Agent	Aug. 31, 2007 Placement Agent	Jun. 30, 2013 Placement Agent	May 31, 2010 Placement Agent Private Placement memorandum	Jan. 31, 2010 Placement Agent Private Placement memorandum	Jun. 30, 2009 Placement Agent Private Placement memorandum	Nov. 30, 2007 MD Anderson Cancer Center	Apr. 30, 2008 BioPathHoldingsInc	Feb. 29, 2008 BioPathHoldingsInc	Feb. 29, 2008 Ogden Golf Co.
Shareholders Equity [Line Items]
Common stock and warrants issued, shares											571,429						6,505,994	6,505,994	166,667	172,414	83,333	164,853	135,135	135,135	125,000	375,000	571,429			89,286	96,154	185,185	185,185	12,000		11,664,665							3,975,000		1,333,334			530,833	1,496,499	78,000	360,000	66,000		200,000	80,000
Common stock issued , value										$ 489,501								$ 6,506																									$ 993,750	$ 1,794,205	$ 1,000,000
Common stock issued , shares	50,000												150,000																						5,980,685												598,069						3,138,889
Common stock issued merger transactions, shares																																																							38,023,578
Common stock retained shareholders, shares																																																								3,600,000
Common stock issued for services, value			180,000												40,000
Common stock issued, additional shares			24
Common stock issued for service, shares	18,500												18,500		100,000
Common stock and warrant issued, shares														660,000																								780,000	2,700,000							900,000
Common stock repurchased, shares																																						780,000	2,700,000			660,000				900,000
Common stock and warrants issued, Value																																						273,000		675,000	675,000	165,000				225,000
Warrants exercisable period																																						2 years	2 years			2 years				2 years
Warrants exercise price																1.50											1.50											1.50				1.50
Warrants exercise price																																							$ 1.50							$ 1.50
Equity purchase agreement value																											7,000,000	50,000	1,000,000
Agreement period																											24 months
Proceeds from issuance of common stock and warrant from LPC							2,515,961	264,709	10,555,344										50,000	50,000	25,000	50,000	50,000	50,000	50,000	150,000	200,000			25,000	25,000	50,000	50,000
Committed shares issued																			2,084	2,084	1,042	2,084	2,084	2,084	2,084	6,251				1,042	1,042	2,084	2,084	566,801
Warrants issued, shares																			0	0	0	0	0	0	0	0
Common stock issued for exercise of warrant (in shares)		1,920,000
Common stock issued for exercise of warrant		576,000
Common stock issued for services				$ 346,201	$ 708,600	$ 795,001	$ 0	$ 18,500	$ 318,500			$ 2,000,198
Common Stock, shares issued					62,219,050		75,380,214		75,380,214																												3,300,337
Common Stock, shares outstanding					62,219,050		75,380,214		75,380,214
Preferred Stock, shares outstanding					0		0		0

XML 23 R19.xml IDEA: Organization and Business - Additional Information (Detail) 2.4.0.8119 - Disclosure - Organization and Business - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P07_01_2012To07_31_2012http://www.sec.gov/CIK0001133818duration2012-07-01T00:00:002012-07-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$P01_01_2011To12_31_2011http://www.sec.gov/CIK0001133818duration2011-01-01T00:00:002011-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDfalsefalse$PAsOn05_09_2007http://www.sec.gov/CIK0001133818instant2007-05-09T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_OrganizationAndNatureOfOperationsLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Nature of Operations [Line Items]2false 4bpth_PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperatingbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truetruefalse0.50.5falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsenum:percentItemTypepurePercentage of Change in Depreciation Amortization of Intangible Assets and Asset Impairment and Other Charges OperatingNo definition available.false0Percentage of Charge3false 4us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00USD$falsetruefalse4truefalsefalse345000345000USD$falsetruefalse5truefalsefalse345000345000USD$falsetruefalse6truefalsefalse690000690000USD$falsetruefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false2Impairment of License4false 4us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse19272261927226USD$falsefalsefalse3truefalsefalse19272261927226USD$falsefalsefalse4truefalsefalse162440162440USD$falsefalsefalse5truefalsefalse952252952252USD$falsefalsefalse6truefalsefalse19272261927226USD$falsefalsefalse7truefalsefalse534046534046USD$falsefalsefalse8truefalsefalse00USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash5false 4bpth_OtherAssetImpairmentChargesSirnaLicensebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse345000345000USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryOther Asset Impairment Charges Sirna LicenseNo definition available.false2Carrying value of the siRNA license6false 4us-gaap_ProceedsFromIssuanceOfPrivatePlacementus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse40000004000000USD$falsefalsefalse2truefalsefalse25000002500000USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from issuance of private placement7false 4bpth_ProceedsFromIssuanceOfPrivatePlacementTwobpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse40000004000000USD$falsetruefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryProceeds form issuance of private placement two.No definition available.false2Proceeds form additional issuance of private placement8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9false truefalsePAsOn06_30_2013_PhaseOneMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalsePhase I clinical trialus-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PhaseOneMemberus-gaap_ProductOrServiceAxisexplicitMemberNumberStandardhttp://www.biopathholdings.com/20130630Numberbpth0nanafalse0Phase I clinical trial9true 3bpth_OrganizationAndNatureOfOperationsLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Nature of Operations [Line Items]10false 4bpth_NumberOfPatientsbpth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse33falsefalsefalse3truefalsefalse33falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse33falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerNumber of PatientsNo definition available.false256Number patients benefited from Liposomal Grb-2 treatmentfalseOrganization and Business - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/OrganizationAndBusinessAdditionalInformationDetail810 XML 24 R9.xml IDEA: Related Party 2.4.0.8109 - Disclosure - Related Partytruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_RelatedPartyTransactionsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Related Party Transactions [Abstract]2false 2us-gaap_RelatedPartyTransactionsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>2.</b></div> </td> <td> <div><b>Related Party</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending June 30, 2013 and 2012, MD Anderson related party research and development expense was $<font style=" FONT-SIZE: 10pt">32,067</font> and $<font style=" FONT-SIZE: 10pt">367,588</font>, respectively. MD Anderson related party research and development expense for the quarter ending June 30, 2013 was comprised of MD Anderson clinical trial hospital expense of $<font style=" FONT-SIZE: 10pt">22,050</font> and $10,017 in technology license patent maintenance fees. As of June 30, 2013 accounts payable related party was $<font style=" FONT-SIZE: 10pt">10,017</font> for patent maintenance fees, accrued expense related party was $<font style=" FONT-SIZE: 10pt">37,050</font> for MD Anderson clinical trial hospital expense (See Notes 4., 5. and 6.), and accrued license payments related party of $<font style=" FONT-SIZE: 10pt">50,000</font> for past patent expenses. As of June 30, 2012, the Company had $<font style=" FONT-SIZE: 10pt">367,588</font> in research and development expense related party expense comprised of $<font style=" FONT-SIZE: 10pt">345,000</font> for technology license impairment expense (See Note 1.) and $<font style=" FONT-SIZE: 10pt">22,588</font> for siRNA patent expense.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 false0Related PartyfalseRelated PartyUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/RelatedParty12 XML 25 R12.xml IDEA: Accrued Expense 2.4.0.8112 - Disclosure - Accrued Expensetruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accrued Liabilities [Abstract]2false 2us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>5.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Accrued Expense</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, Current Liabilities included accrued expense of $<font style=" FONT-SIZE: 10pt">4,892</font> for clinical trial operations management. Current Liabilities as of June 30, 2013 also included accrued expense related party of $<font style=" FONT-SIZE: 10pt">37,050</font> for MD Anderson clinical trial hospital expense. (See Note 2.). As of December 31, 2012, Current Liabilities included accrued expense of $<font style=" FONT-SIZE: 10pt">137,662</font> and accrued expense related party of $<font style=" FONT-SIZE: 10pt">26,000</font>.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 24 -Article 5 false0Accrued ExpensefalseAccrued ExpenseUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccruedExpense12 XML 26 R25.htm IDEA: XBRL DOCUMENT

Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Additional Paid In Capital For Shares To Be Issued [Line Items]

Common stock issuable shares issuable

2,541,700

Other Additional Capital

$ 0

$ 762,510

^[1]

[1]	Represents 2,541,700 shares of common stock

XML 27 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		74 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (1,083,246)	$ (1,310,065)	$ (13,214,531)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	80,312	96,612	1,057,047
Technology impairment	0	345,000	690,000
Common stock issued for services	0	18,500	318,500
Stock options and warrants	29,557	34,067	3,043,311
(Increase) decrease in assets
Prepaid drug product for testing	(84,180)	(142,477)	(279,180)
Other current assets	(3,836)	1,950	(46,411)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(61,388)	(73,108)	267,856
Net cash used in operating activities	(1,122,781)	(1,029,521)	(8,163,408)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	(25,000)	(884,710)
Net cash used in investing activities	0	(25,000)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	2,515,961	264,709	10,555,344
Net cash from financing activities	2,515,961	264,709	10,975,344
NET INCREASE (DECREASE) IN CASH	1,393,180	(789,812)	1,927,226
Cash, beginning of period	534,046	952,252	0
Cash, end of period	1,927,226	162,440	1,927,226
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	448,950	0	1,040,516
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 1,750	$ 210,755

XML 28 R8.htm IDEA: XBRL DOCUMENT

Organization and Business

6 Months Ended

Jun. 30, 2013

Organization and Business [Abstract]

Organization and Business

1.	Organization and Business

XML 29 R11.xml IDEA: Accounts Payable 2.4.0.8111 - Disclosure - Accounts Payabletruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_AccountsPayableDisclosureAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounts Payable Disclosure [Abstract]2false 2bpth_AccountsPayableDisclosureTextBlockbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>4.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Accounts Payable</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, Current Liabilities included accounts payable of $<font style=" FONT-SIZE: 10pt">165,897</font> comprised primarily of approximate amounts owed to the Company’s drug contract manufacturers totaling $<font style=" FONT-SIZE: 10pt">114,200</font>, $<font style=" FONT-SIZE: 10pt">13,900</font> to several companies involved in research and development testing, <font style="COLOR: black">$<font style=" FONT-SIZE: 10pt">6,800</font> in fees for an industry conference at which the Company will be making a corporate presentation,</font> $<font style=" FONT-SIZE: 10pt">6,000</font> to outside consultants and $<font style=" FONT-SIZE: 10pt">15,900</font> to the Company’s attorneys and auditors. As of June 30, 2013 Current Liabilities included accounts payable related party totaling $<font style=" FONT-SIZE: 10pt">10,017</font> comprised of Technology License patent maintenance fees. (See Note 2.). As of December 31, 2012, Current Liabilities included accounts payable $<font style=" FONT-SIZE: 10pt">57,000</font> and accounts payable related party of $<font style=" FONT-SIZE: 10pt">8,582</font>, which amounts were subsequently paid in 2013.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaAccounts Payable Disclosure [Text Block]No definition available.false0Accounts PayablefalseAccounts PayableUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccountsPayable12 XML 30 R11.htm IDEA: XBRL DOCUMENT

Accounts Payable

6 Months Ended

Jun. 30, 2013

Accounts Payable Disclosure [Abstract]

Accounts Payable

4.	Accounts Payable

XML 31 R14.xml IDEA: Additional Paid In Capital For Shares To Be Issued 2.4.0.8114 - Disclosure - Additional Paid In Capital For Shares To Be Issuedtruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_SharesToBeIssuedAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Shares To Be Issued [Abstract]2false 2bpth_SharesToBeIssuedTextBlockbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>7.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Additional Paid In Capital For Shares To Be Issued</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During 2012 the Company sold shares of common stock for cash to investors in a private placement. As of December 31, 2012, there were <font style=" FONT-SIZE: 10pt">2,541,700</font> shares of common stock remaining to be issued, representing $<font style=" FONT-SIZE: 10pt">762,510</font> in sales to accredited investors. The Company has closed this offering at the end of the first quarter 2013 and subsequently issued the shares of common stock to these investors in the second quarter of 2013.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaShares To Be Issued [Text Block]No definition available.false0Additional Paid In Capital For Shares To Be IssuedfalseAdditional Paid In Capital For Shares To Be IssuedUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AdditionalPaidInCapitalForSharesToBeIssued12 XML 32 R2.xml IDEA: CONSOLIDATED BALANCE SHEETS 2.4.0.8102 - Statement - CONSOLIDATED BALANCE SHEETStruefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 5us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current assets2false 6us-gaap_Cashus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse19272261927226USD$falsetruefalse2truefalsefalse534046534046USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Cash3false 6us-gaap_OtherInventoryus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse279180279180falsefalsefalse2truefalsefalse195000195000falsefalsefalsexbrli:monetaryItemTypemonetaryAmount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 false2Prepaid drug product for testing4false 6us-gaap_OtherAssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse4641146411falsefalsefalse2truefalsefalse4257542575falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 false2Other current assets5false 6us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse22528172252817falsefalsefalse2truefalsefalse771621771621falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true2Total current assets6true 5us-gaap_OtherAssetsNoncurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other assets7false 6us-gaap_FiniteLivedLicenseAgreementsGrossus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse25003742500374falsefalsefalse2truefalsefalse25003742500374falsefalsefalsexbrli:monetaryItemTypemonetaryGross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 false2Technology licenses - related party8false 6us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortizationus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-1008544-1008544falsefalsefalse2truefalsefalse-928231-928231falsefalsefalsexbrli:monetaryItemTypemonetaryAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 false2Less Accumulated Amortization9false 6us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse14918301491830falsefalsefalse2truefalsefalse15721431572143falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 true2Intangible Assets, Net (Excluding Goodwill), Total10false 5us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse37446473744647falsefalsefalse2truefalsefalse23437642343764falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 true2TOTAL ASSETS11true 5us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current liabilities12false 6us-gaap_AccountsPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse165897165897falsefalsefalse2truefalsefalse5700057000falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accounts payable13false 6us-gaap_AccountsPayableRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1001710017falsefalsefalse2truefalsefalse85828582falsefalsefalsexbrli:monetaryItemTypemonetaryAmount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false2Accounts payable - related party14false 6us-gaap_AccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse48924892falsefalsefalse2truefalsefalse137662137662falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued expense15false 6bpth_AccruedLiabilitiesRelatedPartiesCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3705037050falsefalsefalse2truefalsefalse2600026000falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities, Related Parties, CurrentNo definition available.false2Accrued expense - related party16false 6us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2truefalsefalse100000100000falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued license payments - related party17false 6us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse267856267856falsefalsefalse2truefalsefalse329244329244falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true2Total current liabilities18false 5us-gaap_LongTermDebtNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Long term debt19false 5us-gaap_Liabilitiesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse267856267856falsefalsefalse2truefalsefalse329244329244falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 true2TOTAL LIABILITIES20true 5us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Shareholders' Equity21false 6us-gaap_PreferredStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false2Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding22false 6us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7538075380falsefalsefalse2truefalsefalse6221862218falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively23false 6us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1661594216615942falsefalsefalse2truefalsefalse1332107513321075falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional paid in capital24false 6us-gaap_OtherAdditionalCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse762510762510[1]falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional paid-in capital or capital from other sources not otherwise defined. Use this element if the registrant wishes to distinguish between Additional paid-in capital from Other Additional Capital. The following adjustments are some examples of Other Additional Capital: recording the issuance of debt issued with a beneficial conversion feature, the issuance of convertible debt at a substantial premium, certain tax consequences of equity instruments awarded to employees, and accounting for certain expenses and liabilities paid for by the principal shareholder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section T false2Additional paid in capital for shares to be issued25false 6us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-13214531-13214531falsefalsefalse2truefalsefalse-12131283-12131283falsefalsefalsexbrli:monetaryItemTypemonetaryCumulative net losses reported during the development stage.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 210 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921 false2Accumulated deficit during development stage26false 6us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse34767913476791falsefalsefalse2truefalsefalse20145202014520falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true2Total shareholders' equity27false 5us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse37446473744647USD$falsetruefalse2truefalsefalse23437642343764USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2TOTAL LIABILITIES & SHAREHOLDERS' EQUITY1Represents 2,541,700 shares of common stockfalseCONSOLIDATED BALANCE SHEETS (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/ConsolidatedBalanceSheets227 XML 33 R9.htm IDEA: XBRL DOCUMENT

Related Party

6 Months Ended

Jun. 30, 2013

Related Party

2.	Related Party

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

XML 34 R28.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Product Liability Contingency [Line Items]
Estimates reimbursable past patent expenses	$ 75,000
Patent expense per quarter	25,000
Accrued expense - related party	37,050
Other inventory, gross	279,180	195,000
Drug Product Testing Agreement Consideration To Be Paid In Stages	340,000
Drug Product Estimated Cost	165,000
Patented Technology
Product Liability Contingency [Line Items]
Accrued expense - related party	10,017
Technology Licenses
Product Liability Contingency [Line Items]
Accounts payable and accrued liabilities	$ 50,000

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References+ Details

XML 35 R24.xml IDEA: Accrued License Payments - Related Party - Additional Information (Detail) 2.4.0.8124 - Disclosure - Accrued License Payments - Related Party - Additional Information (Detail)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_RelatedPartyTransactionLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Related Party Transaction [Line Items]2false 4us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000USD$falsetruefalse2truefalsefalse100000100000USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued license payments - related partyfalseAccrued License Payments - Related Party - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedPartyAdditionalInformationDetail22 XML 36 R10.xml IDEA: Prepaid Drug Product for Testing 2.4.0.8110 - Disclosure - Prepaid Drug Product for Testingtruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_PrepaidDrugProductForTestingAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Prepaid Drug Product For Testing [Abstract]2false 2bpth_ResearchAndDevelopmentDisclosureTextBlockbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>3.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Prepaid Drug Product for Testing</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future R&D activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $<font style=" FONT-SIZE: 10pt">195,000</font> during 2012 pursuant to a Drug Supply Contract (See Note 10.) for the manufacture and delivery of the Company’s lead drug product for testing in a Phase I clinical trial. This amount was carried on the Balance Sheet as of December 31, 2012 at cost as Prepaid Drug Product for Testing. This product was delivered to the Company in the first quarter of 2013 and costs associated with this drug batch were expensed. Another drug batch was produced in the second quarter of 2013 and installment costs totaling $<font style=" FONT-SIZE: 10pt">279,180</font> are carried on the Balance Sheet as of June 30, 2013 as Prepaid Drug Product for Testing (See Note 10.).</div> </div> falsefalsefalsenonnum:textBlockItemTypenaResearch And Development Disclosure [Text Block]No definition available.false0Prepaid Drug Product for TestingfalsePrepaid Drug Product for TestingUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/PrepaidDrugProductForTesting12 XML 37 R5.xml IDEA: CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) 2.4.0.8105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)truefalsefalse1false USDtruefalse$P04_01_2013To06_30_2013_ResearchAndDevelopmentExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseus-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDtruefalse$P04_01_2012To06_30_2012_ResearchAndDevelopmentExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseus-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDtruefalse$P01_01_2013To06_30_2013_ResearchAndDevelopmentExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseus-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$P01_01_2012To06_30_2012_ResearchAndDevelopmentExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseus-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$P05_10_2007To06_30_2013_ResearchAndDevelopmentExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00falsefalseus-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$P04_01_2013To06_30_2013_GeneralAndAdministrativeExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseus-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$P04_01_2012To06_30_2012_GeneralAndAdministrativeExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseus-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$P01_01_2013To06_30_2013_GeneralAndAdministrativeExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseus-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$P01_01_2012To06_30_2012_GeneralAndAdministrativeExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseus-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$P05_10_2007To06_30_2013_GeneralAndAdministrativeExpenseMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00falsefalseus-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4us-gaap_AllocatedShareBasedCompensationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse82208220USD$falsetruefalse2truefalsefalse1341113411USD$falsetruefalse3truefalsefalse1963319633USD$falsetruefalse4truefalsefalse3081730817USD$falsetruefalse5truefalsefalse442632442632USD$falsetruefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F false2Equity compensation2false 4bpth_ShareBasedCompensationStockOptionAndWarrantExpensebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse53185318falsefalsefalse7truefalsefalse13001300falsefalsefalse8truefalsefalse99239923falsefalsefalse9truefalsefalse32503250falsefalsefalse10truefalsefalse26006792600679falsefalsefalsexbrli:monetaryItemTypemonetaryShare Based Compensation, Stock Option And Warrant ExpenseNo definition available.false2Stock option and warrant expense3false 4bpth_StockBasedCompensationExpenseForServicesbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse318500318500falsefalsefalsexbrli:monetaryItemTypemonetaryStock Based Compensation Expense For ServicesNo definition available.false2Stock for services4false 4us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsepositiveLabel1falsefalsefalse00falsefalsefalse2truefalsefalse345000345000USD$falsetruefalse3falsefalsefalse00falsefalsefalse4truefalsefalse345000345000USD$falsetruefalse5truefalsefalse690000690000USD$falsetruefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false2Technology impairment chargefalseCONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/ConsolidatedStatementsOfOperationsParenthetical104 EXCEL 38 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-#5F-S0Y,5\T83$R7S0V,3)?86$U8U\Q.#,W M-3@U.#-C9#4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]A M;F1?0G5S:6YE#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE M/D%C8W)U961?17AP96YS93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8W)U961?3&EC96YS95]087EM96YT#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O'!E;G-E7T%D9&ET:6]N86Q?26YF/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O6UE;G1S M7U)E;&%T,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D%D9&ET:6]N86Q?4&%I9%]);E]#87!I=&%L7T9O#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B M5V]R:W-H965T&-E M;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X-#5F-S0Y,5\T83$R7S0V,3)?86$U8U\Q.#,W-3@U M.#-C9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#0U9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!);F9O'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA M2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^0DE/+5!!5$@@2$],1$E.1U,@24Y#/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M/B@Q+#`P."PU-#0I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&-L=61I;F<@1V]O9'=I;&PI+"!4;W1A;#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%SF5D(#3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'!E;G-E*3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'!E;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\3L@)#DL.3(S(&%N M9"`D,RPR-3`@9F]R('1H92!S:7@@;6]N=&@@<&5R:6]D3L@86YD("0R+#8P M,"PV-SD@9F]R('1H92!P97)I;V0@9G)O;2!I;F-E<'1I;VX@=&AR;W5G:"`V M+S,P+S(P,3,@9F]R('-T;V-K(&]P=&EO;G,@86YD('=A3L@)#$Y+#8S,R!A M;F0@)#,P+#@Q-R!F;W(@=&AE('-I>"!M;VYT:"!P97)I;V1S(&5N9&EN9R`V M+S,P+S(P,3,@86YD(#8O,S`O,C`Q,BP@2!I;7!A:7)M96YT(&-H87)G M92!F;W(@=&AE('%U87)T97(@86YD('-I>"!M;VYT:"!P97)I;V1S(&5N9&EN M9R`V+S,P+S$R.R!A;F0@)#8Y,"PP,#`@9F]R('1H92!P97)I;V0@9G)O;2!I M;F-E<'1I;VX@=&AR;W5G:"`V+S,P+S(P,3,\+W1D/@T*("`@("`@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PS,3(\'!E;G-E3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X-#5F-S0Y,5\T83$R7S0V,3)?86$U8U\Q.#,W M-3@U.#-C9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#0U9C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE&-H86YG92!#;VUM:7-S:6]N(&%N9"P@('1H M97)E9F]R92P@9&\@;F]T(&EN8VQU9&4@86QL(&EN9F]R;6%T:6]N(&%N9"!F M;V]T;F]T97,@;F5C97-S87)Y("!F;W(@82!C;VUP;&5T92!P2!F;W(@82`@9F%I28C.#(R,3LI(&%S M(&]F(&%N9"!F;W(@('1H92!F:7-C86P@>65A6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO M9&EV/B`@/"]D:78^("`@("`@("`\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!"=7-I;F5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V-L96%R.F)O=&@[=VED=&@Z,3`P M)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<^("`\='(^("`\=&0^/"]T9#X@(#PO M='(^("`\+W1A8FQE/B`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-EF4],T0R/B8C M,38P.SPO9F]N=#X\+V1I=CX@("`@/&1I=B!S='EL93TS1"=C;&5A6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!W:71H(&ET2!I;B`@8VQI;FEC86P@ M=')I86QS+B!4:&4@0V]M<&%N>2!W87,@9F]U;F1E9"!W:71H('1E8VAN;VQO M9WD@9G)O;2!4:&4@(%5N:79E&-L=7-I=F4@;&EC96YS92!A2!F;W(@2P@=VAI M8V@@:&%S('1H92!P;W1E;G1I86P@=&\@8F4@9&5V96QO<&5D('1O(&%U9VUE M;G0@=&AE("!#;VUP86YY)B,X,C$W.W,@8W5R2!T96-H M;F]L;V=Y('1O(&EM<')O=F4@9G5R=&AE2!T;R!I;F-L=61E(&-A;F-E#L@1D].5#H@,3!P="!4:6UE7-P M;&%S=&EC('-Y;F1R;VUE+"!C:')O;FEC(&UY96QO9V5N;W5S(&QE=6ME;6EA M+"!A8W5T92`@;'EM<&AO8FQA6UP:&]M82P@86YD(&EF('-U8V-E2!B92!U6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T2!T;R!C;VUM96YC92!I=',@4&AA#L@1D].5#H@,3!P="!4:6UE2!T;R!D971E2!T96-H;F]L M;V=Y("!D;V5S(&EN(&9A8W0@#L@1D]. M5#H@,3!P="!4:6UE2!B87)R:65R2!F;W(@=&AE("!# M;VUP86YY('1O('1E&EM=6T@<&]T M96YT:6%L(&)E;F5F:70@86YD(&1U6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@)B,Q M-C`[/"]D:78^("`@(#QD:78@7-P;&%S=&EC(%-Y;F1R;VUE("`H3413*2!A;F0@=VAO(&AA=F4@9F%I M;&5D(&]T:&5R(&%P<')O=F5D('1R96%T;65N=',N(%1H97-E(&%R92`@<&%T M:65N=',@=VET:"!V97)Y(&%D=F%N8V5D('-T86=E6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/B`@)B,Q-C`[/"]D:78^("`@(#QD:78@'!E8W1E9"`@86YD(&-L:6YI8V%L;'D@:6YT97)E2`@;V8@2&5M871O;&]G M>2!A;FYU86P@;65E=&EN9R!I;B!$96-E;6)E6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`@=&\@87-S97-S(&9O2!P;&%T9F]R;2!I;B!H=6UA;B!P871I96YT M7,@ M=&\@8F4@86)L92!T;R!P6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`@)B,Q-C`[/"]D:78^("`@(#QD:78@ M2!T96-H;F]L;V=Y(&%C:&EE=F5D(&$@(&UA M:F]R(&UI;&5S=&]N92!I;B!T:&4@9&5V96QO<&UE;G0@;V8@86YT:7-E;G-E M('1H97)A<&5U=&EC2`@:6X@8V]M8FEN871I M;VX@=VET:"!C=7)R96YT(&9R;VYT;&EN92!T2`@86QS;R!P;VEN=',@=&\@=&AE('!O=&5N=&EA;"!U2!A(&QA8VL@;V8@82!S>7-T96UI8R`@9&5L:79E M2!D:7-T'!E M8W0@=&AA="`@2!T96-H;F]L;V=Y(&UA>2!L96%D("!T;R!L:6-E;G-I;F<@ M86YD(&)U6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!I M;B!T:&ES('-T=61Y('=I;&P@86QL;W<@=&AE($-O;7!A;GD@=&\@8F5G:6X@ M(&5X<&%N9&EN9R!":6\M4&%T:"8C.#(Q-SMS(&1R=6<@8V%N9&ED871E2!S:6UP;'D@87!P;'EI;F<@=&AE("!D96QI=F5R>2!T96-H;F]L;V=Y('1E M;7!L871E('1O(&UU;'1I<&QE(&YE=R!D2!B=6EL9"!A M;B!A='1R86-T:79E(&1R=6<@('!R;V1U8W0@<&EP96QI;F4@=VET:"!M=6QT M:7!L92!D2P@=&AE($-O;7!A;GD@:7,@2`@=&5C:&YO;&]G>2X\+V1I=CX@("`@/&1I M=B!S='EL93TS1"=C;&5A6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2!E;F1E9"!W:&5N(&$@;6%X:6UU;2`@=&]L97)A=&5D(&1O#L@1D].5#H@,3!P="!4:6UEF4@<&QA;G,@9F]R(%!H87-E($E)(&-L:6YI8V%L('1R:6%L#L@1D]. M5#H@,3!P="!4:6UE2P@=&AE(&%M;W5N="!O9B!D979E;&]P;65N="!T:&%T('=O=6QD(&)E(&YE M961E9"!A;F0@=&AE("!O=F5R86QL(&EM<')E2!M87)K970@:6YV97-T M;W)S+B!4:&4@0F]A2!A;F0@82!M=6-H(&5A2X@4VEN8V4@8F]T:"!A;G1I2!T:&4@ M;&EC96YS92!T;R!I;F-L=61E(&]T:&5R('!R;V1U8W1S+"`@<&]S='!O;F4@ M=&AE(&QI8V5N2!T;V]K(&$@(&-H87)G92!O9B`D M/&9O;G0@2!F:69T>2!P97)C96YT("@\9F]N="!S M='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXU,#PO9F]N=#XE*2X@5&AI6EN9R!V86QU92!O9B!T:&4@#L@1D].5#H@,3!P="!4 M:6UE2!W M87,@9F]U;F1E9"!I;B!-87D@;V8@,C`P-R!A2!O9B`R,#`X+"!":6\M4&%T:"!C;VUP;&5T960@ M82!R979E2!T6UB;VP@3U1#0D(Z M($)05$@I("!A2!A;F0@=6YD97)T86MI;F<@('!R;V1U8W0@9&5V96QO<&UE;G0@9F]R M(&$@;&EM:71E9"!N=6UB97(@;V8@<')O9'5C="!C86YD:61A=&5S("!I;F-L M=61I;F<@#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/C$L.3(W+#(R-CPO9F]N=#X@:6X@8V%S:"!O M;B!H86YD+B!$=7)I;F<@=&AE("!S96-O;F0@<75A2!R96-E:79E9"!A<'!R;WAI;6%T96QY("0\9F]N="`@2!H87,@ M2!I;B!H M=6UA;B`@<&%T:65N=',N/"]D:78^("`@(#QD:78@#L@1D]. M5#H@,3!P="!4:6UE2!H87,@;F]T(&)E9W5N(&ET6EN9R!F:6YA;F-I86P@('-T871E;65N M=',@:&%V92!B965N('!R97!A7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V-L96%R.F)O=&@[=VED=&@Z,3`P)3L@=&%B;&4M;&%Y M;W5T.F9I>&5D.R<^("`\='(^("`\=&0^/"]T9#X@(#PO='(^("`\+W1A8FQE M/B`@("`\9&EV('-T>6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M=#L@1D].5"U325I%.B`Q,'!T)SX@(#QT86)L92!S='EL93TS1"=C;&5A6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`@/'1D('-T>6QE/3-$ M)U=)1%1(.B`P+C(U:6XG/B`@/&1I=CX\8CXR+CPO8CX\+V1I=CX@(#PO=&0^ M("`\=&0^("`\9&EV/CQB/E)E;&%T960@4&%R='D\+V(^/"]D:78^("`\+W1D M/B`@/"]T2P@340@06YD97)S;VX@0V%N8V5R("!#96YT97(@;65E=',@=&AE M(&-R:71E2!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS92!W87,@)#QF;VYT M("!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXS,BPP-C<\+V9O;G0^(&%N M9"`D/&9O;G0@'!E;G-E M(&]F("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXR,BPP-3`\ M+V9O;G0^("!A;F0@)#$P+#`Q-R!I;B!T96-H;F]L;V=Y(&QI8V5N6%B;&4@2!W87,@)#QF;VYT('-T>6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P+#`Q-SPO9F]N=#X@9F]R('!A=&5N M="!M86EN=&5N86YC92!F965S+"`@86-C'!E;G-E(')E;&%T960@ M<&%R='D@=V%S("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXS M-RPP-3`\+V9O;G0^(&9O'!E;G-E2!E>'!E;G-E M(&-O;7!R:7-E9"!O9B`D/&9O;G0@'!E;G-E("A3964@3F]T92`Q+BD@86YD("0\9F]N="!S='EL M93TS1"<@1D].5"U325I%.B`Q,'!T)SXR,BPU.#@\+V9O;G0^(&9O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-#5F-S0Y,5\T M83$R7S0V,3)?86$U8U\Q.#,W-3@U.#-C9#4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.#0U9C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^("`@("`@("`@("`@("`\=&%B;&4@ M8F]R9&5R/3-$,"!S='EL93TS1"=C;&5A6]U=#IF:7AE9#LG/B`@/'1R/B`@/'1D/CPO=&0^("`\+W1R/B`@ M/"]T86)L93X@("`@/&1I=B!S='EL93TS1"=C;&5A#L@1D].5#H@,3!P="!4:6UE"<@ M("!C96QL6QE M/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U=)1%1(.B`P:6XG/CPO=&0^("`\=&0@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6UE;G1S+"!I;F-L=61I;F<@;F]N MF5D+B!3 M=6-H(&%M;W5N=',@=VEL;"!B92`@'!E;G-E M(&%S('1H92!R96QA=&5D(&=O;V1S(&%R92!D96QI=F5R960@;W(@=&AE("!R M96QA=&5D('-E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$Y-2PP,#`\ M+V9O;G0^(&1U2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&QE860@9')U M9R!P'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6%B;&4@ M1&ES8VQO6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA6QE/3-$)V-L M96%R.F)O=&@[34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/C8L.#`P/"]F;VYT/B!I;B!F965S(&9O2`@8V]N9F5R96YC92!A="!W:&EC:"!T:&4@0V]M<&%N>2!W M:6QL(&)E(&UA:VEN9R!A(&-O6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C8L,#`P/"]F M;VYT/B`@=&\@;W5T6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$U+#DP,#PO9F]N=#X@=&\@=&AE($-O M;7!A;GDF(S@R,3<[7,@(&%N9"!A=61I=&]R6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P+#`Q-SPO9F]N=#X@8V]M M<')I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-#5F-S0Y,5\T83$R7S0V,3)? M86$U8U\Q.#,W-3@U.#-C9#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.#0U9C'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)V-L96%R.F)O=&@[ M34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%=)1%1(.B`P+C(U:6XG/B`@/&1I=CX\8CXU+CPO8CX\+V1I M=CX@(#PO=&0^("`\=&0@2<^ M("`\9&EV/CQB/D%C8W)U960@17AP96YS93PO8CX\+V1I=CX@(#PO=&0^("`\ M+W1R/B`@/"]T86)L93X@(#PO9&EV/B`@("`\9&EV('-T>6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E("!O9B`D/&9O;G0@'!E;G-E(')E;&%T960@ M<&%R='D@;V8@)#QF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,W M+#`U,#PO9F]N=#X@9F]R($U$($%N9&5R'!E;G-E+B`H4V5E($YO=&4@,BXI+B!!'!E;G-E(&]F("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q M,'!T)SXQ,S'!E;G-E(')E;&%T M960@<&%R='D@(&]F("0\9F]N="!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T M)SXR-BPP,#`\+V9O;G0^+CPO9&EV/B`@/"]D:78^("`@("`@("`\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6UE;G1S("T@ M4F5L871E9"!087)T>3QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V-L96%R M.F)O=&@[=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<^("`\='(^ M("`\=&0^/"]T9#X@(#PO='(^("`\+W1A8FQE/B`@("`\9&EV('-T>6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U325I%.B`Q,'!T M)SX@(#QT86)L92!S='EL93TS1"=C;&5A#L@1D].5#H@,3!P="!4:6UE3L@ M5D525$E#04PM04Q)1TXZ('1O<"<^("`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@1D].5#H@,3!P="!4:6UE6UE;G1S(')E;&%T960@<&%R M='D@=&]T86QI;F<@)#QF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C4P+#`P,#PO9F]N=#X@86YD("0\9F]N="!S='EL93TS1"<@1D].5"U325I% M.B`Q,'!T)SXQ,#`L,#`P/"]F;VYT/B!W97)E(&EN8VQU9&5D(&EN($-U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V-L M96%R.F)O=&@[34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P+C(U:6XG/B`@/&1I=CX\8CXW M+CPO8CX\+V1I=CX@(#PO=&0^("`\=&0@2<^("`\9&EV/CQB/D%D9&ET:6]N86P@4&%I9"!);B!#87!I=&%L M($9O6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!H87,@8VQO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!. M;W1E(%M!8G-T3PO6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2X@($EN($%U9W5S="!O9B`R,#`W+"!T:&4@ M0V]M<&%N>2!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/CDY,RPW-3`\ M+V9O;G0^(&EN(&-A2!P M=7)S=6%N="!T;R!A('!R:79A=&4@<&QA8V5M96YT(&UE;6]R86YD=6TN($EN M("!!=6=U2!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C4S,"PX M,S,\+V9O;G0^(&EN("!C;VUM;VX@#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UE2!O9B`R,#`X+"!T:&4@ M0V]M<&%N>2!C;VUP;&5T960@82!R979E6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,X+#`R,RPU-S@\+V9O;G0^('-H87)E M2!":6\M M4&%T:"!(;VQD:6YG&-H86YG92!F;W(@<')E+6UE6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,L-C`P+#`P,#PO9F]N M=#X@&5C=71E9"`@86=R965M96YT'!E;G-E9"!U<&9R;VYT(&%S(&-O;6UO;B!S=&]C:R!F;W(@6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/B`@,C0\+V9O;G0^('-H87)E6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$P,"PP,#`\+V9O;G0^('-H87)E2!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$V M-2PP,#`\+V9O;G0^(&EN("!C87-H('1O(&EN=F5S=&]R2!P=7)S=6%N="!T;R!A('!R:79A=&4@<&QA8V5M96YT("!M96UO&5R8VES960@=VET:&EN('1W M;R!Y96%R6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/C$N-3`\+V9O;G0^(&$@6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C8V+#`P,#PO9F]N=#X@6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!S;VQD('-H87)E6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G M/C8W-2PP,#`\+V9O;G0^/"]F;VYT/B!I;B!C87-H('1O(&EN=F5S=&]R2!T:&4@1&5C96UB97(@ M,S$L(#(P,#D@>65A6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C(L-S`P M+#`P,#PO9F]N=#X@6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$N-3`\ M+V9O;G0^(&$@('-H87)E+B!);B!C;VYN96-T:6]N('=I=&@@=&AE6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,V,"PP M,#`\+V9O;G0^("!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O('1H92!0;&%C M96UE;G0@06=E;G0@87,@8V]M;6ES6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B`R,#$P+"!T:&4@0V]M<&%N>2!I6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C(W,RPP,#`\+V9O M;G0^(&EN("!C87-H('1O(&EN=F5S=&]R2!P=7)S M=6%N="!T;R!A('!R:79A=&4@<&QA8V5M96YT("!M96UO&5R8VES960@=VET:&EN('1W;R!Y96%R6QE/3-$)R!&3TY4+5-) M6D4Z(#$P<'0G/C$N-3`\+V9O;G0^(&$@6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C2!S:6=N960@86X@97%U:71Y('!U M6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X@86YD("0\9F]N="!S='EL93TS M1"<@1D].5"U325I%.B`Q,'!T)SXQ+#`P,"PP,#`\+V9O;G0^('5P('1O(&%N M(&%G9W)E9V%T92!A;6]U;G0@;V8@)#<@(&UI;&QI;VX@9&5P96YD:6YG('5P M;VX@8V5R=&%I;B!C;VYD:71I;VYS('-E="!F;W)T:"!I;B!T:&4@<'5R8VAA M2!T:&4@52Y3+B!396-U2`@=&AE(%-%0R!O M;B!*=6QY(#$R+"`R,#$P+B!5<&]N('-I9VYI;F<@=&AE(&%G&-H86YG92!F;W(@/&9O;G0@28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A;F0@=V%R6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C4W M,2PT,CD\+V9O;G0^('-H87)E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$N-3`\+V9O;G0^('!E#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/C8L,C4Q/"]F;VYT/B!S:&%R97,@;V8@=&AE($-O;7!A M;GDF(S@R,3<[6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C,W-2PP,#`\+V9O;G0^('-H M87)E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!R96-E:79E M9"`D/&9O;G0@&-H86YG92!F;W(@/&9O;G0@('-T>6QE/3-$ M)R!&3TY4+5-)6D4Z(#$P<'0G/C$R-2PP,#`\+V9O;G0^('-H87)E6QE/3-$ M)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X@9G)O;2!,4$,@ M:6X@97AC:&%N9V4@9F]R(#QF;VYT("!S='EL93TS1"<@1D].5"U325I%.B`Q M,'!T)SXQ,S4L,3,U/"]F;VYT/B!S:&%R97,@;V8@=&AE("!#;VUP86YY)B,X M,C$W.W,@8V]M;6]N('-T;V-K+B!,4$,@=V%S(&%L6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C(L,#@T/"]F;VYT/B!S:&%R M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!R96-E:79E9"`D/&9O;G0@&-H86YG92!F M;W(@/&9O;G0@('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$S-2PQ,S4\ M+V9O;G0^('-H87)E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S M=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$L-SDT M+#(P-3PO9F]N=#X@(&EN(&-A6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/B`@-2PY.#`L-C@U/"]F;VYT/B!S:&%R97,@;V8@8V]M M;6]N('-T;V-K('1O('1H97-E(&EN=F5S=&]R2!W97)E(&ES6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)R!& M3TY4+5-)6D4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X@9G)O;2!,4$,@:6X@97AC M:&%N9V4@9F]R(#QF;VYT("!S='EL93TS1"<@1D].5"U325I%.B`Q,'!T)SXQ M-C0L.#4S/"]F;VYT/B!S:&%R97,@;V8@=&AE("!#;VUP86YY)B,X,C$W.W,@ M8V]M;6]N('-T;V-K+B!,4$,@=V%S(&%L6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C(L,#@T/"]F;VYT/B!S:&%R97,@;V8@ M=&AE($-O;7!A;GDF(S@R,3<[2!W97)E(&ES#L@1D].5#H@,3!P="!4:6UE M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE2!R96-E:79E9"`D/&9O;G0@ M&-H86YG92!F;W(@.#,L,S,S("!S:&%R97,@;V8@=&AE($-O M;7!A;GDF(S@R,3<[28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!A6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C4P+#`P,#PO9F]N=#X@9G)O;2!,4$,@ M:6X@97AC:&%N9V4@9F]R(#QF;VYT("!S='EL93TS1"<@1D].5"U325I%.B`Q M,'!T)SXQ-S(L-#$T/"]F;VYT/B!S:&%R97,@;V8@=&AE("!#;VUP86YY)B,X M,C$W.W,@8V]M;6]N('-T;V-K+B!,4$,@=V%S(&%L6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C(L,#@T/"]F;VYT/B!S:&%R M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!R96-E:79E9"`D/&9O;G0@&-H86YG92!F;W(@ M/&9O;G0@('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$V-BPV-C<\+V9O M;G0^('-H87)E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF M>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE M/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE M/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/C$L,#0R/"]F;VYT/B!S:&%R97,@;V8@ M=&AE($-O;7!A;GDF(S@R,3<[&-H86YG92`@ M9F]R(#QF;VYT('-T>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/CDV+#$U-#PO M9F]N=#X@28C.#(Q-SMS(&-O;6UO;B!S M=&]C:RX@3%!#('=A2P@=&AE($-O;7!A M;GD@&-H86YG92!F;W(@(#QF;VYT('-T M>6QE/3-$)R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)R!&3TY4 M+5-)6D4Z(#$P<'0G/B`@,3@U+#$X-3PO9F]N=#X\+V9O;G0^('-H87)E28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@($Q00R!W87,@ M86QS;R!I2!W97)E("!I M2!S;VQD("0\9F]N="!S='EL93TS1"<@1D]. M5"U325I%.B`Q,'!T)SXQ-3`L,#`P/"]F;VYT/B!I;B!S:&%R97,@;V8@:71S M(&-O;6UO;B!S=&]C:R`@<'5R6QE/3-$)V-L96%R M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V-L96%R.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U! M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!I6QE/3-$)V-L96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)V-L M96%R.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE XML 39 R4.xml IDEA: CONSOLIDATED STATEMENTS OF OPERATIONS 2.4.0.8104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONStruefalsefalse1false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsetruefalse2truefalsefalse00USD$falsetruefalse3truefalsefalse00USD$falsetruefalse4truefalsefalse00USD$falsetruefalse5truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Revenue2true 4us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating expense3false 5us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse240543240543[1]USD$falsefalsefalse2truefalsefalse252168252168[1]USD$falsefalsefalse3truefalsefalse480354480354[1]USD$falsefalsefalse4truefalsefalse483482483482[1]USD$falsefalsefalse5truefalsefalse75398177539817[1]USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2General & administrative4false 5us-gaap_OperatingExpensesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse428646428646USD$falsefalsefalse2truefalsefalse787782787782USD$falsefalsefalse3truefalsefalse10845561084556USD$falsefalsefalse4truefalsefalse13104091310409USD$falsefalsefalse5truefalsefalse1353323613533236USD$falsefalsefalsexbrli:monetaryItemTypemonetaryGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.No definition available.false2Total operating expense5false 4us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-428646-428646USD$falsefalsefalse2truefalsefalse-787782-787782USD$falsefalsefalse3truefalsefalse-1084556-1084556USD$falsefalsefalse4truefalsefalse-1310409-1310409USD$falsefalsefalse5truefalsefalse-13533236-13533236USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true2Net operating loss6true 4us-gaap_NonoperatingIncomeExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other income (expense)7false 5us-gaap_InvestmentIncomeInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse15311531USD$falsefalsefalse2truefalsefalse213213USD$falsefalsefalse3truefalsefalse16551655USD$falsefalsefalse4truefalsefalse742742USD$falsefalsefalse5truefalsefalse7874478744USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Interest income8false 5us-gaap_OtherNonoperatingIncomeus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse00USD$falsefalsefalse4truefalsefalse00USD$falsefalsefalse5truefalsefalse244479244479USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 false2Other income9false 5us-gaap_OtherNonoperatingExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-129-129USD$falsefalsefalse2truefalsefalse-269-269USD$falsefalsefalse3truefalsefalse-345-345USD$falsefalsefalse4truefalsefalse-398-398USD$falsefalsefalse5truefalsefalse-4518-4518USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Other expense10false 5us-gaap_NonoperatingIncomeExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse14021402USD$falsefalsefalse2truefalsefalse-56-56USD$falsefalsefalse3truefalsefalse13101310USD$falsefalsefalse4truefalsefalse344344USD$falsefalsefalse5truefalsefalse318705318705USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true2Total Other Income (Expense)11false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-427244-427244USD$falsefalsefalse2truefalsefalse-787838-787838USD$falsefalsefalse3truefalsefalse-1083246-1083246USD$falsefalsefalse4truefalsefalse-1310065-1310065USD$falsefalsefalse5truefalsefalse-13214531-13214531USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 true2Net Loss12true 4us-gaap_EarningsPerShareAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Loss per share13false 5us-gaap_EarningsPerShareBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-0.01-0.01USD$falsetruefalse2truefalsefalse-0.01-0.01USD$falsetruefalse3truefalsefalse-0.02-0.02USD$falsetruefalse4truefalsefalse-0.02-0.02USD$falsetruefalse5truefalsefalse-0.28-0.28USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.No definition available.false3Net loss per share, basic and diluted14false 4us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse6660610566606105falsefalsefalse2truefalsefalse5886871358868713falsefalsefalse3truefalsefalse6441257764412577falsefalsefalse4truefalsefalse5862506658625066falsefalsefalse5truefalsefalse4753437747534377falsefalsefalsexbrli:sharesItemTypesharesAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).No definition available.false1Basic and diluted weighted average number of common shares outstanding15false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6false USDtruefalse$P04_01_2013To06_30_2013_AllOtherMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseAll Otherus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_AllOtherMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0All Other16true 4us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating expense17false 5us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse156036156036[2]USD$falsefalsefalse2truefalsefalse168026168026[2]USD$falsefalsefalse3truefalsefalse557135557135[2]USD$falsefalsefalse4truefalsefalse447639447639[2]USD$falsefalsefalse5truefalsefalse48827324882732[2]USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development18false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse11false USDtruefalse$P04_01_2013To06_30_2013_RelatedPartyTransactionsMemberusgaapStatementScenarioAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson for Licenseus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_RelatedPartyTransactionsMemberus-gaap_StatementScenarioAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0MD Anderson for License19true 4us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating expense20false 5us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3206732067[3]USD$falsetruefalse2truefalsefalse367588367588[3]USD$falsetruefalse3truefalsefalse4706747067[3]USD$falsetruefalse4truefalsefalse379288379288[3]USD$falsetruefalse5truefalsefalse11106871110687[3]USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and development1General & administrative expense includes stock for services, stock option and warrant expenses of $5,318 and $1,300 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $9,923 and $3,250 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $2,600,679 for the period from inception through 6/30/2013 for stock options and warrants and $318,500 in stock for services.2Research and development expense includes stock option expenses of $8,220 and $13,411 for the quarters ending 6/30/2013 and 6/30/2012, respectively; $19,633 and $30,817 for the six month periods ending 6/30/2013 and 6/30/2012, respectively; and $442,632 for the period from inception through 6/30/20133Includes $345,000 technology impairment charge for the quarter and six month periods ending 6/30/12; and $690,000 for the period from inception through 6/30/2013falseCONSOLIDATED STATEMENTS OF OPERATIONS (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/ConsolidatedStatementsOfOperations520 XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 108 134 1 true 31 0 false 6 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.biopathholdings.com/role/DocumentAndEntityInformation Document And Entity Information R1.xml true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.biopathholdings.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS R2.xml false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.biopathholdings.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) R3.xml false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.biopathholdings.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS R4.xml false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.biopathholdings.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) R5.xml false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.biopathholdings.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS R6.xml false false R7.htm 107 - Disclosure - Basis of Presentation Sheet http://www.biopathholdings.com/role/BasisOfPresentation Basis of Presentation R7.xml false false R8.htm 108 - Disclosure - Organization and Business Sheet http://www.biopathholdings.com/role/OrganizationAndBusiness Organization and Business R8.xml false false R9.htm 109 - Disclosure - Related Party Sheet http://www.biopathholdings.com/role/RelatedParty Related Party R9.xml false false R10.htm 110 - Disclosure - Prepaid Drug Product for Testing Sheet http://www.biopathholdings.com/role/PrepaidDrugProductForTesting Prepaid Drug Product for Testing R10.xml false false R11.htm 111 - Disclosure - Accounts Payable Sheet http://www.biopathholdings.com/role/AccountsPayable Accounts Payable R11.xml false false R12.htm 112 - Disclosure - Accrued Expense Sheet http://www.biopathholdings.com/role/AccruedExpense Accrued Expense R12.xml false false R13.htm 113 - Disclosure - Accrued License Payments - Related Party Sheet http://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedParty Accrued License Payments - Related Party R13.xml false false R14.htm 114 - Disclosure - Additional Paid In Capital For Shares To Be Issued Sheet http://www.biopathholdings.com/role/AdditionalPaidInCapitalForSharesToBeIssued Additional Paid In Capital For Shares To Be Issued R14.xml false false R15.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.biopathholdings.com/role/StockholdersEquity Stockholders' Equity R15.xml false false R16.htm 116 - Disclosure - Stock Options and Warrants Sheet http://www.biopathholdings.com/role/StockOptionsAndWarrants Stock Options and Warrants R16.xml false false R17.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.biopathholdings.com/role/CommitmentsAndContingencies Commitments and Contingencies R17.xml false false R18.htm 118 - Disclosure - Subsequent Events Sheet http://www.biopathholdings.com/role/SubsequentEvents Subsequent Events R18.xml false false R19.htm 119 - Disclosure - Organization and Business - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/OrganizationAndBusinessAdditionalInformationDetail Organization and Business - Additional Information (Detail) R19.xml false false R20.htm 120 - Disclosure - Related Party - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/RelatedPartyAdditionalInformationDetail Related Party - Additional Information (Detail) R20.xml false false R21.htm 121 - Disclosure - Prepaid Drug Product for Testing - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/PrepaidDrugProductForTestingAdditionalInformationDetail Prepaid Drug Product for Testing - Additional Information (Detail) R21.xml false false R22.htm 122 - Disclosure - Accounts Payable - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccountsPayableAdditionalInformationDetail Accounts Payable - Additional Information (Detail) R22.xml false false R23.htm 123 - Disclosure - Accrued Expense - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccruedExpenseAdditionalInformationDetail Accrued Expense - Additional Information (Detail) R23.xml false false R24.htm 124 - Disclosure - Accrued License Payments - Related Party - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedPartyAdditionalInformationDetail Accrued License Payments - Related Party - Additional Information (Detail) R24.xml false false R25.htm 125 - Disclosure - Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/AdditionalPaidInCapitalForSharesToBeIssuedAdditionalInformationDetail Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) R25.xml false false R26.htm 126 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) R26.xml false false R27.htm 127 - Disclosure - Stock Options and Warrants - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/StockOptionsAndWarrantsAdditionalInformationDetail Stock Options and Warrants - Additional Information (Detail) R27.xml false false R28.htm 128 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) R28.xml false false R29.htm 129 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.biopathholdings.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) R29.xml false false All Reports Book All Reports Element bpth_StockCommittedToBeIssuedDuringPeriodValueAcquisitions had a mix of decimals attribute values: -6 0. Element us-gaap_ProceedsFromIssuanceOfPrivatePlacement had a mix of decimals attribute values: -6 -5. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'May 09, 2007' Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Process Flow-Through: Removing column '6 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '6 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2011' Process Flow-Through: Removing column '74 Months Ended Jun. 30, 2013' Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS bpth-20130630.xml bpth-20130630.xsd bpth-20130630_cal.xml bpth-20130630_def.xml bpth-20130630_lab.xml bpth-20130630_pre.xml true true XML 41 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	75,380,214	62,219,050
Common Stock, shares outstanding	75,380,214	62,219,050
Additional paid in capital for shares to be issued, shares of common stock		2,541,700

XML 42 R14.htm IDEA: XBRL DOCUMENT

Additional Paid In Capital For Shares To Be Issued

6 Months Ended

Jun. 30, 2013

Shares To Be Issued [Abstract]

Additional Paid In Capital For Shares To Be Issued

Additional Paid In Capital For Shares To Be Issued

XML 43 R20.xml IDEA: Related Party - Additional Information (Detail) 2.4.0.8120 - Disclosure - Related Party - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2011To12_31_2011http://www.sec.gov/CIK0001133818duration2011-01-01T00:00:002011-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$P01_01_2013To06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$P01_01_2012To06_30_2012_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$PAsOn06_30_2013_ClinicalTrialsMemberbpthComponentOfOtherOperatingCostAndExpensesAxis_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseClinical Trials [Member]bpth_ComponentOfOtherOperatingCostAndExpensesAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ClinicalTrialsMemberbpth_ComponentOfOtherOperatingCostAndExpensesAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$P04_01_2013To06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$P04_01_2012To06_30_2012_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$PAsOn06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TechnologyLicensesMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseTechnology Licensesus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldibpth_TechnologyLicensesMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_RelatedPartyTransactionLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Related Party Transaction [Line Items]2false 4bpth_AccruedLiabilitiesRelatedPartiesCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3705037050USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3705037050USD$falsetruefalse5truefalsefalse2600026000USD$falsetruefalse6truefalsefalse3705037050USD$falsetruefalse7falsefalsefalse00falsefalsefalse8truefalsefalse2205022050USD$falsetruefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities, Related Parties, CurrentNo definition available.false2Accrued expense - related party3false 4us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse5000050000falsefalsefalse5truefalsefalse100000100000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued license payments - related party4false 4us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse3206732067falsefalsefalse10truefalsefalse367588367588falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryExpenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false2Cash paid to MD Anderson Cancer Center for expenses5false 4us-gaap_AccountsPayableRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1001710017falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1001710017falsefalsefalse5truefalsefalse85828582falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse1001710017falsefalsefalsexbrli:monetaryItemTypemonetaryAmount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false2Accounts payable - related party6false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse367588367588falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false2Research and Development Expense7false 4us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2truefalsefalse345000345000falsefalsefalse3truefalsefalse345000345000falsefalsefalse4truefalsefalse690000690000falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse345000345000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false2Technology impairment8false 4bpth_PatentExpensebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse2258822588USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPatent ExpenseNo definition available.false2Patent ExpensefalseRelated Party - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/RelatedPartyAdditionalInformationDetail118 XML 44 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	3 Months Ended		6 Months Ended		74 Months Ended	3 Months Ended		6 Months Ended		74 Months Ended
	Jun. 30, 2013 Research and Development Expense	Jun. 30, 2012 Research and Development Expense	Jun. 30, 2013 Research and Development Expense	Jun. 30, 2012 Research and Development Expense	Jun. 30, 2013 Research and Development Expense	Jun. 30, 2013 General and Administrative Expense	Jun. 30, 2012 General and Administrative Expense	Jun. 30, 2013 General and Administrative Expense	Jun. 30, 2012 General and Administrative Expense	Jun. 30, 2013 General and Administrative Expense
Equity compensation	$ 8,220	$ 13,411	$ 19,633	$ 30,817	$ 442,632
Stock option and warrant expense						5,318	1,300	9,923	3,250	2,600,679
Stock for services										318,500
Technology impairment charge		$ 345,000		$ 345,000	$ 690,000

XML 45 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (USD $)

Jun. 30, 2013

Dec. 31, 2012

Current assets

Cash

$ 1,927,226

$ 534,046

Prepaid drug product for testing

279,180

195,000

Other current assets

46,411

42,575

Total current assets

2,252,817

771,621

Other assets

Technology licenses - related party

2,500,374

Less Accumulated Amortization

(1,008,544)

(928,231)

Intangible Assets, Net (Excluding Goodwill), Total

1,491,830

1,572,143

TOTAL ASSETS

3,744,647

2,343,764

Current liabilities

Accounts payable

165,897

57,000

Accounts payable - related party

10,017

8,582

Accrued expense

4,892

137,662

Accrued expense - related party

37,050

26,000

Accrued license payments - related party

50,000

100,000

Total current liabilities

267,856

329,244

Long term debt

TOTAL LIABILITIES

267,856

329,244

Shareholders' Equity

Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding

Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 6/30/13 and 12/31/12, respectively

75,380

62,218

Additional paid in capital

16,615,942

13,321,075

Additional paid in capital for shares to be issued

762,510

^[1]

Accumulated deficit during development stage

(13,214,531)

(12,131,283)

Total shareholders' equity

3,476,791

2,014,520

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY

$ 3,744,647

$ 2,343,764

[1]	Represents 2,541,700 shares of common stock

XML 46 R7.xml IDEA: Basis of Presentation 2.4.0.8107 - Disclosure - Basis of Presentationtruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_BasisOfPresentationAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Basis Of Presentation [Abstract]2false 2us-gaap_BasisOfAccountingus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended June 30, 2013, are not necessarily indicative of the results for a full-year period.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).No definition available.false0Basis of AccountingfalseBasis of PresentationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/BasisOfPresentation12 XML 47 R17.xml IDEA: Commitments and Contingencies 2.4.0.8117 - Disclosure - Commitments and Contingenciestruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_CommitmentsAndContingenciesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Commitments and Contingencies Disclosure [Abstract]2false 2us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><b>10.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Commitments and Contingencies</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <b><i> </i></b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Technology License  Related Party -</i></b> The Company has negotiated exclusive licenses from the MD Anderson Cancer Center to develop drug delivery technology for antisense and siRNA drug products. These licenses require, among other things, the Company to reimburse MD Anderson for ongoing patent expense. Related party accounts payable of $<font style=" FONT-SIZE: 10pt">10,017</font> for patent expenses for the Technology License, and accrued license payments attributable to the Technology License totaling $<font style=" FONT-SIZE: 10pt">50,000</font> are included in Current Liabilities as of June 30, 2013. Related party accrued expense totaling $<font style=" FONT-SIZE: 10pt">37,050</font> as of June 30, 2013 represents hospital costs for the clinical trial and are not related to the Technology License. As of June 30, 2013, the Company estimates reimbursable past patent expenses will total approximately $<font style=" FONT-SIZE: 10pt">75,000</font> for the Technology License. The Company will be required to pay when invoiced the past patent expenses at the rate of $<font style=" FONT-SIZE: 10pt">25,000</font> per quarter. In addition, the Company decided to discontinue development of its siRNA technology and subsequently canceled its siRNA license in June of 2012 (See Note 1).</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Drug Supplier Project Plan</i></b> - In August of 2012, Bio-Path entered into two project plan agreements with the Company’s drug substance manufacturer and its final drug product manufacturer for the manufacture and delivery of final drug product incorporating the drug substance for expected delivery in the fourth quarter of 2012, with delivery subsequently revised to the first quarter of 2013. The project plans required the Company to pay approximately $<font style=" FONT-SIZE: 10pt">340,000</font> in various stages as the drug substance and product are manufactured and delivered to the Company. Of this amount, $<font style=" FONT-SIZE: 10pt">195,000</font> was paid for or owed by the Company and was carried on the Balance Sheet as of December 31, 2012 as Prepaid Drug Product for Testing. The drug product was delivered to the Company in the first quarter of 2013 and the Balance Sheet item Prepaid Drug Product for Testing totaling $195,000 was expensed in the first quarter 2013. Amounts owed to the Company’s manufacturers for this drug batch have been paid subsequent to year end. In addition, the Company signed another supply agreement in the first quarter of 2013 for a subsequent batch of drug product and a supply agreement with the drug substance supplier in the second quarter of 2013. Installment payments paid or in accounts payable to the Company’s drug manufacturers totaling $<font style=" FONT-SIZE: 10pt">279,180</font> are being carried at cost on the Balance Sheet as of June 30, 2013 as Prepaid Drug Product for testing. A new supply agreement was signed for drug product for delivery in the fourth quarter of 2013, which is estimated to cost $<font style=" FONT-SIZE: 10pt">165,000</font>.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 false0Commitments and ContingenciesfalseCommitments and ContingenciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/CommitmentsAndContingencies12 XML 48 R16.xml IDEA: Stock Options and Warrants 2.4.0.8116 - Disclosure - Stock Options and Warrantstruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_StockOptionsAndWarrantsAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stock Options and Warrants [Abstract]2false 2us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsedisclosureGuidance1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>9.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Stock Options and Warrants</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Stock Option</i></b> <i>-</i> In April of 2013, the Company made a stock option grant to purchase <font style=" FONT-SIZE: 10pt">25,000</font> shares of the Company’s common stock for service as a director of the Company. Terms of the stock option grant require, among other things, that the individual continues to provide services over the vesting period of the option, which is <font style=" FONT-SIZE: 10pt">one year</font> from the date of grant for the director service stock option. The exercise price of the option is $<font style=" FONT-SIZE: 10pt">0.54</font> a share, which was the closing price of the common stock at the date of grant being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred seventy five percent (<font style=" FONT-SIZE: 10pt">175</font>%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option award and the effective term. <font style="FONT-FAMILY: Times New Roman, Times, Serif; COLOR: black">The Company used the simplified method to determine the expected term of the options due to the lack of historical data.</font> The total fair value of the stock option granted was determined using this methodology to be $<font style=" FONT-SIZE: 10pt">12,975</font>, which is being expensed following the date of grant based on the stock option vesting schedule.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The stock option grant in April of 2013 was not for current management of the Company and there were no other stock option awards during the quarter ending June 30, 2013. Total stock option expense for the quarter ending June 30, 2013 was $<font style=" FONT-SIZE: 10pt">13,538</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Warrant</i></b> <i>- </i> There were no warrants for services granted during the quarter ending June 30, 2013.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 false0Stock Options and WarrantsfalseStock Options and WarrantsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/StockOptionsAndWarrants12 XML 49 R27.xml IDEA: Stock Options and Warrants - Additional Information (Detail) 2.4.0.8127 - Disclosure - Stock Options and Warrants - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P04_01_2013To04_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-04-30T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]2false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2500025000falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNet number of share options (or share units) granted during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Share based compensation arrangement by share based payment award options grants in period3false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse001 yearfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaPeriod which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Share based compensation arrangement by share based payment award award vesting period4false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.540.54USD$falsetruefalse2falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.No definition available.false3Share based compensation arrangements by share based payment award options grants in period weighted average exercise price5false 4bpth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1297512975USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryShare based compensation arrangement by share based payment award options grants in period grant date fair value.No definition available.false2Share based compensation arrangement by share based payment award options grants in period grant date fair value6false 4us-gaap_StockOptionPlanExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1353813538USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Stock option expense7false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRateus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.751.75falsefalsefalse2falsetruefalse00falsefalsefalsenum:percentItemTypepureWeighted average expected volatility rate of share-based compensation awards.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Share based compensation arrangement by share based payment award average annual volitality rate8false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Stock warrants granted for services, sharesfalseStock Options and Warrants - Additional Information (Detail) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/StockOptionsAndWarrantsAdditionalInformationDetail28 XML 50 R18.xml IDEA: Subsequent Events 2.4.0.8118 - Disclosure - Subsequent Eventstruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_SubsequentEventsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Subsequent Events [Abstract]2false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><strong>11.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>Subsequent Events</strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the third quarter of 2013, the Company received a shipment of drug product and the related costs will be expensed in the quarter. Costs associated with this drug batch have been substantially paid.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July of 2012 the Company entered into a Placement Agent Agreement for the sale of up to $4 million in shares of the Company’s common stock to accredited investors through a private placement.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Subsequent EventsfalseSubsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/SubsequentEvents12 XML 51 R3.xml IDEA: CONSOLIDATED BALANCE SHEETS (Parenthetical) 2.4.0.8103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$1false 4us-gaap_PreferredStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false3Preferred Stock, par value2false 4us-gaap_PreferredStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1000000010000000falsefalsefalse2truefalsefalse1000000010000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred Stock, shares authorized3false 4us-gaap_PreferredStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred Stock, shares issued4false 4us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred Stock, shares outstanding5false 4us-gaap_CommonStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of common stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false3Common Stock, par value6false 4us-gaap_CommonStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse200000000200000000falsefalsefalse2truefalsefalse200000000200000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common Stock, shares authorized7false 4us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7538021475380214falsefalsefalse2truefalsefalse6221905062219050falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common Stock, shares issued8false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7538021475380214falsefalsefalse2truefalsefalse6221905062219050falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common Stock, shares outstanding9false 4bpth_CommonStockIssuableSharesIssuablebpth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse25417002541700falsefalsefalsexbrli:sharesItemTypesharesCommon Stock Issuable Shares, IssuableNo definition available.false1Additional paid in capital for shares to be issued, shares of common stockfalseCONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)UnKnownNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/ConsolidatedBalanceSheetsParenthetical29 XML 52 R29.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended	3 Months Ended
	Jul. 31, 2012	Jun. 30, 2013
Subsequent Event [Line Items]
Proceeds from issuance of private placement	$ 4.0	$ 2.5

XML 53 R23.htm IDEA: XBRL DOCUMENT

Accrued Expense - Additional Information (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	$ 4,892	$ 137,662
Accrued expense - related party	$ 37,050	$ 26,000

ZIP 54 0001144204-13-045992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-045992-xbrl.zip M4$L#!!0````(`+-%#T/46@`.AET``*"(`P`1`!P`8G!T:"TR,#$S,#8S,"YX M;6Q55`D``W'-#%)QS0Q2=7@+``$$)0X```0Y`0``[%UMV[FXN+"@2FYS`X%M4"Y[=VX_WX2U(N@0!(45(%; M&Q.SG@*1CU)/*E,ID7SXZ\O<'SVC*/;"X.,)>*>WN8FR= MC/[ZZ3__X\-?QN/1+RA`D9.@Z>CA=73N),Y=Y+A_QNOV(]S\G3$B?ZCCR7(V MA@I01_^CP/>*]5Z#_SOZ]\W7_QM]N;T;C4<_?OQX-\5/2-(GO'/#^6@\7LOY M[,18!G[.'Y^_7XW@.["Z]O(0^=Y[\N\1AAW$[Q\6R=/'DZ\%?^8:D0>^"Z,9OE-13\GE!PQ@?3NY.O4V M#>B;C=/LXN;6G4?_4--[@6W;I^G5S:VQ5W8C?B@X_>/KU:W[A.;.V`OBQ`G< M'!:/@;UXOQ>'&@0FJT5VQ[K!%"TBY)(AKFQCGSJ1&X4^.GUTW&2,7A:^$SA) M&+U>X/]>/\@-ET$2O>;5%B/WW2Q\/EU=3$=FK("Q"C;-EE&$^5?5;G65-(3Y MAE/DE;?!%TKDH!?WJ?Q^W)(JJX'U\I:;",QS/'66S:/#KQ0SJRJPLEO7CQ&?SYXXHB]3*)&+3! M5T^P%8]&'X@AO(]3BG]'CZ/4,-XGKPOT\23VY@N?\#?][2E"CQ]/B)6/UU;\ M[B6>GHQ.\8.RR>(L#!+TDHQND9O@.2B=*+"(;*IP5Q<]3.<;!=SC?XA*[D(` M[]7L[PS2I@4*$B]Y7?VV^=6;DM\?/12-4M@HU\VURL\N_W;R2<$6#%35`M:' MTV+CM:C3@JP<@@6*O'!:1(#M.DKPE(L^K<=4`>OG;*^M'T5U9[IMA&U&!5OA MTU43&A(E?/W32H>K9S,5"^]"Q;A7E?3O(2H6-E$L;F2,5:5+Q:J48M4A*E9M MHEBU.\5"2K'J:BH8JF)A$\6J'4T%6J98Q<**U3+&*M8`%:M88T6KJ]BL43>, MU=[0'%M;L5W.L1HU%6@#GV/K*U;MGK%OP7DU4FQ'C)W$U\'@YM9L99J43)+K M*VU03K\'J5;,@5-.,<>*/@9*KR@W-(5N*5?43)N4,RF_;*XBR:'Z9;.)7S8[ MBB1IQ=H##W@:*=;NR"];E&*M@3/6:J)8JQO&II,D5JX^W$D2JU/O8)+$3GF; M>5.&G7D#2I/,F](-Y3:*A51*Y*,T-+6N6L:?_E`]FK.O?F*$AWR@5VJTK3 M)_??48R%OC!Z"N:/Z!H&9.-O-L$3X7DVJV+`@=# MF[QX\8%57YSPT8P`VLA;79AB("\+WW.]).O`:+K6T\>3U;;D^XKNK"\+J"5# MN"-LV_O3,I1O+7E4GD>6M!H:K?J612_=J92T&AJM^K9/6WJR0-)J:+3JV[F* MTGT"2:N!T:IONR05(7MV:M;'ZIM,YU[@Q4GD)-XS^NF)):08&;8SPG9)K0%2 M:QBANZ36`*DUC/!=4FN`U!I&""^I-3QJ#22,G_C^=?*$HI^/0^3]F_?Y[LNH MG!&52Z8UWY&,!TQL,[O4N MX MH1]@Y_[GF;/P$L>_6`;3*V_N89=_Y3D/GH^[?Q;.%T[P^I.2JH&.I']C^#?) MN;?$N6%X1\FY-\2YOOG6?+FD^YLG)T;70>[TV4T43I=N MFRP"RW7^.6QFB2MJQ3>6[JO9UP0:4]^]?WEJ(#N+TI1:,Z7N^=IC M`^_4E/JZM=J=*0W7"MX(WWJUQ"I/)4F^O16^]2R-5%A>M1HBW"'W*0C]2P@,.,8Y! M&)D!&%;&ZC!97'WUT2*R1:1GI6T5\_XB7*964KK[<^8[<7S]>)N$[I_#)@6C M2^EDD5?#,3=XZGZ-*6W4S<<):,:L9A?)F#?!F*YR)!;%&&LSQURFGPX-FZY6 M;R+O&?^R.>5$/R:+&G\$>"">/.S/L(?'HO!3OCGS@6\WU@EXMKZ/UG2[RU0! M56]W2LM&['@V4OL#&EFC;F;5&5['OWUR(B0VN^YI6=(VVK(-GK,H M'UUI$`R#J#[9*PE>LMKMUQG@/O$+@"V_\-_K,%9F50:<52GP#=3>N,D:=?K9 MY?3KP/`>IE]*L>X_>^&-DSS]&F(%!;/X,G`EUSAPMS6I\^``^H.6W]_37, ML_72+=4I4>_J!'9NE?R&4T$"74O)Q='3T3@&FLQE77WU4#%6'+.IM+8MDY1O M(A$SU"2E37+R=6W$[BZ17VXC/RG)):E:/]$H)UPYX1[OF$61Y&T>LZB8.5O( M9DO*=Y(+?^.L[[-'V*3F;2HU+SV#]`S'M9$&VPEV9]L)FY2(3:5$I(U(&SFR MC=1/Z=C=I736[^8I..@"F8T`1=J(M)$COD^H-'F?,&UT2!LYQKDS:5G]L*RV M3ZU)Z^Z;=K$1M+-&FD;TC:. MOEE3)'D'[\06'(&,FF34)#U"U%9HY_I=4K\.VEHK"Q.O+?-VV8RE8I>]W=#JLZLB$^+6W M-K-&G9Z@ZI^UW'_U`F^^G.?\FA/,!NYX?BY3:N2:MX.\_BE'!6FX?3=_ M`1;^%--YVU:23WMU?$:Y,%->>($3N%XPVXR()/L>'Q:J4N=/S>\^>P'%I,S" MW&2#I3>0WJ`GUF(VL1:SHW2P35F++6,G:2U]LQ:[B;78'9WB5[;6@O^6OD5: M2[^L)3UN5==:\#^=EFQ+K05(WR*MI6_6TN0X8V=OB-%G?U?%F?!O\LA6HUR[ M/+)U/!L!G166VJ2\`)7RVM=&),L/3BO0)&4$NM]SRM-*UBX>:.WB@?!+!L(R M$.Y#(-PS:]D$PH!:-DIKD=;2%VMI%!)W75@DM99581%I+=):^F,MM4N,9(VZ MV>Y2J<_-JRMK@=):I+7TPEJPJ:BUK25MU(VU:)2UK%.2O;"6^_4CKX/5=S[) M2-]$*,;BT'1]%2]6\Z24-C8$&ZL#*4L]<`<^O6V'-,;2S.N9^88TTLS[?=1K:^9/6+(T=&GH-0U]2QMY3FTH'EV:NC3U(9IZ MW[RZ09FZL3'UG_3=$K[>.CW)5CH?* M'T:7-K/)6@G'HTK]XF5IHVZH`BBJ&%NJ2/_4>_]4I%7],Q1J=^?SRFDESW\. M]?QGS_A5*$SRDYX7&.@&_4%J>>08HM[?(?BB@W6!4D>;;M/4V4"R_`%G3E/:,I7ITXPW&H06"^QP+* MH-%**3ZQ1.`Y"L*Y%[!%\M11E+G[T/55JN=B.JP8((X2!)Z-]8*96_'X=,K, M[MAC^,FNQW#R"4<\?_]P6GS2NE?D]PG^ M<4HN7/C.K+8(>/+IT?%CE,G(/8L6LA9^D\Z!7[+`O+8P]20WV58^N$SRA1>[ MCO_?R(DN\"]Q;=E:)CLOM?#0:KD9O&:2]9-/?X=E:(M>;8UI]/+G\=G'RR=152X%`RT#Q9>\B_8YF7IR0_H9> M:V.P\R%9Y8-IR6?+*,K1M*GE`>7DTWB]*<%Z\FZ_+SP?16?XTBR,ZO<:X#GL M%E,!/V/T'2W"*"'<6BTD:2WDQ*Q1;)/WZ!%AP-.4+WCA<1VEF_K3_W+\)<)V ME%*HA+(5H"#%V7P415$7SU;*.X7D,.K!:`O\=OLO#UX]'OC,4B?+Y"F,O'^A MJ;C&-?XL`93L?U60B\+WA5JE7_TX4"_C>%E'HP8?)@=?)G$?;%4J%/`)K6%C M^ZP*Y5E[`RQQ5XU15JG1[A(EY8#WGE"ATFQ.$L#0"NP*!4-P#-B-)U$(^7R` MRL[4Q!"]%\HJI:H'1UESZH0"SF@;LG*D-@97I3X!]V-`"&Q%9VE/$%R3R1,* M>!X!]8E-3_)+":Q0@*HP!>JJIF@<>>E!(+*Q'B0[ MJQ1&5U7`E`Q-&U@4.?)2ZF*HZCWDJ%O/S9,"&++4^VJ%)ZX+E8E#,S0`"C!R M@II`J5*)QH8"=5.O`Z6A0G0V.:`.+6!N<>P#H4H1!A.":0(#`D$$U"[-:G]N M>\S]ERB,8W'%F&S%8,*J)C7U=J1@(C3W'V]""*FBS+\5FWU#RY<7UE\21_Q*& MTQ^>[PL/A<;V$T##?D*E)FD1X>T`KE(WQZGH)@[.U/T`9W>*ZY#M7[`98A>S M,YV*"JW2`]N30%5334/C"G7=<(EG@!OGE417=1V)QG8DP-`MF^YXJ;2FF*H4 MP_8LNID+.AI!HHZ)>*BV]]783@;/?J!:9Z6BVX%;I4^VH[%T"^Z--EINSV(U MT2C;GVB6G8=8+FX/7!6JT]FN`6`+->H@2Y=(NW?M1T>=[0%4,UU%UA'=#MPJ MG;+G?V@H2D.XZV$X7Z*[<$^=LCV"GD\050OUAOSIG/6*8 MEDXMD_FFNX_-LMV'"FU(AZ8"6,)@=H>B^3EZ2+Z%@5M7-VQO00U5N:"F<*K4 MP_8&]>%L]2>N$O9TSZ!++>D5&C#8DSJ#(.S=E#3)+JP#@SUK5VZ>I%(:`:E2 M!WL^K@>$2O_55`=[PDV3MJ6IT(8PJI3!GEQ)4M82AS&93CVR`'3\&\?#J\75 M^75QI?"B

3%Z!P]DC/)5`[B?!GA-7*Q MA;@Z.4D>/,B:3F=&]L=VB-Y6C);)"?4A4`&TU"Y[FTXD3Z$_15&<5?X0'BN3 MLP;03,.TJ:':%=4$3)4J.1&^@GD#E3I@*!\\":;[Z*EFIH'^@53JLF1VJ M"W3B^Z%+J)GNSGUV8C0E)]]0$*:[?`L2--&K`NM=CQ?1J7-CO,\:FZ'ZX`]+W_YMZ_>`]%8Q.QMS3KI/@X8*]^WZ=N_US`F:EQ$Z]^/6" M_(FA_^Y$Y`V`.I[Y%Q2@R/%QX\ET[@7I.P2)]XR:=9V3$E7)RKAA;[I11I[J M[2J#DX15-SGL8RNCW(&WJPQVU&;;4.V9,KID!B_]K/>%&>639;O*X!S',10% MKTM;T@>YL2HXN`BC6Q0]>ZZ@RVA7"YQ`#UCZ=KH0[$711W['CBU85H8VC/?/ MV+$8Y&HAF]%LZWUQ1=RN2\:+8+%Q+- M"*6$8A(\`VG8)UYVWU+@(?I4'B$T[!/G M[(YN`E4_8)]:&2>V$],TTU#M`_2IW%,U[!/;)6F6!4UZ"=ZY017S2^4%?FIV MDNW:5(B#CZ/-&>UT$2BD0 MAQ0'@BM2]H$=*FB6HNK:@>&RM,N)`BQ5H\_1=@J7'^D#A7/X0%?MW/9"3;S7 M"U)SI?UQ-^GV`B1"? M/=&/&Q5G;/^O,%#0R`\!C#6JP.4HR9@-H9.@%K M*!8!V7T[2^\<'DMY;#]@TB=36T8G8!B0[1'P#$>?\A;%E^9:OH5!F#>B^H8! MV9ZAN(F\*W(_9*QA9?N&KI")V`/;.W2-C*6S>D>/VT(F8@:$U M7F3S2GI`%CC6T1]Q=(QQY=3_@$9WZ`3L@5,C1-6*I2C:1\?2'2>C95N=H1.P M"UY-$1TT@+=K.(WM@E-H!&@*Y5TKY>X+D#6\G"4$':6WCD_$.'A':NF7+SH# MR%(@VV>H='C2.CX1"^$>6S`5O0E$E.RSI.;4'L%+:C/W_EY.7!,LC"'DE`XA MRVA+M5K`(L!W3B$0LG16(9UKV!L,2S'LN3]=+BN&W@(8`2)SRGN,=]]D8J+Y MXD0!YGB\KJ?XV8D]E^Q0>/XR*9;3$V%TL1)(>:U'B)$J[^A:CQP@[>!F#;+> M0]PBEF+4P`T/C)NE;[.'N$7LSQ+'#:W&N']'WNR)E%YZQEYHAK(/6%P_IDVI M4HG[FZM`[5O#,!0#T.ZQ&;I.^\B@6J[P244?=%^$+#)QSOD;1J<(1:C`6?,INJGD"KF)8JS_ MGA5KI&O6*3C$FV`%A)REW]'>Y2K`9"\%&[R-M=D.(-6*`W?SW>7-FPZ6*?S.%MX&4-=2<]_LQ56**F^ M)]34VZQ*RI65AA6B`><$NT6?ZQ"!T")L!B=8].+DMQLB].*<8[1P7*DI5AO=P`1,/TYP%T[.6(`=G$(UEJ698!_(%63*#M_M.<]PZL\H7$J7H&@= M/X,MG-(RXP)=CM`)$0)Q7'.108?ZJ"5!T7<^=:*L-NL)57'@!;KIG[,`IC+)#$G$LK?>"11O> MTC%/FR-T0H1(G*HHBFWFB=2\&VDS%'GAM+B*;L`@WFE36\TE%ZME[XV2Q1#. MZL^T;(O>P^T`I0@%V`ZP]"N?XB@9)9A!`0?;S>'E/M0+RA(3B)6@V*D2<@(A MIYB'TDA6.14@IZ8&,*"F<02NWY$B-?UK6PSD%+S(?[)N(Z=4@M!@\0OQ-2%O M/I`M./+W-[[CIL5U)C/\KWIE=R"GB(2F6;D-.1I<`^#Y\DC[`1?V$0TQEU<[ MV@\SIQ*%HBDZ,%K3=A<%MR"G;$577&D+O;`C:Y4U;:%G.S^HZAK(G9YIDS]7 M'G9C?H#[\.?J`T07RV!ZY#4ZEIR66\=,2J(!]DNG[$UX,9 MN@S.T2+"S_[_]KZTN6TD2?2OU//V;+@C()D@QIEUP5?3TIW? MP:0P!WS"A2`\E\Z4;K%@4V\OT_QY&1M8YK@KVT8_U1IRB*M!\(T7!8Z\IGYS M6W%-8Q&UT9L`T2P$>AUYWX$]M/[?^'!0NZ[KR%%7)GU7Y4%6`U**P#D)D,/5 M5&X,:)G-_8?VR:O?1.[/?_K):8)%(V(41A,W0FR+.+GWW3^_&ONN$[T=A/_*=^S!-WDZ]'^[D]-5_SI)3.5AD_#S!G_&G-_PC?_S& M?.8-#<>_\R<3[WL%!.+CU>?;HX]GGRXN__?MK;<`:?+9O1-?PH43G-)W-Q?_ M[\-;8;>6R>FGLR^_7WQ^*^!G^/N#7^;O1.%=BS^PQ(T;>5-AKH304H:$!S^Z MO;JF"9H/?BKDJ^^N;F^O/M';KV#18]?WXZ6#D4M"/_Z^="83]3LA'[@?L)]# MM(+M;Q^^W%ZG5U>_`ZK3L*E^=Q$/??WB_>W?X%9C]M=+S">`(2K?8J3 M*`QF^)M]3+N3?4"_RD?5UDV*>UTSX%4T;S?/HQ/-* M`3$%[A(B]O[EXDE%^M19+$__P^ZU&$A\H`SQ3N&`P?)S[GR:T]L/_W.K*`>/ MQGC3>T6H6S"0A/J=%QY=.\E<>+%P0![J1JX`+5_12%8*D#8^D\0"@)^(,4K" M2$RB=";PEXDW`8EHB4MO&<8PER]^CT9';?'Z\HA_""/Q[OH(&./(/F[9OUI" MWECLWPLO@"%\+_#&\%H2>2".C\7MW!7G:FHG%E-PV2?NA,%(W/$\"/UP=B^F M()GI8?%'X)&;G]R+<"INW1\.K/33>P':$CX&2CYGF,]=C-.)U[Q=>&O=*3RE M'],?VZ>_$O$#7F!BC^ZX`H95*$*;(0CA1Q,7L1`(9@0O"O?'V`>^^>X*7ZI: M.H8P(Y617^`<%LBHG+@^KN)>+,%=F8;1PEPKK1WW(XSI'E)IA%:&SR..YVZF%IR46SA@I%R MC45?@&"3M[G2&/"M"Z9V<2%R-^4&6C2VVC3WQQ*F(%0M'$`__`4&&OLA[+2X M"Z-O.%:$;B=:`'-OR?OWS;T7"S+Y"2X1FV-$,)3B M=#P&+IBF/O"EY_O`'0$93%XB^=%A[ANS9`2J!!D5S7`'9\!`"<@.%(2+$.1+ MZCL@;9CKCT9X\`9?C9RE"_LXEI!$+A4<5HN>]Y_/:#CQY?/9D>]]#"0FWX#T!Q@ M-?IHS\'4@4_H"4!%F,;&BSR@\.\7RWDXDB^KKVF) MT]`'BB>4\5,+?`UU2GY78-M2?Y)Q.2A%V)44D8NLB^#C9BQ0[#"?>`%I).:< MJ9!L>2P^@D@&S;=8^@`^.)A:P_XU]0G[Z&D8`B"`-<&;L!N2A$C9@BY./)[3 M-`BD&"T;`$6MKW$.VAP@$8$[HW[5(&!NX"G+*(!_@3(''Q(<)2`:OX%L(_N!6JZA:.4HC.;18!;G)&T5$QSL"R& MY8#"]69S@5ZW@X$8(2*DFX.HJ;<.,XM-4^02_H>U8XVLPQ*9D,*\GF,9PD7! M`B0-_0EO%R#R!JIM61DP2-BPD6`-1AZ8/P$88K!_7%\@QP13IC$ MWB,X9@-U>/8U/F=8@A_?G^4,0"U8G>725Q.0676AS2-6NHA'FL$T+"\^O\\- M!]H]26-Z7QG&H..!@EU8Q`P/J;H3E(*`;9;1DYS)`7P%YA_PXM@EH!3N"LC# MY^(DG=SK20#3\Q3V6&^8LM!&P)D!6>`X3S+WHHGX9^I$J`<0Z0>>*/,$*JEJ MJI4^%%B`1VX,GS*3\%:0YP!H!?)S&=NQ,W5!^"!M)J!:(V0:4K[9JS@4"7BY MD:PA>4#6Y63"90/CN.$RP9B6&'EH`R!TP+(.6<,T()&?-I<-`<^C+T&V+IQQ M"/:K2RH]FQX)1;,\SS]B<#QW8H%^(IL7E`CP>8P1S*(?<3=W,QN]RIX'MP4E M.:`QEH8IRGSZRT%JACY*`-BTHIQ)A[DGJEE M@`;`R3#4,8-=#(`&G#AV[@UO!11-@1W!E'=B,*H!L7?!4>3.4E]K(>(H,D/0 M9$]<+V`'8@Q"2ZY@C/"AY!(@(!V6-@3/Q%V`:DLBD_"6'QJ7S MN4H@SIWON)E3E#VON[^BI3L'LPN-"1\$%DLYL@,6S@]OD2Y80L'DW998S-XL M*#*9+G$!;0X_\B_'0OP%X`**0(=3?`Z_DT\MP6[G7?7,S"5>`@X?LPP&BM7J M-P!7&/UJ*85C;Q:038&AB?"'-T;"8]F!U@\9Q/AF+R%.T!X0>X M*4[]A&43`Z"LJ9RC]2YTP`)`+PW\MS$,"B3D3+Y[L<(=Q]]0HHQB0A5'D^YA M/61X2$2-G"CR7'S;1$0\)S\'DR%>D++P<;\[?HIB+ENT5'EY:Y&7KF9%H[!R MAV1P!/6P^7VX7`+98>[G7J/)I&84_GD(3%4'/U/*!9^<>B@DF4P9)7I*1<)9 MM&8$[O,4]"$*UDD::=5`\OA(^XHLVC[ M'UZ)7#=#%+K9C)I>/?MF$4+)?1@UHJI@&1M:P_XRHJ70H;`A^<.,J[I!!%XX MD6\.5!A!KJ['%*&YFA:AY=!PC1PZZ)F2GKE6.`8#A!+9A&#>",*P-B56:`U4 M&[BY4W3R,2``KZ/WOL2]/J.PRR<9Q[E4//3Z[-/EKQ9,/O=\!TR?Y1P^/)\# M+7&X^IJ"YC#LN0SJ?#*".MDHYS"*(&;C>2YST1UCMDN<#>#Z5(@>WC&W3SD)4T=#TF18SB:M37IQ5H$`.<7-`L9?B"*'>)=RLWH`/($F,#! MT"OYN2CK4;F@JVZA:XQR(1M-,P1.XD@C7;$\"\9IF$9'=Z[[S>"*\?T84\_N MV$F9,0!X'671`#!7>Y0'B;CD2LB]SH9B3:G$N_1L#GQ4[6C6J_IJ!K+$7T.P MNE$0@B>/:;#C]\<6>Z<8H$'1C=Y5E*C40+8YL+/``Y8XPW^`@B4S7%X>BW=R M\UGRHCVA*7#J17$BN1<(`RQW=*4"[<+1(`I(BDARK3SG2'@H`(4X-8M1)#D$ MY#$`?L82*!@5(UH%"8H*!4TE<-+TE&8,:`8'--H2@9OR<#'6Z'#.F_VMLP5L M!I@/XB8$1PWCA##@7UP,4I+O!:H4LVT+UU5F['MW;)JA]K'X(D&A64VWS@CW M%JP!:33$.O:+SV9>-UH%,ALS4=MG0G]<1S?(F5DB>ER0M-Z0197 MI:A!(S358JD"39T#\Y>9_RS`S":&J)$ITX0NF*EG>]Q=-LT]#FNC0Q''F`%5 M+TH^]1;,Q3+\PJJ0S4J0UT*+I:3VV;&]R[,8BNQ2D!)-:12FT9@ M!#X"R"C'$0;(L%KIE6'BB7F-7O`]]+^3(\!I>HJ2D6D-M)C,PXE&2B$D`NO) M1XRRL(Q.RV2835:$S-3`,F3G8CQ#F%!)(#!]O$D,2;"[7!7;,D7;'!.#,L;B M.2#&R=<`I<%,0"7Z6\]5"RK(-F2')4K-5TD)1)+I6/,P"3.$X"6F#)4/G M4HU9R#*78.9@,$:#'5-,<*@6F`RX?\%!%99>;0T&)$D3@5&5+U-N"'@Y5`686<@X(%45X\#ED0 M<-%0Z`5<0I*O5I&N@E.9MS?B:`[%:["KM^.'YH2<2@8I09J&JA"<`,O2G*+/ M06C3GXH"4BV>0B7TX2D*Z,CEH"F(#I`7S]D_C7-8RH>2,#G]+8&!TMFGJC5#IY1/YR&6!>Q5; MZ$E=Q*E-0Y@5\FTC=X8F$!`.WP!0'<4N%@0!V\1@3",K+^'?3(16512Z"UP8 M&2@+<-UD`@L'8\:(N3C[3I8+:4]"RL!Z.1F<`RRL:(,*]D1!"%49H0GV_:^"ZE*H@RG:^\=9"FZ2:E-?J:NZ,H(3*,2IN2=TD1TZCJ'*GTBTE2IK M\IZM+I76.2PS$<*9.$H384Q-Y1K,Q\URB!4[)5-F""KODR/U)?KP8%82%O,8 M)%R;%B,FQ]D^5JMVJ%P`XT&\<@F1E-(*K#M7!>+!>B>C6Z+;T\:L@@#V$2M` MYHH>-""*&C0QD](`AES(S3(7A#I*EIBJ0;&YT`,A<547O.D>\(@B)KO\4 MBQ"\?[F2B7#_-=,5#H,@D9:2P>(F,\FEVHG58*I6G3-^>E@>S1+H8"!%(`.W3&[A15*2S1S:)0%/G1 MXU27+%5-FEDBL??E\UDIX,B?F@.1C<#XM!FCHSOG+G=O3!'4:` M0WU*2+(9W@L'^4@KC-`R=2=:N:&JH27Z="HF*\2:>"0.R0KCM(>CRUSR*Z)B M:B.F2;*01/X$]CUB[Q#+^Q/TNZ)O;B(+_,)(QGUYB_C<&`<%/5*2Z%O1\83* M6$#EV2'>5=@ZJGBO.N"DCD)964`5/6,.!'*04":[8\B+_XF(0LV'RD14 MY=H3 M))`!,X""V_=I5BZ[("3(D>$AWZ: MN?GD$",3Y1U"8*5O*'/'U`,`'_U%G]^5*DI4J;C.2==JM5JYL[S*QD;]D65Z ML79:W(.6$Q(^G6OLV!;E9!$[()?2,:,`7-Z((@(";6"=!N.=5?@!H3CUI@G5 M)^.9&O&Z$=C=/,1_^E7&&Z5@CUR93J7J9C2V_:F*!N:A&5/G59@+67Z&QQIQ M%2:A:,[**CSS2Z!#M-+HFE"A--5^E8LE39;`\Q7N43AE*$:.;V8*->8J$)<= MF=2+Q">WWVVN;:%`AY\CSH-A5>GX5YV=IMI>>0JLU><0]!^)@V>*HV48R>H! MH`SQT1U%9(WQLP,SK*6+`ZD:$:@/Q72$*IK$T]4,3Y"*WT,?C:EC+$%18Z.2 M7J8CGY4G"X3(0D&7&Y8VJQ M0O2;@?V7T$=Q`)BZ",;'6DY/M!GID!D*BET>S%5O6H+?P,HGF35?_U)QNKS' M!$-A,E4AP]=H4%AY'=\O1J$OKF[/W[U["U[P[5]^E4D2UFR9D"7,KSXXF:%, M15YD<1TY;"JM@-89]WQ0<7,ZAJS\8SFPA7D2/-@)GUOFD7!ZP85=XM,?<5$A MDAF5\.$0'Z)B.C@9+$UJ60LAC9J24VZR_*H/Y.=W'Y]60 M72BX+<^MP5!8\'*$YILL;@36^>__.>;_J;H8,ENI_`6G!;6T0%M=CZ;S&0@X MO"C9T7,+!2T4\"@<*<"X%$JKR,4^`/#I%S3B9?,O@5WG`A01>##/C8#]9(JW MDF??NYANI-#K&9;>RW*_]V#;^"$5BN3.&+X_RY\Q!*30JE'UQF#IQ;H"E\L] MZ%AW"I1.JAPPR#B29[87AVC%"HHG`4\V4Z=%1-NQ3+$^:6C MF,5$/+:(#C'_'X"!]I[%*5&)9!EU,%.69^3--GTFELJ*?WAXJ!XT2P94+53M MXVX>'N!I'ZUY!9<^-1<[/D>T^3)O_"G'H5R=Q!VR^%@"%]7C"0C2F_CRU(UT MC0:KHY#:&8`,H)#YI%Q"QN%?T&?#4*%C*6KH M]`(8VQAV10DB@^0$">)KC/`$[/M@(6E<3M)R^AVL_B.CXJY2-.<3N%P$>`AY MU@N1I$#7F`&#C4^YZPJ%+NE`BXJ<&Q8<%T$NP.8;>^C'L:%3LE]D\'`LK4GE MI`=CCT_-RA:3L6$(ZF)JY%YX,6+M0/PB04&2%J`]G1&6R4CU7FX718_G;1D4\#-`,F!_YE, M6GA.Y0=7WP30^4J6ZU7@FHU!KWF3K]0%UN6^H&VS,RW/5^S,*)=0!*9\&U%E MJ]P//_!^99=6;G;0_3L0B?E*DQWX^FFB(A=\:IL7 M66,`0[[/"%+":X[);>!UD]7+D!LZ5""SOAMNIYV[(ON!"'L:_.?[[NX[_NM; M]W9Z_:YY0^[.-Z!F/8W:&N\2O07,K+ETNH29FJ4\O!_PXS%U?M6=1VHN["1[ ML[&=-=>*M6E?RV`7-[%PP[`Q*3BRLDZK5OWL5#3<:@M1MOJ-MY('G747F+5L M0QXW04&.#LIW,&^.MG,99[JE*@->)0Z.MEX8P-M@VR!9ZF[-YV&,G9R5D")T M/2)YK;E$K=WJ*A.G(39VCL%'7'S]C0F=_M:+7Z.!XBQHOH"C?TW[3[](B#1D0*H^U[3M.KDG,25Y/B8 M\8"+S^\_X!X>,6Y*`0'^O_QNP]B`QD&Y0D33$.#7M7M@\%:D)C_:!AQ[;0M<"(+%0U! MTR@RV/D6&(2%%#D&_+GML7]_G&^.M>%"IGFDB6JD4;85=C*B)BR`?W/*4D^/ M,.80I9JC$85H5DH:Z/+C-C,Z"[K7)E#Z,K3A3.)&SQ M<28:80^+^9A"'4OSE$P5,R%-K>22%3OE:D?28(D'%#@1$Y;IVM,^K2COFK"/ M?]U`C@!KE59.3>.IBB>/_HWBN1L8Q#E'HCI@L1LSNG&<34[QF53537&..R)MPDV.9CR!9 M<:!A/B0YEQMFB'9V$XB;%(F*I7 M*(><]411A^BH1QN:&3(WR+=-B"^$*?S[7G`78KY['O/1$W?J1I$\OB`SV%R> M>H.5WBKKK4_S1>XXG`74\]V)^8X55G^RG$:I8X:79U"]25331_6,7@DEQKD/ M3K'N`)"31IP6C0$TGPT==6$(51MAPR0J(P.4IWBH+HU425KDW.FK#42<8@-Q M=#_@=5QFXVI8>UAA&DQX&BJ=$LLTPD0D-4MPF#]O4CI'>ZY`-.R#%A@(N@5F M!K4KK9SLHH959W#*I7/24HFS;JZKNKJ;Y<_D/5"?T(FNY'HG2XQOYN#\X;;B M49]"!7<;:QS&84S?YZ12E5B2380:A8/4)$"M-B<^HX MQ+O[]'U$5,2/$(RR'1>`!R.@,OPC4=D3UANE%9=&9>;V*!`"<2& M9-3N#RU[4"RACUQS"\H[(+>@X"H5T%Z!=8/@B.(:V8Z;&8#%^+,9\M^-O=@_ MV(L'>_'I[<7MK<"3Q[<"%:,)R6D'JV__H:XL7549.2/3E;65+`7#FD<.'HT\,N?F6H%9^OF:( M[)7-6SXOG,34G%"VKJ>V&HT#6W:W%T3PRH*8JKEW`JZ^*KUP97BGOFBMV\]5;ST'->!63_X8)/L( ME;7<>^KXSHAXBWW$$ MZ>:>1=15;6?E(2>'\I"#J?"3F@J]IS,55!#J6M4%2C7:;9V*%U3IO7-CPO]) MJKO/"@6@*^H_-PQS5E6!;A#L;56\7KHHJU('5QH<,'%54#1?7GV;=>C4LZ`! MD1]+MS^+\7UO,4JCV%5M!:MJ7+.BD]%]SAA9TET**HBM*]VK^Z#5A"ZW4J8R+0/>.-G9H24256_4)[?=@;KN2ZDV=5@;HZ3YL*N70B+X?+^:HWBBZ^ MHV[UN5U:W;:JN6I?J9B+\?<;A&0.U`2FQ0=JYHTQC-VXT8.#1G]"C?YO?@Z9 MV\/C;P-FD^R#W:O<;&R3?XPZ$L&\M!D@>Z%GG^1TA4+51480)O< MD+3MSL`:#(:56UBU*#.XA:=AL,$.%NJ,=0C MM1T]N*>YBZ/+%P04;CVIO2/`[-A?N".`#SMM0G<#J]7N6-W^H)'L4)>Y%.XA M*#7N%Z_I0&`$+ET!6!/:7Y&PW1]\XX#LL>T>R:46YRW>*'"1R4F+P9469>%. M@R*&LB;C#1FS5R4"5PF*JEL,CJNVW&BVLLE^#3:`!9AVX*9K='^XX M3:CR>A:YLK6MNM]AZGB1O)\$3]RI(WDB7=+MUDJ(ZAFY^8$L,J1EGX%*]*O) M?)-EM^OWH+AL!Z,-"WD_=Q"XX^QZ;@][W$_2L7G[K;QF0AY,E?2WY*[S==S& M60P#2>I>"=G+6UF3S9!GXH['H^LJ&YY7L"LH8]4.F%W/,::PE=$A1+O:WL!U MD)Y7QUD+'9$_7GS^`9*91 ML4!'`2^N_8$=RV-Y6AJ'!V,.[^B2UAM?JH.C8J=\N?4\EGJ56]Q2&GU6Q-(FY3>[]L[A?L_3R/K6.Q$*_9 M$R4F>TEVZHNUKK5;EJM$D%N0)\+JE-`ZP=0HEO+PP$ZO(MC1)$2Q24SBEE(I MJ1^ZN+< MFTON[+J3;25W4\U5*[G5UAE[E[NGB?AC"^-PN.&^K=RXS:W23:9N;@"TV]4& MP$K]OU6$,$=%C0V`*BIBK"9E2O(:-V*L()P:G<\L7EZ>OLV';SVVQ/;1WRK3 M;HT9T,P*J#4#3S=L6;BK450OW/P09[/ M!^D/GMT'>4E\_&*E3Y:Y+8H?O%*.8V6LRPPIH4*G'`&5U^'U]>5V1)&77C`. M_0#+][]E=88IW@A_>7F>OY7R\OK#?P^=P;.[/P:$0- MQ*GEF9>D4G`I(CH6?V"FA]:%%Z/KA&UQ2=F:BGV!9;-`;S9/N&.+[U=?U9=Q M`RQ'FBK>@NY7I__3M<5.0WL\'VL\@O'QL3]&$TIJ*XE)HYFGKR34-];I(P9*/"598V%YL;*+,(U]NLO.G4ZY6E]Y M@7\N^;&Z) M<$W?S;4Q%6[3O2-A.Y0 M%QS8%8\2LGK'BKFNAF9,MV];)^WJO+")Z0LYW[6:C\L9\Y?;3G/F]^J+@E?: M0PW9J@9FE4)<#T/"/4J+YL.V[LM27>2)_5%5S:E>6=P<.:/[O"Q/M40UF'(2 M4B1%GFW1R%SE.VDR5?@AD:F*)%81KK1?\-EF2&G7V3"K%E\V6%'(3U*\RMWW M9M3W"E@2Q!0+A6;%&SWLL&4_#!:ZTYU,JH1O0G>SNQ=&LA.G',S0QB5=EXUP M,+&>QL3R5WAX&PKB9D1?H>17B.ZBB&X8F*@O2FLD[8YI?KH`'N-N&R5'K';W M$?BH(G>>,T"4N-P%BG(&X['X'*YPQC-'?'5]2K[S'M_2S$'H4(OM%6NCR[G5 M$+G=>4D,]F+%PHV[3(QNMYMIF;%O#M4W9]L"US\&U5^,DW&>>[70M^/OORK.\^@//'GBVLD+BP+0' MICTP[0N`^B,RE&9;Y%G8A2A,9W.SP->VZZJ;MBY^M/I#;/1>X,?J\H=-#T09 MZ1;[(=G>KC48*70J,C0F35)#$V9ZJN3B%XN3Y3'^F9GF(8#J]5;&2E] MFJ-,#?SM[00*XSB?F#X(EKV".I_QM/?.$NB=6(-NY]_5$N#5'RR!`\.N=KD? MH#9M:]C>K%JR\645%17[.3OA;AX*LZQ(D3')BRP2".^HU>)2#_3U#.[APY1" M5&%;K9/VAD.5Q'53>8V_2^@/>8T#.YGLE#^"LH,T<^!8 MDV/-."AP+%+WPIFX&"=UL3GDTJ$;%W,%?PTYY?:)S-]FW#\86NU![[F8GZSJ MYV-^7OQ*WJ_<*2?@"\1WO67-RWB'/;9/.?-0E/BRE$CI!OVDTG:!I"-K"Z M:P&KZ3.T"H@#<3Z):6IT_2R2YT;9XMI@?8DV]?GV[6G,Z.FE:0F[]'WWPC3V MN8/8+/#^Q7?$$!/B$@]D]63G*%092+%Z>GLIV!^B`6P_C10\4,I39@P5L11" MT@^@E=8`&V0>:.4GH945%YMLK;$Z5J?5LCJ=E;'*$GGDFTICFEB9\*LO;U%= M<.1Y<%)#JP7C@8R>M,9!TY!AAPLQ\<#:1B^"[UBJ@NM`N\\3[P3^-JY=7E50:P1A2X772*H%"CHNKB(7O]LPQ'PR[,'?0B7S$[=G>\34 M7Z%<'%ORK%C$BOC@(3OXW%9M[FI9=55?\YOZ&B8!^EVK,VA9;;M9Q#Q/A/H. MF(D(TR1.'&H/I)H/.]Q[>!FYP+]19@^;SU9=R;O1G?,W32^WJ[P5CV_.XQL8 MK\D:YS8TL#_T%3*X>25>EZ_$:_5O0_BYPS]__2AO$_I$=GL:X_@WJC?0N>_$ M\=64ICO[X<6%"_2&KT0:>#P^X^<5=@[R%HX?__G5Q>>/KW[K=5O=X?"DL.:U MH.]\P?(.P(_P85_O68MKC6,.6%P`+ M0)?`*)^=A5N!MO9Z,ND,^UTPH)^#3/8>?9U:JAL..X"Z_:&[[&9C?KL1GST0 MW06$G:RG-[N#?YY%+.TMVKJU=&:WZ,_^$)KF+;)]=X*!WGK"Z79:@TYG6[KA MRW[K7CD/Z2)EW&SS.K4"2FP[0PG\K'3;IXFZ3.T<&Y!%YRX*EYV@IM]`AMN= MP6`P5%<:;[/*')X^.EY$U'0U/2=+U1BR0"$G$AT#H)`3B8Y!806#>O(>,'6O MG3D'HO%MD8&KX#R+KX*5\#6P'MLG$L"U\S8GN$_JSC,3GVT#G^VO[2']_/6= M%^*=5>IRL8M@O`O2ZC6P(L&M:7>Z_4$3VN(%E1'P15Z^]NZ>GI-^AOF.`74C M?-#U7'@[EW$QUTXP8C?`2*]E$.SF"]R)8'Y2,FE@10X:::C'\*TJ!=!C8:+3 M0%(T4]9U:DK=2)R3@?S"QS"ZX9*,@EHR"`)^9DT]T%;*%W7/F7PY?H!5W&MB MY)DLTF@Y6^J?IUQWO95V\D`M]L75*4_&38'.>W*A0\.G'NZ1L]1K8,+U>@:2 MZM:^GAW`W/J[#/IN@*Y=KK>!799;;[-E;+1RHK&71B=KK,%>MSG*:/U%+2)= M-?G,5?0%F]9_D(?.K[&AM/XREM_&%<;B7N)NF,?=US_@%Q.!;4#@L1F3V`89 M.U'+*_AO!Y[C+A':;Q)'[3V*/J]G8^UF#@TW`26U&F=W:)Y0UL;?[:VW->B6[@0VV]_AJ8)KG\=7$ M"./\]UM>)D*HD)G3(R\-505K_NO2C;[2NBOU:3,(>J?(;N`;#)^; MC5\\DALX),-->7]K-^0GQ7&]\])N;ZO#=RAC7SR.BT[.+B7S@WR::GSOFT\S M:!+5[SU.D'*=>NL:&.SNH54P:!#_[P^>3%'M/;H:9`9RZ'I4E;/WV*HO)P%O M9S\B7WN)NY,7$_FJ)L.]TQ+=AJS[\(*+,)`(^N4H5J4#=?7BFKLNKMGANQF[@P'R$2-G6`6_RDY>RXIVLEQ[` MZ<+_G)'GP^BR+)R'F[C>I3MS_`]!XE7E!@>]U=Q]U`-DMDS;>RO$Y%!;6C:_ M]$*1UW_UVW7[Y)/$SHJU_?N0UM=/7N`MTD5.3F!CF@K4U;LDW9T2W4^.=.=' M4Z0/ZY-8N^-U)7ROHW#LNI,8[X2H-`Y>"I;SB!RVZFVB0C'%6BSL,G=5P)TT M%BK1Q'C%E82]QV7DQ)G4U M=7Y4-R5K1#X/'IO40[6?PI+F]S=6O?N"QP8>2;?7&[3L#?1J&26[QVK?P&I? M.WS[Q^]-"K3:W1UB-]/0M4'!EX*_!OF5VO7=%KU+L6ST-Y+05T#)\5N/X3V=J=U7PI*&W@L M[=;@Y,FU[DO!7X,2L$?6NH`6C2KX>5\U1Z=ULG>"[\6@KH'O87>Z\-^S"[X7 M@](&[L9S"+X7@[_G=S=LH^!%%:'O):H:I4">5O"]%-0U\#;V1?"]$)3:#>JO MGD7PO13\-7!"-A5\6W0+,=&E#A;#9WM3$M.QZ\^3V/WA2;NUGFVKNX;LJEV& M#CG;1LCYH5@LX*&!A]`=#EJ]07=G#3(>#S,[[ZW2L1OD)P@_.^D?\M!\=1X; M^R>FQGK1 M25\63R<4^UFT,LQI[]0N0-W$9A^VBQ5(FX'59%ED.L@WU8NKO.V:];37!.S[ MO;4KJ81D5]ZO;=C+>TC$[?J3V(5P?6.5M(UGL>^8:A"+?^R02MM`55OQPQZB MJOZLPK.$5%X*ZIK4`_7;)_;6/3!W%U)Y*2AM$)Y_EI#*2\%?`]/[L4M7.A)5 M;3`).Q)5[3U$57_O!-^+05T#:]KNP9_^LPN^%X/2)JU)G\/!>R'XZS2(Q3^V MX#LQ4*7BR'N!JJ]JR*O`Y6<0#]>P9)C.G:AOXW?WYMP%!#^.\[&+CJ`_*<*; M-&,=M@?K[T-X=!G[<^]#@ZR#W3II[T0R_[RBY_8NW'H'ZLN=#J)GYPAOX(4- M>W;W^?W:GWP?FB12GEOT[&UY:;8#S MR4*:."W;[H@2MME+Q7YYV3OQ573N.]YBU?'@MF&R%==0;_3WAP"^G8G^C:#9 MX5)TS4W;R$H6EU)_9*+?&O1,\^%!2REM(--GN5M*!NQ."X2;W`[LYT?V-X[NK;CON=.LK^T\&(&CL+0O[ M=](`N6/H[;7;Q("Q>[V37F]K(_L14+#[JOU&5^F>#'LGPV=I&/922OZZ M#>RG`5Y(_.P>VXO!Z%-&G[EI=$W;,6?DNY6-3_>\&72GVP>M)>Y=)XI5;^Q& MRWPX9O;\9I9.=_!%^T//;#.(W8CU^ZL+.XL7)7S\-85EF]PWL`KIU[TFNW@)=W?CFB7VE[%98) MRQ"Y/__I)Z<)[IT8A8"E"$UH$2?WOOOG5V,?]O[M*$SFIW?>!/;?;K7^="KH M\2/?N0_3Y.W4^^%.3E_]YRPYE8-%QL\3_!E_>L,_\L=OS&?>T'#\.W\R\;Y7 M0"`^7GV^/?IX]NGB\G_?WGH+,+G`VA!?PH43G-)W-Q?_[\-;8;>6R>FGLR^_ M7WQ^*^!G^/N#7^;O1.%=BS^P!+@]WE08*]DE'%[`?^$S47C(Q!UM1'E.'N;H M]NKZ[6;+.17RU7=7M[=7G^CM5X#FL>O[\=+!KI:TX?C[TIE,Y._F;BIP;C_\ MS^W1V>7%[["D$$Z'XMO'4 M*RDZ_][.Z*IR,[8F>H4;9[$\_0^[USI]45"K;<0?O.)^TDH\O8/TH-!/'F5? MBXM`G"TCSQ?A5*#@M`1H2R&5B!`+9^(*!S"`8X(5DR\ MR!V#V5`8XEC>,2!D]";7@`$X$U2 MQQ>D=KP`G5Y<>Q3"YZZ"!J;Z3N^[`NT8&$4LV612(/#DEKB;>^.Y\.)F2`L# METR1/-K$-`H7-.P$%"9.P6M"]-"G"BL*5^;Z`3<(CRMU-JP$GY!@2A0!>+\T M@J]UW#W)P^;PIJJ%WL$VX<"H\`DK-)N:+K>Y$N7Y)8U?$ M!5MNX07NA-Z<.EXDOM,=0'+\\K[#HRD!0M^_`WOQF[@9ST,?MG`13ER?)*'[ M`XT2W.DYH(*'!$"3N7\O1FB4B'0)(^;V.Q[/W4GJ5\_MW#D10/\1]@2X9AG& M3/5Z!3A`!GZ>"5.-]I0N]_-[>>??C5W6M&"&-TM[D:)]P0.!XBZ7O33WX=>$FI!?'BPW;ARYSC/X@A'$B9(@PU9 M#K?'8%;F0.(M"7/HA[-[A&+D-I0\=ML:%FC5$IET9;DA^7@"^^C[X1W/6A(Q M.4K.P5_D[>,792*\2,/FMI*&D-MS=@J15!`R"P.[1L2Y,"A(2.+BO`Q2'!JY MX@[_"4*I\7-3,3\?J=@8Y>C]0XS.8V=))6F=AYU?K*;EIT-^=]+:(4#([4HG,IC18 MX:(9N,4_6?#F@8&74HI(/VH.=H;+8B9\=U\:[0PY3#J=O]/Z+X+*X&)E\K@0 MUFF0%BSVI=XIR!LC)-YH^+^[&#YS)V=L^-5=^ML$6\7+$E?=H(LV_088V]V: M=D9?'\$JX;NSXCA=,!B%B?^FC>`\VQ*9=7V-:@+VQ^% MLFIT+A"X".(D2DE(4Q+L=NX$.T)3O]D9^J=>2%65H4<7P,=GP427NH[!M\^, MH0=DEOKV(;/TXC-+R8,R2TF#S)*@[?[S*]SORC13TXQ2T_R1W7K\!)+!6^1> MY[CK9>60Z,.+S^\_(!4<,79+SB/_7W[W8#^RRD-88ZG%G8>+1>^Z/L9_&&&3U>?`XRX=\ M>B]`SKM1'`;B'$M]P;4^QP-$$4=%O[M^N!23*)W!+SZ,$=V+)(,677%0)^"0 M(,Q(U+'WY?.9X#>643A)QPG'IV-C^C6Y)"-J"T!$KK<8I5&Q^/IB+$^HKR1%F$% M0(BP6%]B`"&11`X6-<:S/`NZUR[A"L!>$%0`H33@:< MJR"@*H7!^+U#:99"U*Z$3EJ+BMMM"ENG;[6Z1=BR:;-87^0N^31;+.9A3`4\ M8'#$28;O,4Q+07=`HL.9*%PEQ3DC";2,U)=Q>BS.RHLMD!]:W@L8)M942!NU M=.*D1`1WGN^K,#_EWW[0J_Y]0[ST*_*]-81UG.-YFGSD*LZB90.1B;LYIGB\ MX'L(;W'^HQ)XF4M4"9]F$%=EJ)?`R3+^=HS)H&6[2Y=+W@%2NH_`?[C@1Z,M7*K8CJKA(9P"0VD1+B'=> M>'3M)'-!JHKD&?+Y'=49T(!+'S/`NL@;&`2>-DDPEV4E=84TE2`I85HDG8+' M`KY.1.2&A#7U`DSOX9-*L^4?5,QJ?$@O:\4)\%<-@F6*T3+$8X0JWY8'!P?6 M*4D]FB?SZ=,PC6!M*NBMD40KUD_G&"9ROU/3;*5PIEX$Z,V/T&$!8^(S-L2+ M:6](6;.-T.N<5&@J7-IWK+Y/,?_MS%@O52`&L:NP2(+?0/W$Q'VF!W3!R]64 M$ZI@@H!Q8!GPUIL$PPJAAUFII>--V"J!_^XPX7^?%WD(#M<$1)&7)5#?.3ZM MY6;NNHE4A._=,96CBHX-Q$Z""[ZX!H6(DQ`'7.Z#X`DP1M/)T@4$5@^23PG6\`9:# M9(XS$GN*M#LQ&J?\?G:.9RG#).KJ9?#*.\.O_0 M)"19WZ2]<$GTRHFKL'E-5K9\8',<-FK-MVZ^'%S('I([I*C6Y^!RS0SPA-DU M\--%<,/Z=W.LUE_Q`WH_@WY;J%8M[8-B0-RL+4!?DW/K=2M!S\U:I-5KYA1*GS#>Q9G9_D9-V;9=V&Z%SU>F?'>2H<1$ MQ4@A@'V@$E.O,0U#AV,1G_R?E'&-$QG0IV5$9%IE>:9@M:7RZ)TZB,)B1=62S+91]LOL\339V MQIF"67.SN?*F,MC,X6D5C"VZNSHN*JAR$/R6.!QSCD8Z>ZO\5^G$1[X<_?LS1Z" MET]!+']-_7L=/#;)(Q=X=(0^2"VH=XD0VH+58<'8X=13ND2_\)<3L0`RH<-# M0>%<5Z4#GCOZ@W."O>%.\"@SAO?I+#C&R*(PGWUAK4]&PZZKWZC?R'];TYBX`4P7_GQ%Y\-956+(4A-C6\ M!I4E+3^/I?/JI4CB]Y"PJ^!V./3B#(O@JQ(627&$-"GLY" M;Q[54;'?A$SW,8P6`,C1?^.I-*2Q1,7,HA1/Q*$^`&4PPS-?]([D:..$%#[R MX<=XCH5<@@(V<4P'HX*))?C(!4@,UQ*3D/*8,F4K0/+#S_#5PDGD\R!:P@2> M<3'=/W;CV(E`.7#8$9?ONPF=&,,<*K^$Y][2R$#$,HQEW!,>2_V$3]F%2]74 MT!)C)YZ+J1_>Q9S*)@$T#WW,PQL"2KA4>$99"6`AA!-_)4R"1(3Q4'/!MKA+ M%%E.QG`@J``6`#8^5NH9``"/C>'-CJA8A`-G@H3">S>6T0$8,$.`#+O22:OB MXEE7ZX5FZV1T:K1HO!CDH7/G%*\%2.(4=+0)#L8R850'$]"P33[:$.#WX2(# M!V.F'*%/`R=EP2T-`O_>G-J@S7@>IOZ$\[H.F1&PXG^D`1%D1J5JN.I!$%PF M$B(NH%>S"@#?/^,#DE_<91A1W)7('.G\_^)Z=++M+[#K7*-Q$8R/Q>LDG+D4 M%R=(*/FJ6[-92ND/VNW6J1I"?V2?"JD6C:<*:@\>^E7&>YG8(Y6MBC'GK^+W ML(Y4G)D1;\K_]S=/01!`@EPV]T='2DGZ7O#MK9(Q ME_"+^$$?12%"/T^2Y=LW;^[N[HY_C"+_.(QF;]JM5N<-?OT&'WPEGT_NE_`\ M*%5"]:O?<'`U/-@4\JEYA"KW/Z1:[0WR;\-S#I@XZD/?&;D^??K5?B7>2(B+ M,&\`KWH%)ECX,#QZRVYP],=-'@S8B\2LA8SFV!BR4\\O?L;9+8X8_@O?6X$`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`1Y'JV7U^L---1,CQT!);.(DE@#;`ZL+./`JFM[%QX_@:'H-#>&_Q7UK!_P=02P,$%`````@`LT4/ M0]*F@B*M!@``IU,``!4`'`!B<'1H+3(P,3,P-C,P7V-A;"YX;6Q55`D``W'- M#%)QS0Q2=7@+``$$)0X```0Y`0``Y5QM;]LV$/X^8/]!LD MA0&W">)T&S`,!2W1-E>)5$G*=C;LOX^4[<262(I"W)GR/L51[D[/W7-W?'7. MWRZ3V)M#RA#!%ZW.2;OE01R2".'I1>O3_;7_NN6]_?G[[\Y_\'WO/<20`@XC M;_S@70(.[BD(O["-OB?43UYY\D/7[V53_[3=Z7J_MT_/VJ_/7I[^X?U]^^$? M[VIT[_G>8K$XB80%GELX"4GB^;Y\3XSPES%@T!/`,+MHS3A/SX)`RB_'-#XA M=!J+1G:D5YT-[*=X+O'D3 MY'\5H@R=L5Q_2$+`\U!5XO*T$O(W?R/FRT=^Y]3O=DZ6+&J)&'C>.24QO(,3 M+P=PQA]2>-%B*$EC"3Q_-J-P]O@'G#WPI!DPO`M>`!C*5X+9$E[#XA&G(1? MY*M$Y[CZFB'^4!.4RL`CKA#$81;G`1P*%#OXX))#',%H@U!:>VY%Y#4KWAN3 M<.==L>P6A.X&8_VJO"5,`!OG?2%C_A2`-)!!"F#,V>9)'C:_W5FWAQ?KQY][ MC.6UN+(<@S&,\_=]+@IL@G((>/V,4I'0E2@?Y;;`;G'8H[NX`0TW)L7'$H&[ MS78M$;`L27)K/A)EMM&?4)*HX[9^(3'BS9AX-4FE61"W/$)%.HI15`RB"XBF M,RX^'XH!V?D,@5_]V9EX%S*E&/856H>C?<-GD`[P7/A`Z(,A[D7!IC!0Q*WF MXM09+FP;D$JX49Q8=:2N"[P,L)AY3Y&80JPP?X3\:AG&F1QFWQ,2+5`<&YBR M4W>&.QUI=FXX7%[7"`O_AV@.HR$*(6:P-Z5P-7-]3PDS34HL=!T@L$ZB%NFU M\-#A86P+?3$(8A60)9(-&/420CGZ*P^E'=G6QHZ'?6N7JTO=7^>#"$I06-K\ MCU8\0P3&*$8<0=;#D6K]I\W$:M7#E-L6+COT3A2(+1'%XMCQP^$FN(6S>OZH M$G:+(PLZFK">+>Q"66PM:!3<8J=BBJ]SHCE$W<%\S+L%U*Z@[-2;3*+&)8>G M_,(!FLD);8W&:-!I&GDZ/[[)6KN\5RZ?*%E8]]49P4\\E-4TO72BLRPS> MD[H=TJ34"/IL'%&3]J,+I`T)GMY#FES",?](<%@]1]0HN$66=IZH0>_P>%5K M<5BQ''2`F5JK+)6DPU3="EM09-3*PU]`G$$#5TII!\BRIT?I@<.S^3Y)$H*M MR"F+-HJ9,GR'RZ8716B%ZQ:@:(#[($4P@D*$=_:P[_,*,+3HH9IUKX' MXXU*@'TX7+T*<.)L1'WC\`!G)/+EMY`B(EIC2"&0L5[]K+@*I%,Z3"%^A#P' M1/7QB\D!M?2L23WLA1_.J8Y,Z1APHK&KJB@56QT&'9YC"#>$Q2>#0 M?'>@(.<`9?735$'AMD\.L]2+_LP8ESWNFE#+"P`&G:-@S^"?PTN'IUMC@R0% MB$K\_1F@4V,W-6H=!9M&#QU>7@P8R^3-C)M)/C?KX>A70"D0DQ&1E2-(YRB$ M[(;V8X`2$\,U[1P%YS5]=GCM,A*9"M^)V4+4)TD*,:MJSCJ%H^!5YYS#IPK% M6=\`;VY;FZ>Y%7I'06>%CVI67RE6B2[0FH\SZW.NRF_QV*D?*>U"C]<$138S]MQ]#:41!Q)A;_L:2@<= M7F>)+,VW!.])+_R:(0J+-\)-YYS5N@Y06S^=2Z>AU7Y6[XDE48<('UO]:QTT.%UML`?0ABQ:Q&2/A$Y3KG,4WDMQGACP:#E`)WU4[A\ MH\'@H<,[FG?FXD]GT:MH^#3Z*']EY4.6Z!/&SM;USHLRU2C>Q3D6OAI MW8*=.7+=^F\I!SAS??[YU7^Y^;]9?UE!5DJ[40=E_*7]?!5XA\>C1[Q72[EC M:3Z-*1,ZXS#A5;"7-T4 M]2I'05I%>^Q:7UP\?_PWDGE8_@502P,$%`````@`LT4/0QAP_G&%*0``JZ," M`!4`'`!B<'1H+3(P,3,P-C,P7V1E9BYX;6Q55`D``W'-#%)QS0Q2=7@+``$$ M)0X```0Y`0``[5U9<^.X=GY/5?Z#T_?98VOQ-G4G*;67B2ONMJKMN9-4*L6B M*5CF'8GT<'&WD\I_SP&U41(.%A(0CKKS,N.V`?)\YP.QG`U__9=OT\G!&\OR M.$U^^=#YZ?C#`4NB=!0GXU\^_/9X!?_OD?_^&O_W1X>/`K2U@6%FQT M\/1^=WL%_'G=_/C[_N=_]KX/_ M&7[ZWX/KA\>#PX.O7[_^-((G%-43?HK2Z<'A(7_/)$[^>`IS=@"")?DO'UZ* MXO7GHR/>_MM3-ODIS<9'W>/CWM&BX8=9RY^_Y?%:ZZ^]1=O.T;]_NGN(7M@T M/(R3O`B3:-6+/T;4KW-Q<7%4_16:YO'/>=7_+HW"HE*54JX#M`7_U^&BV2'_ MU6&G>]CK_/0M'RWE@C:C8OF:^@-.CF9__`#J.CCX:Y9.V!?V?%#)^G/Q_LI^ M^9#'T]<)QUC][B5CS[]\>'HM7BI&CD][Q_Q5?[E,DSR=Q"/.Z,=PPM7R\,)8 MD7\XX`_][7=,)'1\79$6]W)'G.$&%%'(43 M6R)O/-2R_`\PX-D47I#?/U^&^8$%7%_8A*L1%%:\VP.C_50+"(89>PWCT556CH=9.BJCXB;-'EE>@$CV$#5^ MBP6$@RA*RX3/BN_ATX39`V7R8#LXLI*-KK^]LB2W"T/WN?90W,41?QNHKII] MW'Q'+=]E`^WR^4,8_K?)9?@:%^$$!O_#"TRR^6/ZD=WF.0AI$;6==UI`_U"D MT1]<0-A:7_]9QC:Y-7RV+33WK]4*"4O,[V&6A3"<+$,R?(&5W<9T&A?5IP%O MA=T!GY3A_!0SB]B:OL0&;^53SOXLX=77;\PN829/MH#D*HU*KD+0X#4HL'BO MO<90=/FCEK*&6;00=_YC_0W+`UV<%$>C>'HT;W,43B8?E/B0H^7B9,C/E"<5 M[.II;46"GV$1`'2'(_8)&VOFC6PM;/>=PRJ9/++,I MZ?ISVXKY`A)E4?G$#I_J>;*P^/.W`CUE_FO@^49%P"R6_@Q7[QE$CZQ2?7N`&\<='LK=7F2 M_)&?+W2DKAH&W>,UB5<4#[)UV6&8+9XZ'W%&<_MSEDZUU#=_9ZJ4NLQ!@O1U MMHA^.$@SV-[]\J$#3ZC&\<\1;!Q@6%Y/JG[P+;`Q_V'U]TF:L]$O'PK8][=C M+6?13^/T[6C$XAEA\,,F3_"KX(Z-P\EL"1U\BT5#2]`JZ'8<,B29YR2,K4A8 M9PL37TQ5=S=:G\ERM;8T;JB\WB3H=AWJ&UNK5\K&=+BMZ2VIQ6IN.26Y4W.P MM0-RJ>[UG9P%?:_$%^N][VLI&.0Y+)^#IYS[F@K)4K#>,.CV73(AVO>U7!0$ M\HNI./%+Q669<2.Y-B,;[8/NB7]B!+J6D2*"(.;FU!B>4M&\ M2*%B`I:"B_5]YDO?]\4+RVX3;OU(LW>)YM<;!MVS_>-``$',QKE7-M9@J1A9 M:QQTS_>4E6T88F8N2*P9NFM%T+W8/SZV$2!GNF,"7\GG-(FTUW%IOZ#G\LQM M>SU70T%(Z_@B[89KD]W%;TMWWF"]WO[2K`T0(=:SK4*Y MRPEZ!&P3AD?@2F9$W]X,$G=Q^!1/0'.,^]8%@1'JO8WN(X(>`;.%D3W)"!G" MK#=S1DUX?7L3WBGH$3!]&!&BY%2$$&'1FY%D(TY0XQ0H[!#T"!A-%*I'YDX< M#\*5-Q/*AJBU6,$58GWFA-V#'@$SBPT><70(J_[,+XM`T$W0`;-, M4_XDD!"';@,[S7;D&O^-X/6ZGY=)]Z!/P!)C1(\Q.H0I;\:9JY(]IJ93)=XI MZ!,PQS3ZP!28$-Z\&6&,YD/!K-$G8$1IQ!."!>''FX7D+DW&CRR;7K&G8F4Z MD'$D[!#T"5A!;&S[<70(<]Y,(#6T>I]4T"=@#+%[-*L@(<1XLY4TLHY(--$G M8`^Q0)L"(<*B-[O($)[%X.N?@?U;."EET;&"UD&?@"5$H70Q4Q@8A")O1@^> M\),F6OQL-@WZ!`P=C<@1(D&8\6?B$.<'RH["XAY!GX`AHQ%/,D`(7=YL%S/W MT5)@-5OB#D&?@-6B$5D2/$APM+?0DBOVQB;I*_=-/!3AF%TG!LSAG5Z#N M*"YJ_MFK,HN3\68/V8&Y]<.#$P*FD49CP!)V9+QX,YQLZ\)H%QJ<$#"4-.(3 MP8+P0\%`(MQ9M_"H!B>TC"<6#GPX3H37N5D"T!^MIR'Z24Y<+WNSAYF*)][V ME$TS%4]<'I]-,Q6Y^K#I:DOJ'R53\<3E0;E-IN+)UI2$B;]7F8HG3L^^C3(5 M3[;LZ$*I]RI3\>2,;J:BEK[)9BJN&ZA@3;W/JB]W5%E$AFQ6A4C;7(<](#@A M<9XU6$0,%R7?%9%:E`6+VD6__=J!Z:D8@F1(HEG MQ;\,:9MU"DY)G#A;4E;#0BR?4B3M?5GP1N_@E(`GWXA%75#$\C5K8ALL=Y)>P2D!_WY3YH1@J*5U;LFK7.:0 M'L$I`9]^.ZIJ0*@E\R;H%IR2<^6T(VT1C+UT3B<6M2<`'"[>HK(8. M8L/3ZQB:[!A@$>>.^G1@"TNGK^'MNNSO;-=GU&JLG>F:[L^^X&J[)U1 MK;)WIE5E[VS?JNR=T:NR=Z:N^G:V;U7VS@A7V=/2-UG;]?(S?8A8$F9QBDPV MTO;!F_X22,*JD'8_C/I[7#U.:!3]0V.*-@(I%^!8*C M'HK$FAD947?]QIG'+$SR,.+ORN6*E_<*SB@8/4PIT,!DS1*,D`%GIBB=)"#" M'XN;<`"C\6T6RZC."C-_6'!&,V8!-QXTQ$C-Z`PP;F$$ M3]F=O%+@6KO@G$!X0D,"4#8WX%$K"S@8_;W,9]=$\43Z*$VB>,+6Y'Y,[7W" M+EX7G!,(D;`Z;)QIB5I%PA70FS33K#V)]@G."41<.*-.-5)$RJ!6IW!5F/$6 M-BYQQN6^?`FSL31I7](K."<0GK%CRE7JH%8LL7+K)1&[?ZY\?K5[%OD%F2Q[ MBR.6WV>7DS"6NK",GA.<$XC^V/'`,%<0M>J+E1_X8P@ZX"<;!H=5Q5H@[A"< M$S"6[)A\B2:H56<$!60LY(FDL__7(>M>NJ/]C."<@-5FUQ.!D7*H%83E\3J_G*[>:V`4/"BX(6(SHS.Z8AJB5K]R&L%'H%O:NV^4YC4:-S@.#"P*& MHP9TZHX+;1U0*Y.I;TRSXBT(+@@8CFS;G4VP4RO#B8C/=SJY+:^1Y&'!!0&K MD@VOD0HCM2*>,%'-E]%!]&<99VSS1A8)SH/. M,0$SG57>3<%3JX-:"<^R.!UMFHTDC..=`"0!4YK1KDH%AEIE5"ZO@AL0G(`A MRYB%F=CRBJ4>8A'*U]=9.BZO@#W+\Y[GY^H<3'2Z`W`")@FSW&9M6`B?#6Q+ M6$$%_@&'\;SZ].Q3YD%P.#7U58^Z:320()=X,-3/WY6/XC>5*5M9:`AR/)_/VQ`C`(-SXN^QE M/BGP6[G@QY7M+QD)]J!7<*R7QRT0 M/-%V$20ZY1[BN6&"C3JR<:'J"Y`)'._M$(<,"CT5(*Q[L^DL:RW)":XW"SH= M`D=VEUQNHT5*8QR3*CDU=^'#7_>QYE3'7X1:TZ)3G8[+8`#3JE.5`K$!O2WW MCU)WJM-Q>9!N4P&FHF&=,!3`7I6>ZG2) M:C"95#DE\D([ZZU`0@HF'?GP%UC"12CVLO14IT/`LF*N?QU4Q.XA^,+>6%)* M`Q\63>`P1M/I+3DDKLM.K5K4,C_A^AM/8=:*`$7[`$2:WG`)/0HPU*H\?6$Y M`WV\#))1[?;?N>S2+TC2#Z`22+]0,(%]74I;,*C5*/J<)NFZK//1I)."HNH+D`DD*I@QIPF*6@&AF8>0HYP)O0BR MD<:NB+L`0`)G7DT>Q"3*H5$K"U2=U+?QRF9)<0^`1^"TW(HY*3)J!7NVA%7O M';$N0:='(.S`+G5KT*@5YT&A-EGP`"(!@T@K]A38J)7=:59FN=,C<#(SW(]L M`Z!6U.8ZS!(>P[.X955CZXAU`8`$CF-F#,FQ4*LPLRGMQS"/(VZVB2=E(;W# M5-$3X!(XILG)T"-0"(Q:I9C?63Q^`>D&;S!IC]GGDNOE_KD"4+OB4Y_>9@\$ MY>S=$:\-4GGA&'*ADL.0E\][844<@;C[&#?9]W8L:QPWV:=T6V>E0/%W()+[ MAXF;[%.]L+.B89TP%,!^Q4WVG7HEF\5-]M672%9R[U?<9)_PM9V:*O_>XR;[ M5&_N%,P_&E"^[[C)/N7+.RO](X3)(7W?<9/]O;B_LRE[#N(F=Q`:@\8"&O0& M]!1L1/)/2\RH-CIKL9H[B951LJK5'Y`3,"`UXM4`'[&HS\&D>C@;B:]14?M$ M]!X`V`EX)LV.QR;([,63(L'58AFJ5-[[ZK6K2X]PSAH^*>B<$/!-ZI'7"J*] M*%.,12X"-I)J=U6AW&GV!S@$_)$FC!D!HQ9*:O]VO\X)T0AN?+I4PI''C>[8 M='Z?C<-D?F,DS`8?RQPPYOE@-(IG`MXFSVDVK?Y^Q8HP-K2>(Q/`QFL_AT69 ML;K!7F8F-WQ"T#VVESRE?"UF)#?H'723J5E MXS+F1L/P+KF%BJ@YV.U=4,5/\7-`<8"YV\4JK+MH'$/IU(JK5+Z4+0T3, M$F^=,QJSHA/R=E?`8/@"!^3[!#>W"EJ!A`1R2A6C7["?%J$@9A1_*)_R>!2' MV?M#.%G>/:YP!F-]`*'W0EZ65B8%1F(&\)J,G\,I_%@KUZ#V/BH[`V:_U<(T M64&HU,1'K9S"#DBEM:(Y9%>UOODKPC#,XK>P8,-)&%66$J4;4MP!0%+P.VI^ M:M@.!4=&S5J^-"M?_UG"R9,;_-.DJDZM&4@EZ@=07<:A[W3]5..D5H)A0U+E M%"ML#]" M]V3(11%2JVL@$%9MZ(%*PQ!TTO2XBBCOX=O3_H=CPF$]@:)+O5%C+X_):8M)JA MT.UX/`1:&!3:&!$J_=UD&N8O,DLOOU>^Z_3JOMV1LP*#L-#` MZ*CQ``#O^RIP.]^@"5R$:WL)E'K"/'Y-T4V3[@."OL]RAM9V/69P$?ZZ7E+T MZG.0L/NK/KZO_455&*_)\X)N MUUO]/#URD/-_<[`_2D)@U^FU869%KYJSM4X_BG.O4@2[;F\,:Y0B6&EQ6]G; MDG22CM_G3JM(C%.:>QJ?)*KW/'8BVZ\A";\TK#'+`XGBD51U!;$]7C79N./ M1T03BLY>?B-"PB"*LI*-[N+P*9Z`[EA>6PS@7Y=EEHF#54RZPP`E<"UJ$]^K M.4IJ*9%7)7M,=4E5=P*0Q"QKIFYT%39J*90(UL7RMF%>'R6U/%*I M9:.IS0=4M>>SN@8\:@FE]E,F^DY=*#M@40G.7G(I%O\+LBMON%EK!(+MZ62( M82%U!?4P8S`21E=9.9X7>;U)LT>6\V.6Z\LT;A.>:)EF[U=QSD,@RXS=J:[/ MD/4)NGU[(U7P(ND5&5A[$&KGX;":FA(,5SF*'R;.U?_ETAILK-.'XMBO.%:" M=TQW-2X\[N[='=-=RG=,:ZJ<;!QKM=%:?KVJ[>:R(6#R;7,U735D0*01I3O> MYVR<2%UO;39>I]S68.V#?J_!3*TGE'0[(VH+K+KG#?QK*/$Y&3S0RU@K.\T'L)2X%\?+5.F`<[)SHH@C31V9*[Y M)+MML(B>42;2PK?6^&Z83DJ;5']#X+F'6VFH@ MQV8O&4F;JO)I$D>KSIM-S)?X`V"DD+!IZBA7_36H<-*Q?CIVX)Z0 MM&>JZ-'PZ)ZX,FHZ\S.>.#T9-_/HGFP9K\1R[Y=']^2"AOVPAU.25R"9DA#6HRZP")V0@MD$9C-MT%>PY*$9%U=9]Z M3QZW-[$J@1*S$#HJF')*H]2;DHTF_M(*W(]1O^B46/$W5WPJL\"]);?MH.[- M*8%,*(TOKKD#O$)(K:#1HO;\POPH7S\%K0&6]_IQ]M9-%*"]>D6V9MJ"9?%T M"/])1[SL0?XY+083_D:`J#'AJKL#=-]U,1N!A$@)R7*'HHTNB/ZI3[S++!F$GNHY2V M!W%)E'5KH7\Y-.=UA!;5&N3Z7V\5=,\\!DU9T;H(D/-R09_")!Q76U+8H<)_ MXS5O?,8^22%1YP6-2*^FP?";3" MS\1]`"*Q*!GS8`%-D/:*[7@NB';F^^XW:^$=^GCEI73\A#O-"]*"%OCTG:]Y M*GZ<*^&ZY]Y\ET2NA#MSN0MO=R5<18YXMFP!]H>)M#KW'J=@@:UU^E&<^Q5X M=>XWZ@#5XK:RM^7>K\"KL7N\WVH"BHYY:BP28./=FU6 M6!H-AF$\NDTNP]>X""8:5MB0R$T+31P7="XO9 M5MKOE^='D.]V*R^E(JP( M[0/J]6Y%:$XG8CN2@R56F*HFX^=P"C_6%A%E0(JZ,V"FD0*A8`6A4A,?L2I5 M.^"4QEEA!^22S4L;9O$;;-R&DS"J5@MED*ZX`V`DX)W6_=#$3,J0N;:27*;3 M:9I4DO/U@2\.LQ5C\2\T5$#5$>3W?1BTN6'2Q$LLF6QV<<)2#7,%2+XR<0?` MYC'ZW2:7.CBEII4=GQNK`<=_S;+\^L\RMNA^QB(8N3K7WJ@\!TJZ!/V>/9O4 M]GNDYSJD.9#L,K05/[\IU228=J08OH?SV,[STR]<'M[U3VQ28L5SEBE*8D>U MMHG-O6.GL;E.LM$OT&,V!I#86TVSZM@G5SS>`R0FD,UNH'H5%&)U)I89^@\12$L M3E4.)E%[0$8C<[W!444"B%KIB(6$OR7Y*XOBYYB-U$X&K`]`I)&3+B$`84P. MB5I=".NLT3JEV*5/F6ONS28PFTY^`QT/RRQZ"7,V&&>L0HY'GNEW!O`$LM@5 MGY:84%UP]FI$(/N.FSB!C2:_57?Q?OFN`VL/XA+(:#?B0@./O>(-EG<>EY,P MSS7#6[`^0:]#([RES0Y$#,I>(0@[O-6E5"YDVXT!%)$X%;G:Q5QA>.S5B"!# M$M%M1GNVE'L,>P:(F[2L3""*=6BM%8A(P,2˛LB,0WWFMB)5O>>94EVM8 MW!I$)6!1,]"T#(:]^A"(QJ]*=A5/XC%/6;A^?DXSR;Y7W@$$)F!.,]"[`HF] MD@Z[2RKN=5R:U9SLEU`8\JH,U%)9>QVGR2R-DH8K-6YK>UMN1-5$\[-!9!J[ MF!8Z5^U6NO;.SW=Q$J639!AF?RQBUF!EOXNG<;$JD/)^F4Y?P^1=4:+/_%$` MUJE!4KXJB(>[8"UHC`RAS]OYNXHKO/^:P,3[$K]65:M87N0?WWE231:.$A@9E`$+VCU`_&]E[@QW;(8`$.B=>W5 MG92)(:^8HNX)$`C4LM%3M"%#=8`(1PT,&9XXHK&1V`59JBU$KX%)!,LEFK_\ M/E'4Q=]J"(+Z3FS4'?H"(A`XB+[MF4$6[WW\FNKI>]D0!/2=?&A!WQMP$'W; MJU:W?"^TTASAM:8@I.]"Q#9TO@D(T;J_(K<+_^ML1\+M6VG"(WQT(S9$_0"J M2Y/?;J(V<&`(A][L"!N2*FT'PO8`S6F@FGG\!DZ`F#D)+(0Q;^8`:XS1V)BY MHTZY'?-6"^_W,,M"#4/.6CN`1"`"4?*AB.D18$#H$;O\"5,QBKOQK)-T.OM M;53A!@@DS=/?-9A2Q.8VR.F'!3"FS\3@>-BB/T>D8.GG!:$2TU\"*G>;`8[ M()76KL(AN\K-AS<[P^WP7EUP9=$&H!`XG.I^4&+"-L`@?'@S&BR+-[+159G% MR7AV1\`LZO\S^UK]26YVU7D`#&G?_@K#2G--\"'D>BRY()3];^&D9"VX7>\/ MT'V[1>Q2*X*'5$NR%],@'6:7:5+`KWA.6@J+"[Q[%A6#.J^:/`R`>HR*;EX, MLCE6A%1[01!2V3ZQ;*RX`UW>%4!X3.1W0U@=&4*/Q7`'+LD77B4V8:./[W4P M=6EJR[V4+:,G`42/6YMVY#4`BG!IL2)#&&?5Q'W_O%&5>E5A>"L;5M(GZ/4] MQK4VYD<-"6'"7I!%[;V;6:1R.I0=`8#'J-;&G&CB0HBQ5Y&Q*LJ>1.M#8R8' MKQ@^B[#%R-'J#$`\&HD;$V2`#2')7BU'H2R#9#1W>,YG62.6MGH#%(]F9+LT M(>`0GNS56ZB)\(6]SJL1C>3LR/J`V+X#*%O.;0@DA`F+&12*85$MATT_F*HS M`-DSXX4I-H0D>ZD4\Q((\U??9U_B\4MQ_8UE49QSY\3L#(!^.%J]`&2*, MP2&5A+W%5LAD9\,LYH-O,=SF?Y79FYH\#A2S9V:+]FB186"I#$5<)5_-!L'L MYTWZ9[^=9VGQZ+J%F&O2"XC6ZP@@]\RP88(+(<^R68-/^7%1L-'J#J`M&^<@ M`F1YK#8EFCX,@.ZM<:,95H14>_:-K8*7\A43:1[T3O;1JB%%@ZC>XR5^:<38 M*+\!W,(MF&0!5/8%R'MF`C&$AK!ISPJB\Y'/SB^VIL?MIP'4?;23M`&+\.K" M<&)J*MFT'YSLMW%$!`?1OL5;Z&1.G>J/FSLB=.EJ\"@`N8_&D\9($3KMV51D MGO&Y3`N13)W0PF<`K'VTL)A#1)CS%B&RFC8VK4,KRS<7),?N?^-)]*R)`]G@R'C^3K<:C*/UZF:#,/WZJ["KV&VNAQ< M%@K:^N'`J[WSQE6<\XN:RXR9<".]&;O%(P&:R_.'\/9LV\0(MK>M-4+G+F[' M)Y3@E703S4JJB]K=Y7O:-SE1M_6[XQ'T;#1X(UEX9BIPE4\2`$'9P*5FSV/ M6MOJ='W[N]T%H/K755BP93('ZF)Q_%Z8$BCD7[L[X>Y&@>+AYS?E>P9@.`F3 MZV\316Q'*R#/"^GLW&],:7^+>5E^/EM0U]@ M=+O8OQD+`1,[@7LGB.[N&FH3,==Y9&5U7ZBNHGB\25,=G88 M-A0AZ)W]_W"VJDMD,'>\.)!F07.5[(-DM*Q*$,6,FA-IF*6C,BIJU\LM9%TY M]^0!K,KN0>_<9W`N)A_F'-+M"L/.9>"@U`FDKW;,):N#[8=QYYQY+^1G1HR& MV^8,OSV8J#/AS&E$8#.WS9G01[8M]WZY;\/5R.[B-S:Z38HP M&<>PF`[RG'&_V:?P[VE65190["D,G@(G1^^7D]C85!A#IF80E0!8B:]U6;?A MDT`=-*Y$,:;0>"3@\.46Q1]L--#:Z?@;%JI]4,=B78_R]77ROJR!H+B_4M08 M!"9PB4NCCT_DO,DQ[MN4\4,!#&+17T6,015G)]_A\',U? M?5EFVMH\$!1&P$K3])-NA1X:'/9/.MC#U<[K>MROO'/0N",13V/B* M=7`BA'F+,*SB,W@QO`1>\"[Y2M<;`A@"L<]MOST1)H0@>_55K[)R/!?\<1;5 MO]P7K]U\P8LV#<,8-FT/13C&B[R&2;*0$TA`D_`6#\KC?V9\GW8V^,8.F`=?'N=`H"(%V" M_K&_R/9UF5017:+F\!6[_"SDJ?Q2E8I7&QS##Q.M=4$FX@$G8YT\%,9^16A= M^`U20+6XK>QMN?%1Z<@2MH?I9`Q;.NTJ0Z?2K6-UD_0.K22.=VE5,#(Q;K MM2&H07-7'9F>"31_;LV(E]E495_95!,II9]VN^Z^9>:UVGR>+MM9?>2?S4JBY! MOTGXC27!,<^TK#D([-*](/1,ZREQV_DCQ_"C>*;[3N]JU#I^J,G8)D$8Z\\ MTWVWURLV\DQ76E2X2?OX38E$/=,@,8U310N5._9,FRX3W`NA6!IXDZ#?]^A! M:;LPK!`X<2[KZGP`LHRX/#>34'07TU8;D-ECB')3K0L@.'$.FP[U6;V^ZV1T M)2XKBK8%#![#C-L.?@$4)SY>4SINXCP*)__!PNP&?J/:5&^T!AP>[=YM*1&" M<>+.;4;*;,CHTU)K#U@\7HYKAY@M.$[!XML4T9TL7EQL%J1ML7-H[S@A?JY6GA4J+6 MFP($C_;9=M2(D+AQJ1I^0X`FX[DG(_;MWY@H0P]M"R`$LBV_%)$4-RX5G7Y MF.=QKO8?\MTPUAR@>+2&-V5%CL:-S]7L0[F))RR[!)'&XD16I&70/]G#PSD* M1.YL%7HA_GK$'_\4YJQ2PO\!4$L#!!0````(`+-%#T.G+M2^!#P```)W`P`5 M`!P`8G!T:"TR,#$S,#8S,%]L86(N>&UL550)``-QS0Q2<RX`Z/E@F8_$1=X+G'.Q75S\^5^_['?@ M&19EFF=_^>K=MV^_`C"+\R3-MG_YZL?U]=D?OP+_^B___;_]^7^'P!EU$5K8LH_K5LY`$2__8/`/_PX6Q9;\_>OWWW`?SR]OWW;__X_3^] M_W?PG_/L0 M/\%]=)9F915E\4D*5R.2>_?==]^](7]%1/?MES+Y"K4!`'\N\AW\!#>`*/!]]7*`?_FJ3/>''5:<_.ZI M@!NQ%KNB>(/EWV1PBSL+?^$[_(5W?\!?^!W[]6WT"'=?`5SRQT\W4H.^Z]3% MA-X@+5WI>0^+-$^NLF$*]Z7=:_Y0144U0O>VO$OMUWD5[0;IW99TJ?$='-;. M)SFG[8N<)AS6OBW)J36N>&VM&Y5KS1W^]RW2H:,=_%+!+(%)HQ^65OA54CGQ MQ\1%XFKSN%/A#COGO!#:2^K:1.4CJ;`NS[91='B#!Z@W<%>5S6_(D'7V]AWS MQK]CO_X;(F$%]S"K5IOK-$,#2!KM[O,RQ6/!\K'$HUC5?)=82[3YFYUXTUY- MBW6,*V"9UT4,K5J+]D-7K>C14BTT4")A/!^`V=F/#U_]RU$,K#;@*`@:2?!+ M(_OO?Z8J].Q:%MU^BXJX41+]J#&,E7@3YV@4/U1G'1LW1;X?TO),FWQ(\[1[ MS0,@U]'CB>(JZ+&"_D#6:"J'TR^D2$BHZ;2N%!^"IK5%0@GC;[?Y\YL$IA0$ MZ(=^WZ-?_>T6#0&[JZQ*JY?EE[04=+RPE+->%^O8[W)2`M`BR%V@0AX[7=&L M38]KVW2N[J;?N\SW49I)^KI;Q&E'][3K]W+3O[2`YQX6M62[>^7-Z,&IH[D2 MO$$_BOBM*NS/N;:ZYI9Y>TM;N(+(L2UB5!E/.?D'GT.`T M[<."%M#.%D$W1Y MO24(9@6#0K)>^4;KB)0/!=@2L(CQK42*.YA?1.63`M7TS\Y!S+3BNAW]VB<\ MW:MUX+91ARBW`(]PFV99FFU!O@&TTEDU/FU:#],79HE.4Y?\;K.D3V>>(N[8 MNZJ>8'&3/2-'DAUNV*Y5^;Z`ARA- M0%+46W`H\J2.*[#)"U#!LD)@\2:^P'V_2UU@,C>X\U[L_,5,Z#FQ^*T>( M$-$*>'A:P)DNW'POV*0+M46#X`4@1]1S`;EU_#U88Z)@/\#9]ALEM&L.L MA,MM`Q6==.ALN/(6:M8?R4Y;M\ M^P)V5*8$9Z"`.Q*W>8B*ZL4_DXSQUV>3)?B\,.HFJU"'I(\[R';AX[C>UZ3] ME_N\J-*_DQ!2,XH95^:3<^86*TEXJJ89P%H5@79-4]-2&.0ZK^6WL+2USQ-# M+?&LH.P@,+OC<%^].UA=?8EW-0Z&_R'/D\_ICH-%J\G,Q)WSU-"J/CXY,BX` MD@1?'V5!(_Q-`,LIST:Z9*8-2OMHZ[T&[2:#M]T%Q;:"=_A+-5ROULM; M$%;L@GK?P!?\;M/H,=VE50K+998\5'G\ZU.^2]"J]NJW&L?\Z?<.S*MP#F$+ MZ[B)RDD41%D"VL*`2@>RNS#&R)OE^_KK\=/77U>WE MU:>'W__NPW=_`E?_Y\>;];_Y9Y$M4OL\&P93+TPT#QU2"?EDFSX.I\VOL"*) MK,QH5-^=A(*BBF%@D2F.',Z+XCBOLZJ\CU[P-0.#PQB)@/MYDTQS;A[%"@)6 M,H231GOE#[2D?]2K$<--NPS@X@WMG^B^Y7U4M!AICGV)N&\FR*S2\6(!F"1@ MHHL`F6)M'..-V2ZUJZUWIT9Y=`Y*@FE#Q43P37;__PX2U!-?Z- MX`NFPZ&=N#.L6UIE`OO>@.B3!A-9QQCA:#A,\KC&IZ?"(\E9NLQV$N/""0RA M6^,/AG/-W>!X6<-U;CN75@DY'QZ5%O11APJ#=1[D9-G*CH8]+)`#3RII;$IP MLTH]P/K#IRFZ?.X[6NTW!K'/J-Y?#"D`UDCW;A1LX%N+YEN*WA">9]LU+/:7 M\+$Z!2.J4"X1<(]TF>8):2D:8`-(.9^H'Z3V`OS/;]^^?8>7I>`9BX!W;Q=OWY+_ M@1)3HP1173WE1?IWF"Q`EC>_35SA)FBA9O# ME"3Y?I]G1B3AB[I/5<)KRX67D"*A<,-288X5"_#^K8(7X'_]\^+#']\NWK_[ M)T*(/[Q'/WZW>/O/;]5L`5&),W[\X?2!_???^S8=W;]Z]7P`D=H!Q ME3[#70"#D0R@7&80)3H='B\F"[< MAN.Q),!%09H!5CB`M?(@,P[,C)@6]@]\#9"X4T83%+F^5GW42<\"F8"GB]0" MS24WJ$\0NE!!QPWTC967(Y]DI6&C1Y6#1\C&D``2[$S?*^YOA90B.AR(MX27)O*[(1)(AKUT5)/E^0G9_[F%!SE>,]_SE%7@^!E!8IMUB1[(`+>:H--T,!4@> MD`K".3(88^)QI]0_P^P0J3X3,(.C+[815(U0AMH=-2S6*5 MHY3RR2*#%4$G8"JHQY9]-GEQ7BWD()@M0%8`!`)[1U,MP%"^H[A0X5, M>\4#P!YBF$5%FB^_I*J[Z)+R_B#5TUN.I:8@@A$J&A*$1$TOQ8Z\W1V"ANGP M8X8OA/P>@!C:MPN`76CP$$.FZ@@.263^,F,7? M[Z*80'6Y1?_Y"/>/L!``0U'6[5Q=HB]W`M44`Z0<^(66])(/8(3>/F>=L[2T MLZFE"M>=V:0>U"/8U4I4]K(NHJQ$DP?4Y*6:9SHIMXS3VM!'1#M_W@MHB_BG MH;4Q'R_!,L/QK6@QA9?![/E`G\1TUR'.V&K&DPYO;4@R@L&W:1;GNPQ]YE=V MZ>ZZSI+;=)]6I[R=+VA)>HBR%S6M!U7EENO#K.5#^TDM&&^_-A5U?`*O+OV>8R/3["Y^N8>;^6X#;VXM0?,8(9G8+OT$6]_&,WV8D.U--->#\ M!>"*P$T&CE6!4UWS)Q`SO.<^B?D7RX>_@NO;U<_@^M/J(UC=7WU:KF_N?@#+ MB_7-3X'DUAL.[?Z:>2RNG=+Y!OF>/;Q5/YW>*^>#A!T]1?RB!<#7N,@W?NZ[ MFAP/FYBRF^\!=Z,+B"8ZWDIU=$Q:'L`"/LK0ZS(/TW_4946RH./TX=B^=`<[ MJJWSZ<;6>3[G(0/4+*W&GSP?/T/S[[,/@99CP=_"?PQL'#?,0.6\&9'/+8[- MF#&GAG^+?XYQ&]:XW=(,Y,=VBXX?\>]9YN0KGRMK;K+Z\'/7>;'/P^G-X;_TY@*G%4-4]/U@WJ=9^7(0$ZG*>*W'N.BL>?K[\9G^( MT@*K=O$4%5ME@GFEE*?\>#(;).G8<'%P*@^80`@YY4PM6173+-A8]CG#WBDJ!=-(!9O[D-A"OY@9Z[8__PF6') M/UG4$.*"T@SPXW",RN("1CC;)?W_]K(<#Z8FVW46=;@?FRSLX\8E)@L:X=Y& M&9$/9)-LC)U?-\+?@*2Q-,U`1.3\T\L:HMPX-`R?/DEXDSVC^6M>J!]+T\@% M0+:N'5*"?=U(?(.!UQ*::8BR2\!L:]9]`8=SJ7#J_OAD9!TU MI'F6-N#120I`@X%)@[X@)H;M++:C9H?"BD(@F]I2RWEB.U5S\)-%2XN_3MH# M=U!/10\#L,7<48M>GV1=QG%>H]7Q??2"HXB66<*>M3=[AG=HA0&0U]!RP[EH M4QM@U9&M!U8A@K"P4LJHMMKIG<*SJ%=TSL#._=\_@YNZGJX?7@8%=_#_B:K'_V&2.1R[IM!\,0A\I)ALB@ MAT;[>:QH4`QW'FMNFQZ-?`7S6`5PAP^`@9'S.LVB+)YH'JNL+!2RJBVV MFL<>JPKOGLTDQO=FL=8`%_#X),\@.#&00M^S(\BJ$L=`` M6OPS,(:X03_#`9LFKC3E!E%+.":*V@4]LU)0FR4=G)HC=:L[.$C+<%HT( M3:@<'$T,`-:GB3&Z_(PCIP#O5E)AP]%$(NMU3)'9HQY9CM<7"(E.>:-#&6%, MK<+SUD-GK"FC'724G=STDM:H[B)&I:W;)FW#VD'EM*0T&Y6OP57)-]40:T"V M$)>5DRPG@UY&VN_YB!:0X>[YF)M,]GP([39'"U_!AH\"MX\'JP2+- MDWXTA(*)*B'W+_&H+!#-&A>`%@>"^!^??+(RY.YJ#6[N+CY=+1^ND/Y7]*=O MT.\`WH_Q3QX]L+@W>`Q1Y?"B8'TX[$BJXVC7/&EP17]A]$R%D;C[2X1F5G'7 M\5IBIVWH++FX>+V]7#CY^NP.H:G+8W;^ZN M5Y\^+MT+=V\[F1&E^[*3#4MEAYZN@ML,..TC*4(@Z_EB@IFZ%2X2`F2%4!#<&)#CP.VB'<_9[I!Q MZ,=3_$B6"+86+M,RWN5E74"#-%\@2QO6*6MN"N\9RP,Z3C5 M',A::(:&056=T6V[('?LIB*&:&MB.E:X?&L;'R"6:"[=)&3:X_M-[%P1)N]4 MGD`OZ^'5;;T]?.:M1N:8;&P!J!PX"OI]@'N(47PZL?J`?A-WK`WP2-P8DOP3 MW59X=/G&*'M75\VG;C$/+XIVM!0GVZ)_][I_IU93@'O_D!8!@'_@5-;[KM<[ MQZ=6S1(YB"4\K7]$NDL6%J>7<4/8X#'L`O%Z0]/^(_9FE[L=23^B?H:M7\KM MSBNG(W=W?;=C&6^\/XEFKJO/_=/)6M39UJ@8IYV=4!5(74:4/L.L5H:QG(IX MB!4]:L<'AM(_!;#/J=?2OQ_O]S,?Q2GJ9(>)\INK\5&YEV M2A>ME//@M]5V\&Z2EB=[E2V)AB!!./D1)B4G";]9(*;N&/^D-Z(,/]H9\\4= M^7^`&7)'.YS#*=FG68I=$0XWU]-?*^G<`>AMZ2.-2=#<91V9@)S`<+-^'^T/ M?P)11\H_>0PAUZ>/%=X\SB%MYHXAS!F-YHH!T,!$<:)D*\%7N+-$X]FA=UP; M/24L+.T/V\IW;D_H[CPN',!=$3/]\:60$\3EKPI[P;?^W5XM5!Q>N,JSO*L- M8YU)V@Z]K/OK50;V"&(5\CXAF%0@&P1#K*+[LBGC-QL&)/=6G%Z6,D4<=T?* M#FXNC\MPE`=>R5"UFI!%Y7F93,3#@9E4>_[$K"G*:+(`ZF!2-^RPLH"%ZE)> M^&>##CO\09\)6!5J+O8EPK&">^O>5JH'PKD-9`1/MZI MPXM'P.NWB>0B_B$OWT$18%ZY^3A<=[OL+]8FA+,"UD!'BWS/^SS2"=B0-4)( M:P/#-<'7K'@(ZV0;6^B6$"5#WQ3_K-"BRG@=X(L75U&1(5W*>UB0!SP-ELYR M$>>L4&C?!U)3%-^*!*1P(.MC"QOP9@M`\`$E+N@?_CKP]-%OAAQ_X#^/RC3& MYWOIKD:CN04'.$GO5.!MT3-B`8@4/;BE<@&<'-A;AK=8=QVN+,#CT;*$RH5' M'PG\="Q28L\=F7Z&Z?8)?7_YC,:W+;RK<8CB:D-47-556:&V1VJ;QP;^I2?@@J!1*1)H_"MI,.*3I/&F.M"H;P&\\]K6L`Q:Q/;%$SD MFOCBP&!>!1/%IG49AO*A1;1)<:B/:PO"<\2BH"T;4#SI8"NO?JO3Z@5/ MFH^%_?/,#HU]H@V!XHB;I.*OD%O/JP/^$3'^9YII6TZCP36YO9$ZR%;NPCU9 MM9[S=*(W\6E%9!Q@5]1?;IW&;&)=?K*N2;^N/,X;;9W1O=A9^W71[=BE M:<[ACZ3O&!^&/R#S==5X\P.(YC85Q[);RCOV-N5UBN@F\3#-9 MQADP&WE_GF6L@1MD13FO%68>Q&M/N7,5ED3K.HA!+!OA%E;%-LK2OT?,^9S7 M99K!4G4CVDS,K1/06\&%R;0DR%#;R`21$<6F:SKXL>H7AU$T4547<+5AEP#R M3/F4B:"P^[@9D<;<>2$IA(]93L6\ALR;*"U%OO]%G1PF7#R,!B,N#RW(D]CW M^$7L-9JXE3CE(]+'("!&+^KAN$)K#;_Y3=\$)S*@+12$*[7M)W[[VZ:3_./N ME%]S#;]4YSOU"W16M02#1K&-%L!L9Z/%50!2A^?3M,EL#9=L"G":\DZ+S!&3 MX7O\9&::7!;U]K[(DSJNT)1[S;+9:F;$9K)NI\6&]O#O`Q(Q@.4`$R0K+"8: MA%^W[K#./-F^MT;`2GR":N:H;2MP"S`;RXP/S0-RSJ.-%%)I1^]1/A]8Y-'"DP%'2X`Q2QEW43<1IUS]S0$@[VIA(!@(BE8M2HFC^<443<#:=75Z3Y;KO&/\$ M5P\6MNQQ&,`3QT4-D]LT>DQWY"V.B[HH<.;L+,%O=[!_Z/>M;"MR']!C:ZD` MHK@"T*HAB)%G7%=R43`C^M$I;-N$PL%QG-YVFUZ#:_0!Y(&V:YTN":(4P#R@ MU=C^QQDT[ZM1@W+]("SR#:.WD&ZQ?3"IQ/08TMDX\F M1!@P:=#=H`YA?!G6B?WYSY`>'/.&=^:-1_.X^"#V> MW&.CP,MU?@[I4U>ZL5!>WD-$MUAO87QO"=8Y.(?LO;1PQC5=^_.1NMK&GQ`- MVI%)(>`7#RJ_(P1$&)MO-F8LDR3%;CK:D<>CP4T&+J)#BE,,DH[O+*)%>23M#/"YDJ2X0AVTS@][_[\-V? M`+M'AN6"&!3L.DGX9J5A#_D&G-WVF$4=@<#0;`[E>(&MV>DBM M"W:/GUXT.^X'.1@4DJ.&/]1I$F4G:2<-)&>[_T%C(FKTAY))>>'.4>`WWE.2 M"Q^[KXL\PU&$,(L[!SL&"PS+>IP[`5L[^0W/HSS!&T`+*1G5N']@C>C8P M&)L,;[85A0ED]=:]*9(#6;O,:_$K8:EV_!D#7(?["?5C"7^K<<*W9ZA>]^A% MW.\6R+7G9D#'HH"6#6I@T'4#MTXVZ@-_,#+:AI++>`>2'!TDVWR8D__KMD\&ENKV[VET6V@6JU+LW2T3N1: MM<[_-(/1`=R<37*F:)2SHT M.G*;M#E&1)E2T+B(Q;TR=7(+,'=)%*[S/=1 MRKD'WE:1C"_D"/67P(?NH#2EP2^T?#@8DO>%!$BZCAB3_N,I*N$JD^>-%Y9R MG-*CKR/7[[@`0"6\IGJWT?4&Q$@\C=&[V-3PTWPSV4U[OFYNQ[T+H.DD2[D$2L20HJC?_*,')-IYB-J.0_! MT&H[^"@O5KZ)?CY)A#,S,>D;/BS8N&,Q!$.U,0E#62W137U]1.,_QZ9X0I@ZV2OL'M!06HJ@B M!28_SMDOYZ6_Y M`ZZTQX,9P`0M*NQUOQS_F&;IOMYK>[Y7SGG?]_7L]S[[>Q!CDZ&N_B$J[/P^ M2!4][Q"FT10=OB4E/>-(ND0Q2$HA'%UJ/+!`5X]X!I@92-X.;:'E@)\`@SN$EQM@Z,*7"; M'O(239%VX(?B\>P]J`H85?+3<3=D-CH'U*I; MG(CC">]JWF27\%#`.*4LW^=%Q1B_VMR@DMDVQP-R M(MVDBO>8JWFX@1=14;S@-VN?HUU-'`.J"I3II[LEV,UJE]G:SV//N5ORV9&N MN]X;PCBG-PIC")/R&EF,46G=?RO.7SE\D*29&UN?^"&>@W=PI":L'.Y_N8UOMNA;@_*7_ M%I?OO`V3((`[=1G?_0Z#"HU4U$686E3B/B31QD+^`?;NVW%AQ$_8=QH7UCBP MQ_P`4QM>(2KL%6C2@(H>H(()I)`WMPHZ$V>&^)@L,_SF0)Y=X!E"<8$F!;!0 MYXE0R[C=(-#HST7O):`I#Z@`H!+^& M.[=^D\7Y'AYO$M[B+YGD$M#(.7?V.COZZ*+EP>EN:",1T!A@U#?]X<"B8T:, M#&L8/V7Y+M^^L)VH4CTJR,N['1$4>O<16_L>!NZ_7+":54J'X>'E`UDZ&O2)H8DV>U_'$-*CJ2.-9`WE?#4%325>`?; MX"[M/2,]M#^];Y\UJN'][O;VRL]I]=06L=]3,Z\YE(TVB[90;Y:TA!0$@^XK_<6", MGPAG5;^6=PMF:IXS<0-M6@WTFMXP&$TIR4,&$_%IA-NXR?"]K+QX:;U%I7J_ M0%[>+<$5>O-+(E:T^X::]R<)9C7!&4ET`.H@WPP]T\+Y5G<'4"WC'=:WBDMA M8ES1R_8(R@'(7%9MTR5 MZ-L'0U,,L'*!>&U5:W?Z7M_4[K8Z>KIPZ-/97<'H^\TB)00RY#^'EC&+W89DNJKI1O'O5LT%.'""P`$PF*0Z:V'&F3 M4UMBE2T>^2/"EX8RY(#1C[:1NID;M'5^G2'3;/!!H[F.$PKX= MC-@B(^H144!EC\\_!N5:7HEQ`YV*F753>Q1\D/;8O`;^.2T@_2MMKPUMKY*I M$YZ[41!8XVNT[)WD!!U]MZAA$]XS\LS_2?/,&!U>5=7BUW^(L(OP;7\DS$/=S: M,+**CQT@8H#*D<#Z$B!)><_Q5SILNVW$Q.`6;LG>A/K&7K^4VR&> MT[$/#5(`[Z[YOY-GKJO/R<1D+>IL3B#&:6?@5X%T!$/(0X(D3GT#B^46*IZ! MT)1WRQJ%WORCN/A9RJ8L((7]4VFX`1OH=RMLWJ9WQCD=\COL,X/]"!XVUT;4 M[.N7#C+4#?[#)6U2>1IFI/9Y01@[1#%!5"QZ3GB;)H2^X`WV0X M'W'Z#)>?HR+1).C12#E.T:.S@7]BKQ$`1PE`1/P3;(PQYWE6EW2')MIY3=/C MK$?<9>HQ(DHW5X\%2\;I@!;4,Q^!W.HN1%E6$MY1R*WB=H[Y,<%M`->H_I&L MG>P$R)'!01T%<:2U/@Z2,';*@`F6]`EI@?NY["1RG22(8O@'/`=6C&@9@V`+ M5CMHJN\EN7Y=,1CS--69O+'.>LWU"@,VQA)/'<0Q#>M&.)I/<`,+B-J%'A>U M%%0DX]((N74(.@OXO$.L?',2V+Y*K#AN=L/9":WQS"0C9'7880&K.1`O/0\W M$PL$]8KDY`K<*P^^/2-_B$6A8E]\#]*I&985?J<5;FB&A]Q^>U&F5X+=>Q60'DEI1NV@QCU)A]X>,Z[3Y*DYOL(CJD5;2[SHN' MIPCU^3H_A_A9-)BH`^1MJW&\-VQM);=]>%KYXRKP6]:L$I+W7+%%W:X,T-I>R];]I.UPUFF)W__NPW=_ M:IKC-6W-#V2%9"M^%"7&!(9C/]+YKG*"*"WN."Q27N&):I;NOTH*^CAGEE/4U$V6ES`ZR:DM;8!O!0,7/3.QLV=-#OC!MFN!]!Q-4V@=D/^6YSD1>'O"`]H*:B2L(M M&96Z]S%!"@-<&K2*^^?C<",D>8_Y(":(D*'_P'.0O_;^PNP.=H0 M->5]CG.SMKZS(4Z'_-26&WK`GW,&IK8_>AHFOL,8-_7I,W7#5#?J^4XX&^KR,WP+`"`8SIIJIZ';HG:D]WH[00I-VQ M68'022)4Z+FZFB:RTK[B3'HZ*T(I6-B$=_X,U]WKW=6Y6MQ#7(H(YY+0$SG( MQT27U/`RW:5;?-?@:K/)"\56C4[`<72(0G,NZJ&&X%@8L-+^Z6=I0K^LUYB4 MF5O?72")C@#=0!$S]+M;19`7AU:?,X2UI_1`LGW"LBK/7^ZBO2X;L(&L\S6& MB3WYL8'?96F>'U'/2K1B[I\75ULA#1\ZBAS?X?$_ M3YG4'-\OC+OJ%V=QD# MFL>_TDP/EW619EN:GX\>S=_!S^1/ZH!0LPH\1(<:6B9^=(KE_J"B30I&%G2! MI.G?Y]K[-6+#8`,O\OT^ST!)[,1ISC]3))8@);4M0*D(B7$;%&N#3CY"UAZ: MWIGW4[2KX0CB]>5#X1UGESGM%H`(+^;GG6%"NJ$F=HA'N1:@`QEB!EB`9RP6 MK,L0T\K08Z@X-?;M3)E_NLBS"OT*Q_?G69DFD%Z(E!XP#:S,PZN;`RRV'Z)/ ME8%N;7X?[)S`=C'[5".VH[5EJ'WK;I4ZAL_\5^=:$`^ MYVB-/0JI:)CN1&J6R'GL26%0G=+(EL'[$ZF!=S5>38-\PRP@/[6M36A?5D\0 M'&A_'NJBK/$61Y6#B+6&)`5$&*ZD2T%SQR'BWU@W\0E649K!Y/REG8FK_;U6 M>F*EU["LR8,3L;55[%.:6LA)>CL'6\>OM'-6^_4Q8ZWNN)RB,;YLU16,MYFX M@Q^[';Q@/;PP[F*W[F80E7GO,X+'8^ZA1FE!EFFK#05<>,6^? M[[F%"56Z=V.->3+F>>=3S?T;@FH6&P@Z?OC9P!()#2B#^5N>GCD]PJ(V\!<@ M.EGF?\AWW$_.^&W,I.[KTG8T&G,CIL3+K;CK3>B73QH9JW?LT]CR;VB4LLX2% M2+#5@Y5/$$@'X!1$-AG#"Q_5-]+S9JT8Z!9,K),%'QC%'GCT"Z-Z;MGJN86R MZ_RZ!BGE]+Y!P[=I5@:?X(%ELTS4+D$MXVT](-)?.<5L"?AF_#`SFFV_HT`( M!'?1(SZF^U)ZR&;Z&F[,.**3_82A`SH3#FL\;RP:-IS_-.,NU_C17&:;/I)P M3KLF&T[.BF]5@+N#:F+&<9J)DE:^*3^GVJ;KZ M`HLX+?&[/?2X4CJJ&TH['M]-;9)F%FUB[%<%(,*@)7NSF!%8UBH';PO4NS'&N"QOZIB MJ(=5YRM/L:W5]@A&\,6UM[SI,U`)]GX0<4N%UEVX*7$NR/8\`M2V? M2QA_N\V?WZ0D"0]E,_VYSV/Z6Y:M!_OJ1I&.?@+&F@HZXZ:Q)>($3"05_6E+ MJ,L_'TP;;$]PG++#6,.>(0`;&SR'9]QI5<'D]-PR=^U@&?]6IV6JC_VWK\Q# M"-T`B\5!5L>*ND]U=R-UZ1JN79_?4+H)K&=/%C7;-J>W7/S'R^?*^TS74_ MJ>Q_/3U;B[M+'Z9&>C=GF`G,9YX6T)WZJ>8%HMK"FQ@(;1XQ,V"1&J]F:F!D M_\ER=O=EUBO&D\T)!O6M:E+0A-F_LEF!G-?6TP(=J2!NM^D>50XRH&=3XP87,6`7)S!06H[SJ1_[8W\&03MX'5170+5ZIM?:W>FF) M(X6.E85YS]?8<%DT[G'/+M\<`_&^3C/F,K[Q/G48;3AW'UAZ#3@J0010B7I7 MX>+X+X+6\7[2/X+VYC>%33@_O>LBFQGLJ\U';?.=2.H(PEG)[+/P4G1'LSF_ M.U82FG8E__2,M[E95U`\OG5@2Q\6J%, MIWM--QE"V9[T^?*QK(HHKF1^9FRMCM\0'-L&W%-WQPK9U(A5V8U>;-V$:U4+ M?FDJ]IT_=AIH=!_.FQ`7SD&_QI$\TR*>5?D:X-Y8/RW62:VO$^@=.$R`<@$6 M'.;5Q#/8)*4B1^^@%_VJ))AG);9K!FPKNE4DW M)ZCD#JGRNKM&D^S_D: MZ%'=0$V*&%;.MH&<)M:6C0$Y MKM+*__X,\74)F"P1NJ,MU-U:\*)%>&YOTC8>XA7+X3._1AO`U'%S56,JYSE_ MRVM\:SEL=@@^-\T>L68/Y7:)1\=B[9_G\BJ3[%?3$#:BYC)+CDGMXQ2./:@9 M7K.OW>L1;:'8Q&[52K:P._4./;-Q<^(Z=].<:1KG[!4=:8TEDF3#?QH6N9OI MW1=Y4L?5;1H]IKNT>CEI_"([[C(7=3ZG,K"&?ZV=B("C3`O3+_[/IVS[J3_: MV762.]Q=IUE:P=OT&28WR*MEVQ0ILRQ+B(??C]%_Y`6YD+W\DJH.EJQJ<8Y& M.QNYC-A$&A!Q<)('M`)\2$2J`#0_P2^XE@!P.J!?^Y`=W*E!H/>DX%VTAY?Y M/DI%+W@,KBDD%$MLM41R&\:X'O`+K2EL-*OZV0+1^DX>$S%:'PZ[E^.M.\U3 MYN+"CF-`)1ISBVA2KG4GTO^#Y@,U]QJA.4]KNXNX5.&[&UJI![?#.7=4(1U@ MLH;Q4Y;O\NV+]KUSN8C[.;9<>VYNS8J"4]FYB6JX!3C."/\#DPY"W#+`"#]! M+#NYP!>[I:8=W3P;%\@BFT.EQ4);`DF'^?_RLEIM M/L%T_U@7)!_AU1>\\ZW:W5'(N,_DI]"?OQQ35O@6;+LT8,6]YN*SL.&JK-(] M\M@E*-I6'")DVH%X<@"IL,<[+\;@XC+MF2%KQ+IG&<=%C<]N<%.QRB_JHD#_ MDJU^E")NUT!J[;FL-K0TH,4;I`,FX&TY9&?$?0?4^#03_%9'137;2\%&RZ,I M.F*A[@EG2R4#2G063,9\<#>*(97R.JO*^^@%.XUEEC`EFS$WA253$?WM#C6* ME/+CJW0^!HZP7H!44A5@=9&3O`:^K>J""-:=P^Y#R^Z(V;T[5>=_3!T+]?Z0 M.PW.QX_(K<]]@COD6Y"#*=!>H2/.Z!"6I M!WQ.JR>NADJ>,R.0O*:HMP0U\8`V\C[)Z$\7X$E=!DHU45&W?B7W& M^I-N&-+X017JIJ=NSZ@ M;7-O<#$Y.96+^(:-ZA"1A\[\AZ*FEXEFM<(C"[0GGF90&C$;.H_*M%QM[NGT MUFC&HQ1Q.ZM1:]_'!BF-SRW;Y<,9DPVZHC/N&O>#.V?)5&);H6ANK_"2@K+. MW:-(7S%J\@TXE4*C*OQ2@7-DSJ]>XT4&ZN_?#TJ!TG>`&I2,60>R)<,R2ZY0 MS=6+S:+/2-;Q"L_,'FXIP\0`D@-4,-`EBT5_==JHB4&^0W5Q9\C2:"T%4U#Y!TV:OD&,>;N/>6LZWQ_R#'UAM5E53[!8'MK51D(&95H!G;*0*<*P#D`@TXK%8-0%<:!G1 MM=UWCD?TZYAGU=IA*#+,]0HY?D*MIZ$DPFG>0$23$Y@@%#5[(VT"3=T]AR9" M:/<1-#D\QUSQFC11&OG7)5+T.DH+DG=<1K;YO^OXXMG\[:A*!*/-!0M$N6"; M3,LL_\Y-DW^'_@)@!0#6@";,]^AT/+?NM#D8Z2]`@EMW@UO7_QNR__C-Z_N< MV96?[=Y:=.ID'9Y;G+*BWR-4Z2^CR`3_7K(JP(]96C%'#;"(WRG@ M0#LH5YNX/O];=&H`<0<5!N@)*+>BC-1'VB[+LMY3AO>RC_V4[U!M^/K9)\1S M%:$<*A%>9L4I6WB&=+.G*1MH*2)(JGA2!F!M`L^J.'NKCTM8R]HTRK(ZVH'G M''TM(DU;2)LVJ,R)D[N-R1+;CO09K\`U7_U6D[W[LBK(;+TDFV/KIRAS]F2! MM0JOQRW;MZ[8/1@^NR)<:E,=0$L)MN^+U9`NQ%^I1YZ@PA8.KA&(='4)2R>TQA?N5.UT*L8;P;ZPLE&FU&.<-P5M_8=NUM%,)ZFO/.+ M;#*]M1='_8?A.3#!Y1TN)8+ZU[8,X#/-3:TF'T6"3_FD<2?2\MYN6O7U5EXA M.A8F![C>$B<$K;[MW:;)+?!QKTB(?MF](07TQYQ_%WD,85)>(R7Q`\$1,@!' M5Z;/Z%/WNR@F(^+ZOP/&YN85E@M121!9@8=!(TR!:(@^.%0!4@\]# M]RFLQ`$_(#I=WDD;@_,-?MZ!&'QHZO)Z<#^9M4H30?4Y]WTL9$W,;DC`,%:. M#1=XRG<)&H?H1%D[3U6*>#BDEVHO7/2STLWZW7.W9\ MC:H5((\OXB5&G&DGC0O'?P\C$+S=CJ+@;[X1Y^K9)?I<@C]YO8M$%Z8$99SV M;5\_;KNG^3O`!?SVKK`MV]VK:,BYF4OW0J^RY%(<-Z`HZX7+?7VEI&8!D:@D M"8<,@]_"UA817='4)KCHU/>(T*Z>NLPPEQ(<"@1M+X<)]*FGPLIZR)*TFS[ M\+)_S+E>8?;TRCA%1%^_/@K8WP$MX+??A6W9[FM%0\[5O_2Z*G[N,,_(P399 M#I>KNBJK*$O$]^M-!9TBP<@2+D4[O8U,I0`16]#PD1*T)/WBQKR/VF"R[:!Y M$?8);E-\#SJK\`-92DSUBWI`$:>M!#>GA!8$I"1`14/`@Z2U!9Y"U=1S(8+EI3U-@M5K M5WEQI[A0:,U=,:=%.PN5,%:QNJ9O(\2LW>=U&]?I#A87Z*/;O%`[C5Y)#RZC MKZO$89!BH"D7@K<0-C+O*Q0M[#"Q"7>N(UFUBD5\)SBY51RQB9.67N&4F M$G__Q_=I=/#"THPG\2_O>C]]?'?`XE$RYO'DEW>_/5R]/WUW\(]_^Y__X^__ MZ_W[@U]9S-(P9^.#Q]>#RS`/'])P]$>VJG\`U7\Z/A`_]-^?SR?O#S_V^@?_ M]^/ASQ]/?QX<_K^#_S_\\E\'G^\?#MX??/OV[:-NSK,&6SD(\O MT_EDF";C^2B_2M('EN70#\N^JIMRT-?ST2B9QWDV#%_#1U'_QF`N5#J,A M:-!U?!'.>!Y&H#_WSV'*LH?D$[O.,NB);?\M&G:`XSY/1G^(7L!L_/G/.;>6 MMZP!5_VZG0E)9#"5_!ZF:0@\UNF%]H%35\DL9@U8!GDS+:7 MRI9<9CEF5K[2\M&YLZ'W"B%7&61'PL9IM/821V#??/C%D+7=&.@UZ6IT-W(C=N=<>[`'>( M:G_%_=[!'2B;AIWO.)S",&UW+_L4Y\CJ?FNONQN'J-U\W4[* M,23+#^QV_^4.6]V/[YI`PFY9WN2>"N0R^_\QR/@KMF3%KU''_[W/X;Z$/ MMT^W,V'8$FK?H.]8@WOIMRL"C%K?(:*+,'N^BI)OKH@HM>>@UY_"C$.CL)G, MH/DZ1C5I"[L[A;DY:CD_J30XCI3Z,BL)\08^O=$I]CUG\5C85A:_%0TYL'L6 M]EGX=I2,-CX7";K9^3`=K9J''RNT;MK:ER4^S(H)[/WHF4=O&O&4)M-:DEWV)C$% M-L^@B\ELL3"_.TA2V#+^\J[W[@!@/K$TA0/"0DXHC`)#(%(.?KD#!?"P27R33D,4)6N0C`//3-E%3R58*J MW9:STR?,CD0I8;EBU[!)P8:6J@KH\IEO]FS'F1Z/G-9!"VA]@&8U-(HBP6#P MD2!M6S3@U*TQR*DZ(DS5.0`8"Q!743A!N-HH`T`IKF5:LB0@Y&P=$V9K!7S( M4I[`9FQ\";M_S0C;*`O`O:]O38::!(R9IN[./4QQ&L.."G:+/1DJG&@_!) MV6BST,XK'K'T`G!,DE0]*#=*!H.C5IIP4"@(@4U,.2"5#]N.N1T[[)3!_RX< M=LK@08W#SJ1NT#O^:*_^2&?O0,:@3L_G,%+9"XN2F5"72QC!49+-4_8`@OX$ M#?Z!]=BX`>BV5R.9I7PWQT4=J(X<>3E+,W;C=PNRQ MP#?/WD_"<+;8A;`HSU:_V=Z.+'\=O`4)AX\\XCEGV7+7!;/2UR0>+?^!#Z)Z M#0&5Q\WV7(T@;P2NQ^-JW\T&9L,600A>C\I-J-L$V:Y7ZS56-`[\7J4JB-\ MR8K9`'N'QIKY15<78ZYRB40SQ+#R0,.ALQ&U_1'MJ$$K0+>\NCP-9"89"!HX M7=HQ2NY)>]@U5GOQ-WEPT=\IV>)=3N MK#=8+@`GBPMR!4ZWQJBK`0.GOD;56B%NGRZ2J3CF%H0L]SD7299GQ>S]*Q4S89:PU;!J%X]8F8$R^_#KGXT6&(T^C4Y4#P\,ZJ>B. MD86R5CM![[3G:[P;==1D>-LU!)"]QEPVX$D^O.O`[]`:NYTJQL<6=_MVL\'F M%JD"]`R\;6NW^F2TC<7J`!"O87AF@D8VK&I0W1D\-3(6.;E7NMZ06'1`>^.T M4:M`;8V[J`C`K0Y\#?-B\[6^IXY=/K6H#1TFU=^8]%DLJ^2I!U6[3N<-:?UNSC+:Y3>]9^L)'#!ESJN(@ M#/\!1/4'GQX:G4NMC7D6AZ`EO@P=I-HZ(!82IT2<,B7%&""_-V*QJ,7G,&.W M,?O"IH\LQ79%FZ4`CE?GDZ&\)7L;&0Y'5U^W3Q1^CI!\S,/T]3Z,8'(JK):: M"1>M`[+Q'Z36?-;5X*-S8;8![6M@XB[,[=-#&L89[/#%N5$W!^LK@Z#(V!(4 M3"+T&\*C<]FVR1+,7\*<#:-P5,24H#.ZN@((A(;+TY`Z;"G&L3FZATM@PE^E ML%LX=H5[*8D+.YMFTE?5`QEY#79T-?'K,1*ZX5M?![;@:2=\:7F0AU=SE@5I M8-9.ZY6R(`>OUBL#DG#GF@2)JWN^_B?P.Q'_J9FLW\H$ MT/,.3,Q;>`C=]FW(HW9@EDH!=J\V+80,!6/E?A.ZT5N?LR\\YM/Y5,O:1CG` M3\(R5:%$SIRD[ZXN\_J?/+^$W\T(+)<#(9`P79D26.T[0F!+[54E3[]('6A@ MK9+4`,%TQ5:%HD-H;YFIJHI0;Z'"ZH!O&MSFSRR%MM() MRY:RDZ8-W.OW@\->"T)`]`JV7WDABMM".UD!<@O[$K-B1Z&H!0+R>HYWH%#& M*!$UL+:P^5<#\4R3RO`-?P;(_N]%NR%V#0=AT-K>MHO=(JY]]SR-PV6J`W2K M:%8=Q.#U&.!J_K>"B[!N;:FK7H?W$AXX8FR<78%(Q=5_AY`6#0Z\^:&OA M(I:Y*J8?Y2;3(0F_LX2`3::PKG?_QM*A]T>)9'*OLE/I=!>N*[WII2EB8S@WRH&P6#0Z^>9`TQ%(1*@/1F;M*1J8\$JY?G`R5V0X]F5D?S/QS55BMKF/APY8_A"$O M&!S22)ILR9\$A*/;0428W!"(D?MD53@X)'%+H!:C52"=N09D2NB6"$C<";#E MLHK!U2V>/,G#B,KHM,KHKZP7]$D8;(SW/GHPKB[T^!^X5SSF.;OA+V_9Q<\G M*2OV_=FO:9*I#I_:ND&?A*5'SZ=<#\SPN;H*1,%'5D);3>9$PM!PB M8J8>AHT%?1(W&QSHBPW@QM>/SA8*%+.):-^K`FWC_LKRS]]'T5PX67Y-DO$W M'LD>\;6I'O1)&+CJ*HDQ1%Q&DW>N2H_O MB)0VE"Z],;66E3GKTNI!GX0)SX4. MX/@HW*YRIA'R%__4:B"O$_1)F/SJV%1,A/>P7N1 M,N5S#'V:I3QCE^R)CWA>BNNXG*<\GFS74!E3&C<>')$PN=72'T?H$5TS-\@1 M"IZIRM%JOQ\9 MH$Y[P2&-#`9F1"$3=GW@/TR:`R)Y#NHSM4D]BO%'2(A`+R."44J$CN1$,--< MW2LFQHV`X$AXP9P-W;HBZ$(6AC(R;:;W:F$0!`F/F2UU>@4HXR/Y+NR7,9P" M8/.?Q!$BXS[0,6A%?QM:%5V3O@!.0YS-, M?26;[^?O,W$%5__$F;XVB(J$A\V`3VP9-\3H*,%$L[O)R/+^P$;/<1(ED]?E M[>I,O;1CY0$I"3>:-9L&J)QEEG`?5?[VB.;M4^$+?,O\?Y%DXE6`I39B#P%; MMQ$ABP,0F=2B&'R`\U6]B%E3R58*JW?8;GFH^5:K,VMHZ`-6_I\IF,!DBB>Y];DU&;I]HK8B4'/LTGU3 M_IIR!R@K"YWQ_[ZUH@""I'<72W#G(HUP()^3?O.E"!*B9'-Z`(LKZ;&!>_V8-6945?KYA)-*U1?9"$?P.T#/$1]=<:@Z MN6?I"Q])8U+,*X,0_-NB'5",0G-U\8F*<5J$AR^/I/N+T[/=4S.?&$W5NMB_BL?%XR:8Q)I%6VITRM` M&9_??%QDG=''Y`ZQ]<:]%J0CNS9%_IMF<#JF[)I<,UC'0UU@ZT+RKCUD<#HF M<1?+@,_Z'NH"HR-SMO\0RZ]A#B?8VZ?5X56]#$A*@SR\WKUR-_VCX!R9JCU/ M^Z!K?#J$_R1CD3`E^YKDYY'XH@C5T\_^^NH@+!(WNE`>LTBOV74,)/=X0F)'&:-.,2!44A9 MU<`]>&,93ZMN!$32\#OQ?Z_",9WRF;^!>'Z8P*%3$D?N!DQ5PU2D&'^`.*)3KZ=N5/)5@JK= M)IE'Y4Y\FL'I?W'Z+$U9BDN%L M!K8#[B@\Q[^*.,_4?]J.S+@%BW(-T*';42R.#W/'VX%P&/+Q=7P1SG@>1E=) M>O\,8LX>DD_L.LO@5+EKLT?E>QHK!E8>&*IAE,#,AL;B45\SLFL&(/@W*ZCE M*[,8U@%)QSC0P!0U?\SXF(?IZWTHEJ$BTD`3UH;6"0[/"-QIJ$,E8CA2`Z5C M2VC`_QK8UW`*/Y:6&VV8F[XR"(I$#("&281^0WA=N/TT3/D+[!B&43@JHAVT M\3A0%^HN?@UG^\]_SOD^XP4,OVT>'V#9(+!YXFRB M+;1LX]O*(S92'+KD/YU#0X%*IE8EVBZ>2>",B,4%(]7*5(TB[,)QNVG> M@/Y'$G$:MM3I%:",KPOG:?$D109M:\_1FP5!`"3L)1@U,32"R;N@&@N)"GJ`%X2SP)8 MT*:'0\#7C]#WB2=#.&3\^_*0<1V/U-1AY0$GB5P9%K2IH1#PO2.4W4[&+/XU MB9XNDG26I(6$U:3A-0`KB0`+"]IT8#J3Q.(MT\?]B,5ARA.=OT]6'F3B_[I( MC5.'`DP7$E>L4/T69S,VXD^,U.X87JA[[_% M/!_.T]%SF+'S2'QC^:505(DF%X^7X(@JSS#`$!ZL3]'O^0W":+,MR0*Y29WB=L\8FXU?+YZ2E)%=M2=06` M2L($9,&9!@N%9!/[NUS<[_F/"+'8DJ`07&6*('QYN-_S:M1!15]EJ-IMA)Y] MV6^P?),\'B51/`S3/U912+#HWO`IS]<92EXODNDLC%\U22GMFP+)>+7@R)F2 M3)BUL2%1`=:V'/_GP"+*[/9;#!UYYK,BXQG+\NS3JXA@UIP'M75!6/YCB6J< M"PV!(5K0KK@A!*M`JCTN:NN"G$C8@0P)M=*&;92(-K0K5,C5C8S^(8F0(4/J MY+RKH"%D4\BJNHJ+*9R0(CYJ]1:@>IW75`/8).Q`M1@U!XCP2B*":"%P-EX9 MM6'ZTOA2C>H!2U3(^A-=] M/?*#Q=\O>WH;:_+\5PH"*O\7F4R%+^$-`8301"'J:-7CAV^)&5=O!0&:?\.2 M`ZZV`"%<[3702,<5E#(<6:6B`,]_R)`+OK8A(8Q96Y[\VR#>?'N+E5_86Y)8 M1$V8^J-E]4!(_M\?;N*3QD$A5Q7:&$GT!D]K:Y"6!WG0B!?2DR9G6X$*8;E= MUJ7?PS0-#NIYR\\YM/Y5,O:1CG`3R(8J$*) MG#E)WQ'N]AH'Y(C`\+L9@>5R(`02<4*F!%;[CA#8PCRP;G/4]?O^#3QU#B-J M0`C;[7IQ>=?)Z`9]&D<4-94(_X;P$$7P$:34X/;\\%9_<7Y5!G"3.*.8,B3G M=PL.0J.U26DG><2JT]>-+I^<%8J]T42Y_`K<1LHB6%7PQ;WYO%UH$YC("***X12!YJB M112"0EB3$M47EDXTK[2KJP)\BI&J#K9-JJ)1`.Q3QVAL37@(KH`86K=E_1&T^#9$AI%*(ERH24,>C385<(!#Y MC1>1M&AHL4EE$`'%,%0]N1;H$((I!%E)49S'XZ5+>[FF6#%#:OY&`&%9*C=ODWO^.0Y__R=I2.>"?/PXH2'#EBCVB"$UAFX MK.$A'+3+OZILH'6:`Y&VSAS6'"^B0GLUB,E2,/#B,MM" M@18_;ZO.XK?+6V\B-'4%<`.W1$G,*H)X6F-VS8&(FJQT:P>6D0A*-C-*NDFU3L$I'C0/VJGM4R)!Z&MA0%I MPS09,3;.KD!BTHVN8L'7U@5AMQ;PLH66F5V_,3V88=L'PGV[)5X+;O;%M>KRO*![4;-`G0_)_87+`C MV=*"1O,"11CG65X7,'#UQWFK= M+?[S3Y;E;\;=<"E0\)ZZB1W:5$<;9P%?^Z#'/V=OT0]4?N^+LP&=%( MKK,35=ZC".7*:QW;0F(^7Y]0AE$8?_XNA*:<>J45@)`.JY8)=KE.[#G'D^>= MZ=LP.<^R^70QHK:6@G\FXID8\?[;'8RK7>Q;K3L!"Q*)5Y6([FIKRA,Q+UO' M#K5Z0"P\<-=QEJ?S8A=5O+/T\!S&>S-`6'8AZ)_\-1@<2Q,9"HT#JCSX31?1 MP`7R\WC\EO5HQ-D>?:>VG3#WG]9M&7@^]!?/D(SGH[STKNJJUZ^87]6T*L#R M'^'LBATL\,%$!#^,K_2$Q./L9J08^$1/\.>R"'-G[1,]\>KA1B6O\XF>H![K M=OE$BZ^#!N!`3GU0?>9)361>O(9TE&3;09T*N% M01!>7=MUJ=,K0!F?(P=?3:*1K><#&SW'291,7F_X2)A\-(_^8N4!(@G_&29\ MB4%5#<618VLGV5YXS$=A])#R,-+0)2L+^$@8-"VHPF$X98QX9_Z$OYGDA8Y231+K44K0?^4A#FDR5IK#=>1>\/K8JL` MO8:\?MZ\GK;(6@(1DO`76[-NK3PX>D>^$+>+^/U\-HM>W[)9:%Z\E14&<"0> M`JO%B#?#*HKPS4%'XYB M!;TQ"$TVJ0Y":ZWYS!XGHARMO/B;Y;=/=XQ/'^=ID>Y0'P:!U@'A>+7&V1,I M5P0-0(1]"D]:G(]&Z5PT45@$O=VJ;DTPP?0F<+K_<" MU&0>Y]DP?!5*>QZ/E^!7DN,L6T*'OWU-XA&J&DV;!-&2,/Y%<(?(:QK#!UX5,\1F01`$ M"1-`TW$O0X70:VU+'+,G<8J!9GZ=\['(.>/N#GHZGRRA/RPN8[P=<3<>YQ() M[88AAS/4?1Y.\#11==L#@9$P%S0:^OL+B6'^8B+,S$J=KG(A-XE`(/T"4V9G7\!-4\E6" MJMWN0I39MHK"]S1^;J0&B(2$6<)TS!G!Z4*`F`2@UCN-U@&QD`A@4;)F3'09 MD]\0L9U0K75)2LL'@X\D3$L:OHQ(+B,B$%7FZG(M'*/$47EQ;4C<-4KB8L.H MF;A5]4!&)*Q+UM.W'I2C.#6O(WL+G78"EY8'<9`P'1EP)B=;@:H+T66E?+G: MJ;M2%L1`(HQ$P1'F$I8B<13MY7^ZOA.W/W77-%9E`#N)8`_;:7@+@*M`+[\W M*P0F[4`LE0+L)$RV6V0H&"OWVU58EE?.OO"83^=3+6L;Y0`_"7-1A1(Y%P%15$( M99"_YC=,^0OL$=1."JV^>H`6(,&0'`4K4Y;Q,J5P0;A[H*:O"3UB+,DXF/A M\_T41@+W_3-C(N!+R/J9Y>):F9TWU+$!Y?;IBL?0,1Y&PV3QT*#"4VI3/3CR MYQA==4_K$MTH&/A]BADALKVF,S)&[T_]Y4_;&V/D\?TY2_B_E,XOJBH'?9_<8/: MP3$)GZF5!IC"ZHP#M?*,K-'RKJ@5^'V_L2GK4CC=2:WA[L%LOT\TNJ&Y!&57 M"9$4.S@G6R_+SBZ(7L;#P6W+I8);]WWPJOQ&+&UPJH>WM56#/R^M6C%I`6B M77EX/7MVWL24W3[=SI;7-C,?7IWK&#K(WOICX,A!:@2]GK>TZW6=-[T>B8VL M4J)&'IL"R(_BLNGU:&U$2Q3HG39%Y[OOM>GUR*5!+R2O\=L4W>Z4X^9^Q.(P MY8GI+8=R>1`'K>TA.M(,8'3!B;-"]5N144&%W6FT\U2`(>&^U0M;\G>7H:#@`\%X09+HJ_F2ET+,--PA%IS M9X*K,TZ2IO$-O4-:_D[S!7(+0QRX(..7F;O>^, MIV)I`(DGRV28F8$1`JT#LJ'JGE0PJX'3'3?%'9`!@GP^C\>7H,U1,BMNM&I3 M_"KK@9!(V'$T+&*#6HNL.RZ,7UD,(HI$UM+QE,=YMY'H1!PC]9BV@$37>NL;T!7)BT;Y+,B-QU:1`(+9.3W?*] M#<19*N\D#R.OS'Y-XF03Y5*'#39KVKH@+%JF*"/6#6&YNI[F?W2+],-9\>;O M`NYU#'UBTB2MNBH@&A*V+4,.Y0J@!NT;X!HGUSY;\!ZSB;"^TESJZRSQ(!X2EK9& MW&O0.ZM"@$)R[`WLWGG\7.8QB+Z;!7:;K!) MQZJ`:$@&?VMJ@J!(',351)J1+X6& MZ$`+[6F_,SYY!ESG+[!$3=C7N7#4WCX5T$NQT>:J4:]!$&L+#_%-L"(JU,W@ M9._Y9QQ&*O?/?(W5VI'*`Q(G**5$-1$')2`_3*3R@,391T;!)EEHYW^`2.6! MUW@!5/)5@JK=_BM2^2U<=$`B`D`_T@Q@_!6I7(E5'-`R,%0Y0TA6(^K"XQG* M\!5]&FA];1`5#?N#FDNY`ACC(Q`=O9<('ZU&&-4'F9$P3M32"0N$?\59KP[P M`UJF!?/E?0M#%^*LSZ.B<39>&=?$ZZ13H;P%'WIGD5D#(#`2SF*,2CGQ-M@( M1'`C5V+DG2\NZ]\6_879Z_$0E;AQGOC4!2B.O&-$!T'E/? MJR2]9^D+'^$/=9O6!T'0LI$8L&T%K3O!VT4$Q'F6L?QZ.@MY6KP[#IHO?Z[= MH!8(B.Q=#7R&UP)R%:D]*Q)XOQ#U#%R$V?-5E'SSDK6DE._\K1]V.>@KU8+C MUCD%3FBMDYA0C?P")S^06^"$UHJW)D#O%#CY(7P")^1<`B=ZC\#)7PZ!DE7V MA*(_H#K&]"#^\@9LV]9."#L#3FKX`DZ\NP*0,^#;.TOG$Z9X%QLM&YP0M]R? M5(RT:BP$K/3[S&%R0MS(CM!G@(J`81TA$DYNHR2*H?-_7(0SGH?1U3P>W_`I M%]<">/C(H^5#P6'\JF:W1E/!"0T[NRWE=:%V)N=[4P?+"8G;>/;;I4T$C@SJ M7O=*7UDNCM'#-'GA8S;^]/I;QL;7\=L5XW.8S%YXSHW2I-@W%IQ0=;J0+KVGOGX@O'#-KX,MLI(W_C:]B$*N/!=9 MM1.P*R$D]WTO%4<8OL4S%\C2LW1LIZP2D)LY\=IZ9Z ML8VS2REZ)!(3^[V+>2KDO1":W1Q3J1Z).])T!#@BZRMCCRI MBL:",Q)V1Q>>5!U*5XF0*!@387)=;AO.1W_.>2JR^H;QA(L)5[>OUM8-SD@8 M#6O2+-<9,]"(BIC;FPEMKD1[[(W(5!>E*QZ'<$1Q MLR@I&@O.2!@-72Q*.I2(SK30K`S(1XR-LRN0XT4"0R3-Q>QZR1Y5RJ&H%9R1 M"/.L22RR#&G@(NK00E/P'9LME]S;)W-U4-0*SDB8@9VJ@PXNH@ZMM`:757_M MH+U(IM-E$@+#64):-S@C80?>V5R!@T94I(4O+)H+S\EF(^A])&$$=JHSMO"1 MJY@M3"9?P&8I3\;;)DF%MN"50#PD#+56>U`='(1M>XLK";8UO`)D$F92:P87 M'4>XLL_/4>@#="+-6\!8^XR1ZXXCC%G;%Q>,?8[];M?NY[-95$@AC%89,SXO M?F&4Q,2@.HB-A*'1BF]S8(@^V#^KZ/[^9K%0A'Q\.4]A4[!8,D3`-LZK236` M3<(&:$[1)L7F&!%J6Q@NNGH-4$!6.KO7Q4`$7LUSYC1A+NMM+`B=+33"+0)' M'L+O+-,RNE$2!.'5VM:<5`D3:*DFQN M]*16TZ9!U"0,CT21KA=ZD$5+Y(MJW%4I8?$F^+) ML>SV:5AJW2[5)G)"D;2K.YTHJ@2#WL#7J%AV:QD6"=)3#(U*6>BXUR.5F6#E M>H^`<90_DX#NWZ:3,%[>;X:)XM,\XS'++%/-(OJ/M*T;`YIJ0>_(VSCX&N8P M898?ZU.Y<2J%H>O^1X*1>!'/#(*H.\.AG-',1[IE+*.:P1E(5Q6H.O$U;K"^ MK3\P_/L'T>O',&.%E/\;4$L#!!0` M```(`+-%#T.@%E-^20X``#2=```1`!P`8G!T:"TR,#$S,#8S,"YX\]I"1;ED6*DCU9+J"7C"SQ M''Z''R^'AY?Y\(_71>@]8RX(HY>=DZ/CCH>ISP)"9Y>=G\=WW1\ZWC]^_/:; M#W_J=KV/F&*.(AQXDY5WBR(TYLC_+#)Y#\2/WGORX:Q[%<^ZI\WEY.0I`0Z0T'/ELX76[,A_AS_$">1'B,QP] MH`462^3CR\X\BI87O9Z4FQ"V1-%\SD()4PGW9%;'[\\D_!`O,(WN&%_*B\DRFM?0J82VTK^<'3$^@R3')[U?/]V/%.I,>TCH MYZW4KQ,>9NG/>O+S!`F<)9=?@V@MD$_\KI=\7"<-#7I_O0?%>:7$D)A0$2'J M;T#L@$Y-/#D_/^^IKUG26'1G""W7B:=(3%32](,JN.[Q2??L)!/Q64PCOMJV M46#_:,:>>^G',K&8!7?UZ>7GXI$2#T&8NH M7"3Y5B)$$?%%N8SZ)$5.MD4$\UT@C-)X4:XDB'A/(NY! MHBZDPISX:[EJH50`>A3/^X`H9=#50!>E?LLWRR6A4Y;^A!>R?E](P&,0]^3# MST^#RAY"67C+_%CV.%/X15'F)+B^G[$.OJ.';;XKJ8X&#(?U1/0./`K0I6=EYI/)I$K/L)I.Z MDCX*_3C49IJ*];8HR:GW5N'_K75_=7SW<]+W13_W^>-12U)2B1P2]?33'$0%T%7QM MIS63=V9/GO?=EN*_MF36('-=QF(X'2ZE(PF`2AJ>)IV9Q.]-)([&\,^G_@,0 M.+SSAH_]IZOQ`!*T].U-7T6CM!$R$_NN";%M.ST0T3=(S.]"]E+13#?)S&2^ MMR?SYFKTDW=W/_RE;:55Y%TC08"$QYS="5UE'\P$_4WZF$3X(1,QQ_!#J?#8 MU,LK:1FI8&3(9XB2_ZB\P5._C@6A6*2-2/?1S,P/16;R:CP$TX%,4$V[*O*'OH1I:(!+<\GCUR%L2^#-2-L8@@ M6<*%,861FY/C(C>I+D\J\U)M'LR6O51?2U<%75>^"LZ!Q[9"DQ`G#!5?FDDY M*9*2B7NI?$M"-0D\QD'_=8FIV'"0?V>FX+2$`BGMI>(M`W8,W!-?%A?46^7W M[HXC%NG,3)WIF$I5>IG.=N"I2V$0*,@H?(0184!OT))$*(2Q932'N:(8LVL\ M$"*6:T2*2OOT9DJ_WZ%TK=F3JKT!]5+E'FCW$O7>F'G7V$MR:,FM('<4,?^S M?(VYZ'^)2=8>2]Z;R7I7)"NOX2]_/CO_NY?H:2FQH62X5/$>F.7\@CA'-(NS MZSZ:R7E?2HZ7ZE%SH$Q32T]EP&>Q()$:2H"`&T:E.XRI3_`ZU*-/8*9I)X:0 M4Z5(VE+6,E75D.*)P%]BL+G_C#W-JBC!53,I.^$ MR/21S);VO6DWA#(KJ6\H:Z9_)QIGC)"V-6#_AE^(EE:W^!H"9JYWHG4[D=>6 MWYQ"^4>>C7O"4T\=.KN0YWDN.X(LEG+_2?)NSO'TLB,/\76S0WJ_@=%'KXLP M2R)S,!Q_4]6B6$YIQIF*]`B3^5`<*&%+S"-HJ+T,?,?K'=`P8*2N8=LDNFE6 MB"9US0(1'+IK$32`NA85VLQA[4K:6_ZH&_S*'X53K\`LQB./EAZUU9T934[I MWC-?J3*(R%_=3*XK7W5/3KMG)T>O(MB4?AT0&QOK@1R-YT-ZIJV6\XWFH"5"*6/N\+I.S8L`V2O%SV8V\L M94>1K<#D!=>_NALUC>#LG%JV@;(64D_[ELCNB68;#!NIY+&[4=`(1?&8M`V& M3$8^[)U_\02U%8!,2#TU@+![&EL--A3/9+C1KN<*.=^2DMW7N>PV3][O#<.R M\\Q!B`Z2O?E,NBVDO);^1DD#A,:;"6QJ2B8C'QHT6//9>:L"*4KMRU/YL?]Z M2!A]:`S&?&%"\Y%7Z=)3E%Y:H@#EUB?0A(1$>G:YM0GX=:.&":BRB6>JKOJX M6#!H)HBO!A%>R*E5QT,3(:]7B2X[4Q2JZT940G`6"0O&2C3QS$`3)6$HEQXO M.Q%DG26=)&>J+SL^QS!#A0*`R6M$HEB:_Y&S>)GE3B#79.HL?>+?K"W0E(`, MB#"JHF(RT"V1)='O[->V[2+Y=A#+;4VT@*@Q[C&$&J?N@YC!GT]X,<$\LR>Y M$N,B8`M$:)E!>7KR]@0Q3T_^-36H');&AOQBV9@C*@"%1"+>;/Q)?[F=TM#6L3-&6@VUSJ M3&.M!*@;(TW;[)RQS@ZE=@@5&.822'[+DS,LZY%9FN(:<09\)C>H9'.*.QQ5 M`=08MJFA=8[0N&/WOOCM7+X'%,D<MJ':P:(;3`:2D,R+/@`B! MU<8P]3!8P&2`IQ>]JID]Z.(S+-)BE#?WLU37*F3J@I)4 M>$0X1:FGXO"DW=H"30E\"J#0,!>,WLC\^0U\G7'I90WV@$_9^D>EVG;YA05S@GX1EQ]4K>ON>&838@`%;>MS\H^OQU M<%>UAA*:`!E1NVF1\E9M`N>9PZ3':&^60.<8ZCX?_("O"EB98ET$\"8E_1T)@\8"Q_KT$V@=6O2>*::B#,N51&0*3*EUMZGX#`[M==!#TUC2^8\ M.6-!$9!NLH$H2@*^`RHG?C(<_()XX(P=50!U3CKTFO)J]S$GT)$[8TTYK#VZ M,X?RNJ?P'1[0R=&SN60&TKGFWJNDZT)XK M$>JW+SP3%KO3,14!Z;HDZVL/W/.SZD+?NPA MO*7'N8JOA:@QZ9JP1Q3-?TI/28/;Y4POI8>F6TV8!9A^9.'TAO$E2[)WQAH3 M.(T]=X0BZLO@Y(QC]<$9:_30=+:`MRCKI#L6%`!5#@!)W^D,?ATP73\>XUMP MR^4M$K@_A2XO4M!#@8P>P!`2)Q MO7?/SJ[$V,-(9;]\&I,Y/2).YM$^E!%,%^O$+_GR_5`'AE)^?P MD&0Y"!G]:O4Q4Y1V"0?PH+[R;$"'NEX)J":^/A.?*'&_W[*VPVX5RO+V96>7 MHFKC/VBQ.+=FM9<9E453]])F%VM-QN0J_KC%O3FQDQS6R&K(5390N5++E820/M;E\V4MSDZK' M`IOKREWLY6H"U^UH0(+`Q/$Q=YVW.\8:P>F897ZA^E0_76"$X:]*&7W/RK;/L_4$L!`AX#%``` M``@`LT4/0]1:``Z&70``H(@#`!$`&````````0```*2!`````&)P=&@M,C`Q M,S`V,S`N>&UL550%``-QS0Q2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` MLT4/0]*F@B*M!@``IU,``!4`&````````0```*2!T5T``&)P=&@M,C`Q,S`V M,S!?8V%L+GAM;%54!0`#<`Q0````( M`+-%#T,8`L``00E#@``!#D!``!02P$"'@,4```` M"`"S10]#IR[4O@0\```"=P,`%0`8```````!````I(&AC@``8G!T:"TR,#$S M,#8S,%]L86(N>&UL550%``-QS0Q2=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`LT4/0T?2RLMD+```&^X"`!4`&````````0```*2!],H``&)P=&@M,C`Q M,S`V,S!?<')E+GAM;%54!0`#<`Q0` M```(`+-%#T.@%E-^20X``#2=```1`!@```````$```"D@:?W``!B<'1H+3(P M,3,P-C,P+GAS9%54!0`#< XML 55 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued License Payments - Related Party
6 Months Ended

Jun. 30, 2013

Accrued License Payment Related Party [Abstract]

Accrued License Payments - Related Party

6.

Accrued License Payments – Related Party

Accrued license payments related party totaling $50,000 and $100,000 were included in Current Liabilities as of June 30, 2013 and December 31, 2012, respectively. The amount included for June 30, 2013 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license.

XML 56 R21.xml IDEA: Prepaid Drug Product for Testing - Additional Information (Detail) 2.4.0.8121 - Disclosure - Prepaid Drug Product for Testing - Additional Information (Detail)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_InventoryDisclosureLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Inventory Disclosure [Line Items]2false 4us-gaap_OtherInventoryus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse279180279180USD$falsetruefalse2truefalsefalse195000195000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 false2Prepaid drug product for testingfalsePrepaid Drug Product for Testing - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/PrepaidDrugProductForTestingAdditionalInformationDetail22 XML 57 R16.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants

6 Months Ended

Jun. 30, 2013

Stock Options and Warrants [Abstract]

Stock Options and Warrants

9.	Stock Options and Warrants

Warrant - There were no warrants for services granted during the quarter ending June 30, 2013.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

XML 58 R22.xml IDEA: Accounts Payable - Additional Information (Detail) 2.4.0.8122 - Disclosure - Accounts Payable - Additional Information (Detail)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_AccountsPayableLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounts Payable [Line Items]2false 4us-gaap_AccountsPayableCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse165897165897USD$falsetruefalse2truefalsefalse5700057000USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 5 -Article 9 false2Accounts payable3false 4us-gaap_AccountsPayableTradeCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse114200114200USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 5 -Article 9 false2Accounts payable, trade4false 4us-gaap_AccountsPayableOtherCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse68006800USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accounts payable, other, current5false 4us-gaap_AccountsPayableRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1001710017USD$falsefalsefalse2truefalsefalse85828582USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false2Accounts payable - related party6false 4bpth_AccountsPayableToProfessionalFeesCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1590015900USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable to professional.No definition available.false2Accounts Payable To Professional Fees Current7false 4bpth_AccountsPayableToPublicFilingServicesbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse60006000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable for business wire and public filing services.No definition available.false2Accounts Payable To Public Filing Services8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$PAsOn06_30_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Research and Development Expense9true 3bpth_AccountsPayableLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounts Payable [Line Items]10false 4us-gaap_AccountsPayableTradeCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1390013900USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 5 -Article 9 false2Accounts payable, tradefalseAccounts Payable - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccountsPayableAdditionalInformationDetail210 XML 59 R12.htm IDEA: XBRL DOCUMENT

Accrued Expense

6 Months Ended

Jun. 30, 2013

Accrued Liabilities [Abstract]

Accrued Expense

Accrued Expense

XML 60 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2013
Basis Of Presentation [Abstract]
Basis of Accounting	The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended June 30, 2013, are not necessarily indicative of the results for a full-year period.

XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 R13.xml IDEA: Accrued License Payments - Related Party 2.4.0.8113 - Disclosure - Accrued License Payments - Related Partytruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1bpth_AccruedLicensePaymentRelatedPartyAbstractbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accrued License Payment Related Party [Abstract]2false 2bpth_CollaborativeAndLicenseArrangementDisclosureTextBlockbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><b>6.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>Accrued License Payments  Related Party</b></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Accrued license payments related party totaling $<font style=" FONT-SIZE: 10pt">50,000</font> and $<font style=" FONT-SIZE: 10pt">100,000</font> were included in Current Liabilities as of June 30, 2013 and December 31, 2012, respectively. The amount included for June 30, 2013 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaCollaborative and License Arrangement Disclosure [Text Block]No definition available.false0Accrued License Payments - Related PartyfalseAccrued License Payments - Related PartyUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccruedLicensePaymentsRelatedParty12 XML 63 R23.xml IDEA: Accrued Expense - Additional Information (Detail) 2.4.0.8123 - Disclosure - Accrued Expense - Additional Information (Detail)truefalsefalse1false USDfalsefalse$PAsOn06_30_2013http://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3bpth_AccountsPayableAndAccruedLiabilitiesLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accounts Payable and Accrued Liabilities [Line Items]2false 4us-gaap_AccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse48924892USD$falsetruefalse2truefalsefalse137662137662USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued expense3false 4bpth_AccruedLiabilitiesRelatedPartiesCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3705037050USD$falsetruefalse2truefalsefalse2600026000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities, Related Parties, CurrentNo definition available.false2Accrued expense - related partyfalseAccrued Expense - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/AccruedExpenseAdditionalInformationDetail23 XML 64 R26.xml IDEA: Stockholders' Equity - Additional Information (Detail) 2.4.0.8126 - Disclosure - Stockholders' Equity - Additional Information (Detail)truefalsefalse1false falsefalseP08_01_2012To08_31_2012http://www.sec.gov/CIK0001133818duration2012-08-01T00:00:002012-08-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli02false USDfalsefalse$P10_01_2011To10_31_2011http://www.sec.gov/CIK0001133818duration2011-10-01T00:00:002011-10-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P04_01_2008To04_30_2008http://www.sec.gov/CIK0001133818duration2008-04-01T00:00:002008-04-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$4false USDfalsefalse$P02_01_2013To03_31_2013http://www.sec.gov/CIK0001133818duration2013-02-01T00:00:002013-03-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$P10_01_2012To12_31_2012http://www.sec.gov/CIK0001133818duration2012-10-01T00:00:002012-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$6false USDfalsefalse$P07_01_2012To09_30_2012http://www.sec.gov/CIK0001133818duration2012-07-01T00:00:002012-09-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$8false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$10false USDtruefalse$P05_01_2013To05_30_2013_IPOMemberusgaapSubsidiarySaleOfStockAxishttp://www.sec.gov/CIK0001133818duration2013-05-01T00:00:002013-05-30T00:00:00falsefalseIPOus-gaap_SubsidiarySaleOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_IPOMemberus-gaap_SubsidiarySaleOfStockAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false truefalseP06_01_2010To06_30_2010_WarrantMemberusgaapStatementEquityComponentsAxishttp://www.sec.gov/CIK0001133818duration2010-06-01T00:00:002010-06-30T00:00:00falsefalseWarrantus-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_WarrantMemberus-gaap_StatementEquityComponentsAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli012false USDtruefalse$P04_01_2013To04_30_2013_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-04-30T00:00:00falsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false truefalseP06_01_2012To06_30_2012_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2012-06-01T00:00:002012-06-30T00:00:00falsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli014false truefalseP06_01_2009To06_30_2009_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2009-06-01T00:00:002009-06-30T00:00:00falsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli015false USDtruefalse$P12_01_2008To12_31_2008_InvestorRelationsServicesMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2008-12-01T00:00:002008-12-31T00:00:00falsefalseInvestor Relations Servicesus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldibpth_InvestorRelationsServicesMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16false truefalse$PAsOn06_30_2010_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818instant2010-06-30T00:00:000001-01-01T00:00:00falsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberUSD_UnitDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.biopathholdings.com/20130630Unitbpth0USDUSD17false truefalseP05_01_2007To05_31_2007_FoundersMemberusgaapStatementClassOfStockAxishttp://www.sec.gov/CIK0001133818duration2007-05-01T00:00:002007-05-31T00:00:00falsefalseFoundersus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldibpth_FoundersMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli018false USDtruefalse$P05_01_2007To06_30_2007_FoundersMemberusgaapStatementClassOfStockAxishttp://www.sec.gov/CIK0001133818duration2007-05-01T00:00:002007-06-30T00:00:00falsefalseFoundersus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldibpth_FoundersMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19false USDtruefalse$P03_01_2012To03_31_2012_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2012-03-01T00:00:002012-03-31T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20false USDtruefalse$P12_01_2011To12_31_2011_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2011-12-01T00:00:002011-12-31T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21false USDtruefalse$P11_01_2011To11_30_2011_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22false USDtruefalse$P06_01_2011To06_30_2011_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2011-06-01T00:00:002011-06-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23false USDtruefalse$P11_01_2010To11_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-11-01T00:00:002010-11-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24false USDtruefalse$P10_01_2010To10_31_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-10-01T00:00:002010-10-31T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25false USDtruefalse$P09_01_2010To09_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-09-01T00:00:002010-09-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26false USDtruefalse$P07_01_2010To07_31_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-07-01T00:00:002010-07-31T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USD_UnitDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.biopathholdings.com/20130630Unitbpth0USDUSD$27false USDtruefalse$P06_01_2010To06_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-06-01T00:00:002010-06-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USD_UnitDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.biopathholdings.com/20130630Unitbpth0USDUSD$28false USDtruefalse$P06_01_2010To06_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxishttp://www.sec.gov/CIK0001133818duration2010-06-01T00:00:002010-06-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseMinimumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MinimumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29false USDtruefalse$P06_01_2010To06_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxishttp://www.sec.gov/CIK0001133818duration2010-06-01T00:00:002010-06-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$30false USDtruefalse$P04_01_2012To04_30_2012_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_ScenarioOneMemberbpthPresentedScenariosByScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseScenario 1bpth_PresentedScenariosByScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ScenarioOneMemberbpth_PresentedScenariosByScenarioAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31false USDtruefalse$P04_01_2012To04_30_2012_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_ScenarioTwoMemberbpthPresentedScenariosByScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseScenario 2bpth_PresentedScenariosByScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ScenarioTwoMemberbpth_PresentedScenariosByScenarioAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32false USDtruefalse$P04_01_2012To04_30_2012_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_ScenarioThreeMemberbpthPresentedScenariosByScenarioAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseScenario 3bpth_PresentedScenariosByScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ScenarioThreeMemberbpth_PresentedScenariosByScenarioAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$33false USDtruefalse$P09_01_2010To09_30_2010_EquityUnitPurchaseAgreementsMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxis_ScenarioThreeMemberbpthPresentedScenariosByScenarioAxishttp://www.sec.gov/CIK0001133818duration2010-09-01T00:00:002010-09-30T00:00:00falsefalseEquity Unit Purchase Agreementsus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EquityUnitPurchaseAgreementsMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMemberfalsefalseScenario 3bpth_PresentedScenariosByScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ScenarioThreeMemberbpth_PresentedScenariosByScenarioAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$34false truefalseP06_01_2010To06_30_2010_FinancingAgreementMemberusgaapStatementScenarioAxis_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdeiLegalEntityAxishttp://www.sec.gov/CIK0001133818duration2010-06-01T00:00:002010-06-30T00:00:00falsefalseLPC financing agreementus-gaap_StatementScenarioAxisxbrldihttp://xbrl.org/2006/xbrldibpth_FinancingAgreementMemberus-gaap_StatementScenarioAxisexplicitMemberfalsefalseLPCdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldibpth_LincolnParkCapitalFundLimitedLiabilityCompanyMemberdei_LegalEntityAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli035false truefalseP06_01_2011To06_30_2011_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2011-06-01T00:00:002011-06-30T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli036false truefalseP01_01_2013To06_30_2013_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli037false truefalsePAsOn12_31_2012_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli038false USDtruefalse$P05_01_2010To05_31_2010_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-05-01T00:00:002010-05-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USD_UnitDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.biopathholdings.com/20130630Unitbpth0USDUSD$39false USDtruefalse$P01_01_2010To01_31_2010_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-01-01T00:00:002010-01-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$40false USDtruefalse$P12_01_2009To12_31_2009_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2009-12-01T00:00:002009-12-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$41false USDtruefalse$P11_01_2009To11_30_2009_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2009-11-01T00:00:002009-11-30T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$42false USDtruefalse$P06_01_2009To06_30_2009_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2009-06-01T00:00:002009-06-30T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USD_UnitDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.biopathholdings.com/20130630Unitbpth0USDUSD$43false USDtruefalse$P08_01_2007To08_31_2007_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2007-08-01T00:00:002007-08-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$44false USDtruefalse$P11_01_2010To04_30_2011_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-11-01T00:00:002011-04-30T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$45false USDtruefalse$P08_01_2007To08_31_2007_AdditionalSharesMemberusgaapStatementClassOfStockAxis_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2007-08-01T00:00:002007-08-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseAdditional Sharesus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldibpth_AdditionalSharesMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$46false USDtruefalse$P01_01_2010To01_31_2010_AdditionalSharesMemberusgaapStatementClassOfStockAxis_InvestorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-01-01T00:00:002010-01-31T00:00:00falsefalseInvestorsus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_InvestorMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseAdditional Sharesus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldibpth_AdditionalSharesMemberus-gaap_StatementClassOfStockAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$47false truefalseP06_01_2011To06_30_2011_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2011-06-01T00:00:002011-06-30T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli048false truefalseP08_01_2007To08_31_2007_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2007-08-01T00:00:002007-08-31T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli049false truefalseP01_01_2013To06_30_2013_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli050false truefalseP05_01_2010To05_31_2010_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-05-01T00:00:002010-05-31T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli051false truefalseP01_01_2010To01_31_2010_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2010-01-01T00:00:002010-01-31T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli052false truefalseP06_01_2009To06_30_2009_PlacementAgentMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PrivatePlacementMemberusgaapOtherOwnershipInterestsByNameAxishttp://www.sec.gov/CIK0001133818duration2009-06-01T00:00:002009-06-30T00:00:00falsefalsePlacement Agentus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_PlacementAgentMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalsePrivate Placement memorandumus-gaap_OtherOwnershipInterestsByNameAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PrivatePlacementMemberus-gaap_OtherOwnershipInterestsByNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli053false truefalseP11_01_2007To11_30_2007_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2007-11-01T00:00:002007-11-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli054false truefalseP04_01_2008To04_30_2008_BioPathHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2008-04-01T00:00:002008-04-30T00:00:00falsefalseBioPathHoldingsIncus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_BioPathHoldingsIncMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli055false truefalseP02_01_2008To02_29_2008_BioPathHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2008-02-01T00:00:002008-02-29T00:00:00falsefalseBioPathHoldingsIncus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_BioPathHoldingsIncMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli056false truefalseP02_01_2008To02_29_2008_OgdenGolfCorporationMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2008-02-01T00:00:002008-02-29T00:00:00falsefalseOgden Golf Co.us-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_OgdenGolfCorporationMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli01true 3bpth_ShareholdersEquityLineItemsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Shareholders Equity [Line Items]2false 4us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse571429571429falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17truefalsefalse65059946505994falsefalsefalse18truefalsefalse65059946505994falsefalsefalse19truefalsefalse166667166667falsefalsefalse20truefalsefalse172414172414falsefalsefalse21truefalsefalse8333383333falsefalsefalse22truefalsefalse164853164853falsefalsefalse23truefalsefalse135135135135falsefalsefalse24truefalsefalse135135135135falsefalsefalse25truefalsefalse125000125000falsefalsefalse26truefalsefalse375000375000falsefalsefalse27truefalsefalse571429571429falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse8928689286falsefalsefalse31truefalsefalse9615496154falsefalsefalse32truefalsefalse185185185185falsefalsefalse33truefalsefalse185185185185falsefalsefalse34truefalsefalse1200012000falsefalsefalse35falsefalsefalse00falsefalsefalse36truefalsefalse1166466511664665falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43truefalsefalse39750003975000falsefalsefalse44falsefalsefalse00falsefalsefalse45truefalsefalse13333341333334falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48truefalsefalse530833530833falsefalsefalse49truefalsefalse14964991496499falsefalsefalse50truefalsefalse7800078000falsefalsefalse51truefalsefalse360000360000falsefalsefalse52truefalsefalse6600066000falsefalsefalse53falsefalsefalse00falsefalsefalse54truefalsefalse200000200000falsefalsefalse55truefalsefalse8000080000falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock and warrants issued, shares3false 4us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse489501489501USD$falsetruefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18truefalsefalse65066506USD$falsetruefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43truefalsefalse993750993750USD$falsetruefalse44truefalsefalse17942051794205USD$falsetruefalse45truefalsefalse10000001000000USD$falsetruefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Common stock issued , value4false 4bpth_StockIssuedDuringPeriodSharesContingentConsiderationsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse150000150000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35truefalsefalse59806855980685falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47truefalsefalse598069598069falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53truefalsefalse31388893138889falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesStock Issued During Period Shares Contingent ConsiderationsNo definition available.false1Common stock issued , shares5false 4bpth_StockIssuedDuringPeriodSharesMergerbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55truefalsefalse3802357838023578falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued during the period pursuant to a merger.No definition available.false1Common stock issued merger transactions, shares6false 4bpth_StockRetainedByShareholdersSharesMergerTransactionbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56truefalsefalse36000003600000falsefalsefalsexbrli:sharesItemTypesharesStock Retained by Shareholders, Shares, Merger TransactionNo definition available.false1Common stock retained shareholders, shares7false 4bpth_FairValueOfCommonStockIssuedbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse180000180000falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15truefalsefalse4000040000falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value of common stock issued.No definition available.false2Common stock issued for services, value8false 4bpth_CommonStockAdditionalSharesIssuedbpth_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse2424falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesCommon Stock Additional Shares IssuedNo definition available.false1Common stock issued, additional shares9false 4bpth_IssuanceOfCommonStockSharesForServicebpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1850018500falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse1850018500falsefalsefalse14falsefalsefalse00falsefalsefalse15truefalsefalse100000100000falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesIssuance Of Common Stock Shares For ServiceNo definition available.false1Common stock issued for service, shares10false 4bpth_IssuanceOfCommonStockAndWarrantsSharesbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14truefalsefalse660000660000falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38truefalsefalse780000780000falsefalsefalse39truefalsefalse27000002700000falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46truefalsefalse900000900000falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesIssuance Of Common Stock And Warrants, SharesNo definition available.false1Common stock and warrant issued, shares11false 4bpth_CommonStockRepurchasedSharesbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38truefalsefalse780000780000falsefalsefalse39truefalsefalse27000002700000falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42truefalsefalse660000660000falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46truefalsefalse900000900000falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesCommon Stock Repurchased SharesNo definition available.false1Common stock repurchased, shares12false 4bpth_IssuanceOfCommonStockAndWarrantsValuebpth_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38truefalsefalse273000273000falsefalsefalse39falsefalsefalse00falsefalsefalse40truefalsefalse675000675000falsefalsefalse41truefalsefalse675000675000falsefalsefalse42truefalsefalse165000165000falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46truefalsefalse225000225000falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryValue of issuance of common stock and warrants.No definition available.false2Common stock and warrants issued, Value13false 4bpth_ClassOfWarrantOrRightExercisablePeriodbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse002 yearsfalsefalsefalse39falsefalsefalse002 yearsfalsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse002 yearsfalsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse002 yearsfalsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalseus-types:durationStringItemTypenormalizedstringClass of Warrant or Right, Exercisable PeriodNo definition available.false0Warrants exercisable period14false 4us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16truefalsefalse1.501.50falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27truefalsefalse1.501.50falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38truefalsefalse1.501.50falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42truefalsefalse1.501.50falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalseus-types:perUnitItemTypedecimalExercise price per share or per unit of warrants or rights outstanding.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Subparagraph 4 -Article 4 false0Warrants exercise price15false 4invest_InvestmentWarrantsExercisePriceinvest_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39truefalsefalse1.501.50USD$falsetruefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46truefalsefalse1.501.50USD$falsetruefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalExercise price of the warrants.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 12 -Section 13 -Sentence Column A false3Warrants exercise price16false 4bpth_StockCommittedToBeIssuedDuringPeriodValueAcquisitionsbpth_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27truefalsefalse70000007000000falsefalsefalse28truefalsefalse5000050000falsefalsefalse29truefalsefalse10000001000000falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryStock Committed to be Issued During Period, Value, AcquisitionsNo definition available.false2Equity purchase agreement value17false 4bpth_PurchaseAgreementPeriodbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse0024 monthsfalsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaPurchase Agreement PeriodNo definition available.false0Agreement period18false 4us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsepositiveLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse25159612515961falsefalsefalse8truefalsefalse264709264709falsefalsefalse9truefalsefalse1055534410555344falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse5000050000falsefalsefalse20truefalsefalse5000050000falsefalsefalse21truefalsefalse2500025000falsefalsefalse22truefalsefalse5000050000falsefalsefalse23truefalsefalse5000050000falsefalsefalse24truefalsefalse5000050000falsefalsefalse25truefalsefalse5000050000falsefalsefalse26truefalsefalse150000150000falsefalsefalse27truefalsefalse200000200000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse2500025000falsefalsefalse31truefalsefalse2500025000falsefalsefalse32truefalsefalse5000050000falsefalsefalse33truefalsefalse5000050000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from issuance of common stock and warrant from LPC19false 4bpth_StockCommittedToBeIssuedDuringPeriodSharesAcquisitionsbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse20842084falsefalsefalse20truefalsefalse20842084falsefalsefalse21truefalsefalse10421042falsefalsefalse22truefalsefalse20842084falsefalsefalse23truefalsefalse20842084falsefalsefalse24truefalsefalse20842084falsefalsefalse25truefalsefalse20842084falsefalsefalse26truefalsefalse62516251falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse10421042falsefalsefalse31truefalsefalse10421042falsefalsefalse32truefalsefalse20842084falsefalsefalse33truefalsefalse20842084falsefalsefalse34truefalsefalse566801566801falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesStock Committed to be Issued During Period, Shares, AcquisitionsNo definition available.false1Committed shares issued20false 4bpth_IssuanceOfWarrantsSharesbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse00falsefalsefalse20truefalsefalse00falsefalsefalse21truefalsefalse00falsefalsefalse22truefalsefalse00falsefalsefalse23truefalsefalse00falsefalsefalse24truefalsefalse00falsefalsefalse25truefalsefalse00falsefalsefalse26truefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesIssuance Of Warrants, SharesNo definition available.false1Warrants issued, shares21false 4bpth_StockIssuedDuringPeriodSharesStockWarrantsExercisedbpth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse19200001920000falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares issued during the period as a result of the exercise of warrants.No definition available.false1Common stock issued for exercise of warrant (in shares)22false 4bpth_StockIssuedDuringPeriodValueWarrantExercisesbpth_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse576000576000falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryStock Issued During Period Value Warrant ExercisesNo definition available.false2Common stock issued for exercise of warrant23false 4us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaimsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse346201346201USD$falsetruefalse5truefalsefalse708600708600USD$falsetruefalse6truefalsefalse795001795001USD$falsetruefalse7truefalsefalse00USD$falsetruefalse8truefalsefalse1850018500USD$falsetruefalse9truefalsefalse318500318500USD$falsetruefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12truefalsefalse20001982000198USD$falsetruefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Common stock issued for services24false 4us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse6221905062219050falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse7538021475380214falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse7538021475380214falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37truefalsefalse33003373300337falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common Stock, shares issued25false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse6221905062219050falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse7538021475380214falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse7538021475380214falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common Stock, shares outstanding26false 4us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalse36falsefalsefalse00falsefalsefalse37falsefalsefalse00falsefalsefalse38falsefalsefalse00falsefalsefalse39falsefalsefalse00falsefalsefalse40falsefalsefalse00falsefalsefalse41falsefalsefalse00falsefalsefalse42falsefalsefalse00falsefalsefalse43falsefalsefalse00falsefalsefalse44falsefalsefalse00falsefalsefalse45falsefalsefalse00falsefalsefalse46falsefalsefalse00falsefalsefalse47falsefalsefalse00falsefalsefalse48falsefalsefalse00falsefalsefalse49falsefalsefalse00falsefalsefalse50falsefalsefalse00falsefalsefalse51falsefalsefalse00falsefalsefalse52falsefalsefalse00falsefalsefalse53falsefalsefalse00falsefalsefalse54falsefalsefalse00falsefalsefalse55falsefalsefalse00falsefalsefalse56falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred Stock, shares outstandingfalseStockholders' Equity - Additional Information (Detail) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/StockholdersEquityAdditionalInformationDetail5626 XML 65 R28.xml IDEA: Commitments and Contingencies - Additional Information (Detail) 2.4.0.8128 - Disclosure - Commitments and Contingencies - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]2false 4us-gaap_CostOfReimbursableExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse7500075000USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Estimates reimbursable past patent expenses3false 4bpth_AccruedPatentExpenseCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2500025000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Patent Expense, CurrentNo definition available.false2Patent expense per quarter4false 4bpth_AccruedLiabilitiesRelatedPartyCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3705037050USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities Related Party CurrentNo definition available.false2Accrued expense - related party5false 4us-gaap_OtherInventoryus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsedefinitionGuidance1truefalsefalse279180279180USD$falsefalsefalse2truefalsefalse195000195000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a -Article 5 false2Other inventory, gross6false 4bpth_DrugProductTestingAgreementConsiderationToBePaidInStagesbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse340000340000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents consideration to be paid in various stages with respect to agreement with its drug product manufacturer for testing.No definition available.false2Drug Product Testing Agreement Consideration To Be Paid In Stages7false 4bpth_DrugProductEstimatedCostbpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse165000165000USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryDrug Product Estimated CostNo definition available.false2Drug Product Estimated Cost8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$PAsOn06_30_2013_PatentedTechnologyMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalsePatented Technologyus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_PatentedTechnologyMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Patented Technology9true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]10false 4bpth_AccruedLiabilitiesRelatedPartyCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1001710017USD$falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities Related Party CurrentNo definition available.false2Accrued expense - related party11false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse4false USDtruefalse$PAsOn06_30_2013_TechnologyLicensesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseTechnology Licensesus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_TechnologyLicensesMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Technology Licenses12true 3us-gaap_ProductLiabilityContingencyLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Product Liability Contingency [Line Items]13false 4us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5000050000USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(1),(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 1, 5 -Article 9 false2Accounts payable and accrued liabilitiesfalseCommitments and Contingencies - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/CommitmentsAndContingenciesAdditionalInformationDetail213 XML 66 R19.htm IDEA: XBRL DOCUMENT

Organization and Business - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended	74 Months Ended
	Jul. 31, 2012	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2013	Dec. 31, 2012	May 09, 2007
Organization and Nature of Operations [Line Items]
Percentage of Charge					50.00%
Impairment of License			$ 0	$ 345,000	$ 345,000	$ 690,000
Cash		1,927,226	1,927,226	162,440	952,252	1,927,226	534,046	0
Carrying value of the siRNA license				345,000
Proceeds from issuance of private placement	4,000,000	2,500,000
Proceeds form additional issuance of private placement		$ 4,000,000
Phase I clinical trial
Organization and Nature of Operations [Line Items]
Number patients benefited from Liposomal Grb-2 treatment		3	3			3

XML 67 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity

8.	Stockholders’ Equity

In October of 2011, the Company issued 1,920,000 shares of common stock for $576,000 to investors who exercised warrants from September to October 2011.

In August of 2012, the Company issued 50,000 shares of its common stock for the $18,500 shares for services previously recognized in June 2012.

In July through September of 2012, the Company sold $795,001 in shares of its common stock pursuant to a private placement, with shares to be issued.

In October through December of 2012, the Company sold $708,600 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of December 31, 2012 the Company issued 3,300,337 shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.

In February and March of 2013, the Company sold $346,201 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of June 30, 2013, there were 75,380,214 shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2013.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

XML 68 R22.htm IDEA: XBRL DOCUMENT

Accounts Payable - Additional Information (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Accounts Payable [Line Items]
Accounts payable	$ 165,897	$ 57,000
Accounts payable, trade	114,200
Accounts payable, other, current	6,800
Accounts payable - related party	10,017	8,582
Accounts Payable To Professional Fees Current	15,900
Accounts Payable To Public Filing Services	6,000
Research and Development Expense
Accounts Payable [Line Items]
Accounts payable, trade	$ 13,900

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

XML 69 R15.xml IDEA: Stockholders' Equity 2.4.0.8115 - Disclosure - Stockholders' Equitytruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:001true 1us-gaap_StockholdersEquityNoteAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stockholders' Equity Note [Abstract]2false 2us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00 <table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>8.</strong></div> </td> <td style="TEXT-ALIGN: justify"> <div><strong>Stockholders’ Equity</strong></div> </td> </tr> </table> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong><em> </em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Issuance of Common Stock</em></strong>  In May and June of 2007, the Company issued <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"> 6,505,994</font></font> shares of common stock for $<font style=" FONT-SIZE: 10pt">6,506</font> in cash to founders of the Company. In August of 2007, the Company issued <font style=" FONT-SIZE: 10pt">3,975,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">993,750</font> in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional <font style=" FONT-SIZE: 10pt">1,333,334</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">1,000,000</font> in cash to investors in the Company pursuant to a second round of financing. The Company issued <font style=" FONT-SIZE: 10pt">530,833</font> in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued <font style=" FONT-SIZE: 10pt">3,138,889</font> shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued <font style=" FONT-SIZE: 10pt">38,023,578</font> shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained <font style=" FONT-SIZE: 10pt">3,600,000</font> shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued <font style=" FONT-SIZE: 10pt">80,000</font> shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued <font style=" FONT-SIZE: 10pt">200,000</font> shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style=" FONT-SIZE: 10pt">180,000</font>. In April of 2008, the Company recorded an additional <font style=" FONT-SIZE: 10pt"> 24</font> shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued <font style=" FONT-SIZE: 10pt">100,000</font> shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $<font style=" FONT-SIZE: 10pt">40,000</font>. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued <font style=" FONT-SIZE: 10pt"> 660,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">660,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">165,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style=" FONT-SIZE: 10pt">66,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">675,000</font></font> in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors <font style=" FONT-SIZE: 10pt"> 2,700,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">2,700,000</font> shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In January 2010, the Company also sold an additional <font style=" FONT-SIZE: 10pt">900,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt"> 900,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">225,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with these private placement sales of equity, the Company issued <font style=" FONT-SIZE: 10pt">360,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May of 2010, the Company issued <font style=" FONT-SIZE: 10pt"> 780,000</font> shares of common stock and warrants to purchase an additional <font style=" FONT-SIZE: 10pt">780,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">273,000</font> in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $<font style=" FONT-SIZE: 10pt">1.50</font> a share. In connection with this private placement, the Company issued <font style=" FONT-SIZE: 10pt">78,000</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a <font style=" FONT-SIZE: 10pt">24</font>-month period in amounts between $<font style=" FONT-SIZE: 10pt">50,000</font> and $<font style=" FONT-SIZE: 10pt">1,000,000</font> up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $<font style=" FONT-SIZE: 10pt">200,000</font> from LPC as an initial purchase in exchange for <font style=" FONT-SIZE: 10pt"> 571,429</font> shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase <font style=" FONT-SIZE: 10pt">571,429</font> shares of the Company’s common stock at an exercise price of $<font style=" FONT-SIZE: 10pt">1.50</font> per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC <font style=" FONT-SIZE: 10pt">12,000</font> shares of the Company’s common stock for its due diligence efforts and <font style=" FONT-SIZE: 10pt">566,801</font> shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July of 2010, the Company received $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">150,000</font></font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">375,000</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">6,251</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the <font style=" FONT-SIZE: 10pt">375,000</font> shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In September of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">125,000</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">135,135</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November of 2010, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">135,135</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From November 2010 through April of 2011 the Company sold shares of common stock for $<font style=" FONT-SIZE: 10pt">1,794,205</font> in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued <font style=" FONT-SIZE: 10pt"> 5,980,685</font> shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued <font style=" FONT-SIZE: 10pt">598,069</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2011, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">164,853</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October of 2011, the Company issued <font style=" FONT-SIZE: 10pt">1,920,000</font> shares of common stock for $<font style=" FONT-SIZE: 10pt">576,000</font> to investors who exercised warrants from September to October 2011.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In November of 2011, the Company received $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In December of 2011, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">172,414</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In March of 2012, the Company received $<font style=" FONT-SIZE: 10pt">50,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">166,667</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">2,084</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">89,286</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $<font style=" FONT-SIZE: 10pt">25,000</font> from LPC in exchange for <font style=" FONT-SIZE: 10pt">96,154</font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt">1,042</font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $<font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">50,000</font></font> from LPC in exchange for <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt"> 185,185</font></font> shares of the Company’s common stock. LPC was also issued <font style=" FONT-SIZE: 10pt"><font style=" FONT-SIZE: 10pt">2,084</font></font> shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">150,000</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style=" FONT-SIZE: 10pt">18,500</font> in shares of its common stock for services with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August of 2012, the Company issued <font style=" FONT-SIZE: 10pt">50,000</font> shares of its common stock for the $<font style=" FONT-SIZE: 10pt">18,500</font> shares for services previously recognized in June 2012.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July through September of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">795,001</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October through December of 2012, the Company sold $<font style=" FONT-SIZE: 10pt">708,600</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of December 31, 2012 the Company issued <font style=" FONT-SIZE: 10pt">3,300,337</font> shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February and March of 2013, the Company sold $<font style=" FONT-SIZE: 10pt">346,201</font> in shares of its common stock pursuant to a private placement, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April and May of 2013, the Company sold $<font style=" FONT-SIZE: 10pt">2,000,198</font> in shares of its common stock pursuant to a private placement, with shares to be issued, and $<font style=" FONT-SIZE: 10pt">489,501</font> in shares of its common stock pursuant in a direct offering, with shares to be issued.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June of 2013, the Company issued <font style=" FONT-SIZE: 10pt"> 11,664,665</font> shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued <font style=" FONT-SIZE: 10pt">1,496,499</font> shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, there were <font style=" FONT-SIZE: 10pt"> <font style=" FONT-SIZE: 10pt">75,380,214</font></font> shares of common stock issued and outstanding. There are no preferred shares outstanding as of June 30, 2013.</div> </div> falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 false0Stockholders' EquityfalseStockholders' EquityUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/StockholdersEquity12 XML 70 R20.htm IDEA: XBRL DOCUMENT

Related Party - Additional Information (Detail) (USD $)	6 Months Ended		12 Months Ended	74 Months Ended		6 Months Ended			3 Months Ended
Related Party - Additional Information (Detail) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 MD Anderson Cancer Center	Jun. 30, 2012 MD Anderson Cancer Center	Jun. 30, 2013 MD Anderson Cancer Center Clinical Trials [Member]	Jun. 30, 2013 MD Anderson Cancer Center Research and Development Expense	Jun. 30, 2012 MD Anderson Cancer Center Research and Development Expense	Jun. 30, 2013 MD Anderson Cancer Center Technology Licenses
Related Party Transaction [Line Items]
Accrued expense - related party	$ 37,050			$ 37,050	$ 26,000	$ 37,050		$ 22,050
Accrued license payments - related party	50,000			50,000	100,000
Cash paid to MD Anderson Cancer Center for expenses									32,067	367,588
Accounts payable - related party	10,017			10,017	8,582						10,017
Research and Development Expense							367,588
Technology impairment	0	345,000	345,000	690,000		345,000
Patent Expense							$ 22,588

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

+ References+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

XML 71 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2013	Aug. 05, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	BPTH
Entity Common Stock, Shares Outstanding		75,380,214
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Central Index Key	0001133818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

XML 72 R21.htm IDEA: XBRL DOCUMENT

Prepaid Drug Product for Testing - Additional Information (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Line Items]
Prepaid drug product for testing	$ 279,180	$ 195,000

XML 73 R1.xml IDEA: Document And Entity Information 2.4.0.8101 - Document - Document And Entity Informationtruefalsefalse1false falsefalseP01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:002false falsefalsePAsOn08_05_2013http://www.sec.gov/CIK0001133818instant2013-08-05T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli01true 3dei_DocumentInformationLineItemsdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Document Information [Line Items]2false 4dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse0010-Qfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false0Document Type3false 4dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false0Amendment Flag4false 4dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse002013-06-30falsefalsetrue2falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false0Document Period End Date5false 4dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse002013falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0Document Fiscal Year Focus6false 4dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Q2falsefalsefalse2falsefalsefalse00falsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false0Document Fiscal Period Focus7false 4dei_TradingSymboldei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00BPTHfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringTrading symbol of an instrument as listed on an exchange.No definition available.false0Trading Symbol8false 4dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalse2truefalsefalse7538021475380214falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false1Entity Common Stock, Shares Outstanding9false 4dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00BIO-PATH HOLDINGS INCfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Registrant Name10false 4dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse000001133818falsefalsefalse2falsefalsefalse00falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Central Index Key11false 4dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00--12-31falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false0Current Fiscal Year End Date12false 4dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00Smaller Reporting Companyfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Filer CategoryfalseDocument And Entity InformationUnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/DocumentAndEntityInformation212

allow Bio-Path to develop MD Anderson's neutral lipid delivery technology;

give Bio-Path ongoing access to MD Anderson's Pharmaceutical Development Center for drug development;

provide rapid communication to Bio-Path of new drug candidate disclosures in the Technology Transfer Office;

standardize clinical trial programs sponsored by Bio-Path; and

standardize sponsored research under a master agreement addressing intellectual property sharing.